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Abstract
Abnormal levels of serotonin in blood have been described in
several cardiovascular-associated diseases, but the role of this
indoleamine in the establishment or progression of these diseases is
not well understood. It is known that patients with essential
hypertension have lower blood levels of serotonin, and there is some
evidence to suggest reduced platelet uptake of serotonin.
Angiotensin II (All) has been shown to increase serotonin synthesis
and to alter platelet aggregation; since All is important in
regulating sodium retention, the effect of sodium status on blood
levels of serotonin and also platelet function required close
examination. In this thesis, two assays for serotonin were
developed, validated, and used to investigate the relationship
between 1) platelet aggregation, serotonin levels and sodium status
and 2) serotonin levels and platelet function in patients with
cardiovascular disease.
A radioimmunoassay (RIA) using an [^^I]-labelled tracer was
developed and validated for the measurement of serotonin in human
platelet-rich plasma (PRP) and rat serum. Antisera were raised
against N-succinamylserotonin conjugated to bovine albumin and, to
improve assay sensitivity, the analyte was made chemically similar to
the immunogen by conversion to N-acetylserotonin prior to assay,
using the specific amino reagent N-acetoxysuccinimide. An assay for
serotonin using high-pressure liquid chromatography with
electrochemical detection (HPLC-ECD) was developed, and used to
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validate the RIA. There was a good correlation between the RIA and
HPLC-ECD reference method both for human PRP, and for rat serum,
indicating that no significant cross-reactions were present, and that
endogenous N-acetylserotonin concentrations were negligible compared
with the levels of serotonin in human PRP and rat serum. The RIA
can be used to assay up to 100 samples/day compared with 10-20/day by
the HPLC-ECD assay.
Studies carried out in rats showed that an increase in sodium
intake resulted in a decrease of serum serotonin; a similar effect was
seen in normal human female PRP, although the difference between the
serotonin levels was not significant when corrected for platelet
number. In agreement with work by other groups, sodium loading
resulted in an increase in platelet aggregation, although no effect
on the rate of aggregation was found. This increase was blocked in
vitro by the serotonin antagonist ketanserin, which also reduced the
rate of aggregation. This suggests that the observed increase in
the extent of aggregation may be mediated by enhanced release of
serotonin from platelets during sodium loading. There was no
correlation between plasma All levels and serotonin concentration,
although a correlation was seen between plasma All levels and
platelet aggregation.
The group of essential hypertensive patients studied in this thesis
had lower levels of serotonin in their PRP compared with controls,
but after correcting for platelet numbers, this difference was not
significant. Radioactive impurities in the [^Hl-serotonin tracer
used in the uptake studies contributed to the total observed count
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rate, but not to the radioactivity incorporated by human PRP, and, if
tracer purity had not been not corrected for, this would have
resulted in a falsely depressed value for the amount of tracer taken
up. There was no difference in the kinetics of serotonin uptake
between the controls and the hypertensives.
In a group of patients with heart failure, chronic therapy with the
angiotensin-converting enzyme inhibitor captopril resulted in an
increase in PRP serotonin, possibly reflecting a prostaglandin-induced
reduction of in_ vivo platelet aggregation.
The results suggest that the serotonin assays developed are useful
for determining serotonin status in physiological or patho¬
physiological conditions, and may also indicate changes in platelet
activation in vivo, since, unlike other markers of platelet
activation (e.g. -thromboglobulin ), no special precautions have to




All = angiotensin II
AIII = angiotensin III
ACD = acid/citrate/dextrose anticoagulant
ACE = angiotensin-converting enzyme
ADP = adenosine diphosphate
APUD amine precursor uptake and decarboxylation
AR = analytical grade reagent
BSA = bovine serum albumin
BTG = /3-thromboglobulin
cAMP = cyclic adenosine monophosphate
Ci = curies
cpm counts per minute >
CSPPP charcoal-stripped platelet-poor plasma
CV = coefficient of variation
DARS = donkey anti-rabbit serum
DMF = dimethyIformamide
dpm disintegrations per minute
EBSS = Earle's balanced salt solution
ECD = electrochemical detection
EDTA ethylene diamine tetra-acetic acid
GPR = general purpose grade reagent
5HIAA = 5-hydroxyindoleacetic acid
HPLC high-pressure liquid chromatography
HSA = human serum albumin
5HT = 5-hydroxytryptamine, serotonin
5HTP = 5-hydroxytryptophan
KHS = Krebs-Henseleit saline
Ka affinity constant





MPV = mean platelet volume
5MT = 5-methoxytryptamine
NAD = nicotinamide adenine dinucleotide
NAS = N-acetoxysuccinimide
NIGPS non-immune guinea pig serum
NIRS = non-immune rabbit serum
NSB = non-specific binding
NSHPP = N-succinimidyl-3-(4-hydroxyphenyl)-propionate
ODS = octadecyl silica
OPT = o-phthalaldehyde
PCPA = p-chlorophenylalanine
PPP = platelet-poor plasma
PRP = platelet-rich plasma
PVC = polyvinyl chloride
RBC red blood cell
RCF =: relative centrifugal force
REA = radioenzymatic assay
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RIA = radioimmunoassay
SAGPS = sheep anti-guinea pig serum
SEM = standard error of the mean
SD = standard deviation
TLC = thin layer chromatography
TXA2 = thromboxane A2
UV = ultra-violet
V = volts, voltage
v.^ = initial rate of uptake
= maximum rate of uptakeIlld J\.
WBC = white blood cell
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It is nearly 85 years since Battelli (1905) described"the
vasoconstrictive properties of blood sera from various species of
animals, and almost 40 years since the probable structure and
biochemical properties of that serum vasoactive compound (serotonin)
were first described (Rapport, et_ al_., 1948a, 1948b). Even so, much
remains to be discovered about the physiological and pathophysio¬
logical role of serotonin in man. This chapter is intended to serve
as a general introduction to serotonin and its measurement; for more
detailed reviews of serotonin, the reader is referred to, for
example, Garrattini and Valzelli, 1965, and Smythe, 1979.
1.2 Discovery of Serotonin
Serotonin was discovered independently by two groups: following
their studies on the enterochromaffin cells of the gastrointesinal
tract (e.g. Vialli and Erspamer, 1933), Erspamer's group found a
compound which was apparently specific to the gut. Rapport and
colleagues (1947) isolated the compound which gave blood serum
its vasoconstrictive properties, with the view that this may be
important in essential hypertension (plasma was found to have
virtually no vasoactivity). Erspamer's group named their putative
hormone enteramine, whilst Rapport and his colleagues called their
discovery serotonin, and described its possible structure and
chemical properties (Rapport, et_ al_., 1948b). Later work (Erspamer
and Asero, 1952) confirmed that enteramine and serotonin were in fact
the same compound, the indoleamine 5-hydroxytryptamine (5HT; more
correctly named 5-hydroxy-3-(2-aminoethyl)-indole; Figure 1.1).
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Figure 1.1 The structure of serotonin.
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1.3 Biosynthesis and Metabolism of Serotonin
The major site of synthesis of serotonin in man is in the
enterochromaffin cells of the gut (Erspamer and Testini, 1959).
These cells (originally named because of the intense staining after
dichromate fixation (Ciaccio, 1906)) have also been described as
amine precursor uptake and decarboxylation, or APUD cells (Pearse,
1968). Serotonin is synthesised from dietary L-tryptophan via the
intermediate compound 5-hydroxytryptophan (5HTP; Figure 1.2). This
is not a major metabolic pathway for tryptophan, as only 1-2% of
dietary tryptophan is converted into serotonin (Levine, 1974).
Since the enzyme converting tryptophan to 5HTP is not saturated with
substrate in vivo (Friedman, et_ a]^., 1972), and since 5HTP is rapidly
decarboxylated to serotonin (Tappaz and Pujol, 1980), it appears that
the rate-limiting step in serotonin biosynthesis is the 5-hydroxy-
lation of tryptophan by tryptophan hydroxylase (Lovenberg, et al.,
1967; Friedman, et_ alL., 1972). The hydroxylation of tryptophan into
5HTP requires the presence of a cofactor, a tetrahydrobiopterin
(Figure 1.3), and it has been suggested that the concentration of the
oxidised form of this cofactor (dihydrobiopterin) may also play a
regulatory role in the rate of serotonin synthesis (see Boadle-Biber,
1982). However this seems unlikely since an increase in tetra¬
hydrobiopterin concentrations _in vitro did not lead to an increase in
serotonin synthesis (Bullard, at_ a]L., 1978).
The production of 5HTP from tryptophan by tryptophan hydroxylase
is inhibited by £-chlorophenylalanine (PCPA; Koe and Weissman, 1966);



















Figure 1.2 Biosynthesis of serotonin from tryptophan.
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Figure 1.3 The role of tetrahydrobiopterin in the
hydroxylation of tryptophan.
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which can be used to investigate the effects of serotonin depletion
(e.g. Jequier, et al., 1967). This is preferential to blocking
serotonin synthesis by inhibition of the enzyme which converts 5HTP
into serotonin (L-aromatic amino acid decarboxylase), since this
decarboxylating enzyme is also required for the production of
catecholamines (Lovenberg, et al., 1962). Once formed, serotonin
can undergo several other reactions, the major pathways being
1) conversion into N-acetylserotonin, which can then be
converted into 5-methoxy-N-acetyltryptamine (melatonin; Figure
1.4a), or 2) oxidation to 5-hydroxyindoleacetic acid (5HIAA) via
5-hydroxyindoleacetaldehyde (Figure 1.4b). Formation of melatonin
from serotonin via N-acetylserotonin occurs primarily in the pineal
gland (Pang and Tang, 1983), and is of particular interest since
there is a marked rhythm in the levels of melatonin in blood, and
also in the activity of the enzyme N-acetyltransferase, which is
responsible for the synthesis of N-acetylserotonin from serotonin
(Pang, et al., 1980). The peak of N-acetyltransferase activity is
greatest during the hours of darkness, and coincides with the peak
levels of serotonin in the pineal (see Sugden, et al., 1983).
Serotonin is oxidised to 5-hydroxyindoleacetaldehyde by mono¬
amine oxidase type A which is located in cellular mitochondria
(Pearce and Roth, 1983). Further oxidation by aldehyde
dehydrogenase produces 5HIAA, large quantities of which are excreted
in urine (up to 50 p,mol/day; Udenfriend, et_ al_., 1956). Serotonin
is metabolised in this way in the liver (Drapanas and McDonald, 1963)






































Figure 1.4 Metabolism of serotonin
a) conversion into melatonin
b) conversion into 5HIAA.
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1.4 Serotonin and the Platelet
The major storage site for serotonin in human blood is the
platelet (Rand and Reid, 1951; Udenfriend and Weissbach, 1954);
however, in other mammals (e.g. the rat), serotonin is also found in
mast cells (Benditt, et al., 1955). Platelets are small blood cells
(diameter approximately 3 pm) with no nucleus, and therefore little
capacity to synthesise protein. They are formed by fragmentation of
the cytoplasm of megakaryocytes, which themselves derive from
pluripotent stem cells in the bone marrow (Thompson, 1986).
Platelets contain definite internal structures, (Figure 1.5; see
White and Gerrard, 1978), notably dense granules which are the
storage sites for serotonin (Davis and White, 1968), and -granules
which store the platelet-specific proteins f3 -thromboglobulin and
platelet factor 4 (Day, et_ al_., 1973). Serotonin is stored in the
dense granules complexed with di- and tri-nucleotides (e.g. ADP, ATP)
and heavy metal cations (e.g. Ca2+, Mg2+; see Pletscher, 1968).
Serotonin is released from the enterochromaffin cells after
stimulation of the gut (e.g. by vagal stimulation; Ahlman and
It
Dahlstrom, 1983) into the bloodstream, and is then available either
for metabolism by the liver or the lungs, or uptake by platelets
(Toh, 1954). Platelet serotonin uptake can be either a) active or
b) passive:
a) active uptake is energy dependent, since it is inhibited by
metabolic poisons (e.g. cyanide; Born and Gillson, 1959). Active





Figure 1.5 The internal structure of the platelet










Todrick, 1973; Nelson and Rudnick, 1982; Rudnick, et al., 1983),
and internal K+ ions; it is thought that serotonin is co-
transported with a Na+ and Cl~ ion, in exchange for a K+ or H+
ion (Nelson and Rudnick, 1982). Platelet serotonin receptors in
man are of the 5HT2 type (De Clerck, et al., 1984), and are
further divided into two sub-groups of 'A' and 'B' type receptors
(Peters and Grahame-Smith, 1980). The 'A' receptor is of low
capacity, but high affinity, and is thought to be involved in the
serotonin-induced aggregation response of platelets whereas the
'B' receptor is of low affinity and high capacity, and
participates in the active uptake of serotonin (Peters and
Grahame-Smith, 1980). The 'B' receptor is inhibited non-
competitively by the tricyclic antidepressant chlorimipramine
(Lingjaerde, 1979), which reflects the similarities between
synaptosomes (the presumed "active site" for tricyclic anti¬
depressants) and platelets (Sneddon, 1973). It has been
suggested that the related antidepressant imipramine "straddles"
two uptake sites, since studies have shown that binding of each
molecule of [%]-imipramine requires two Na+ ions (Rudnick, et_
al., 1983), compared with the 1:1 ratio seen between serotonin
and Na+ for uptake. Active serotonin uptake is rapid,
saturable, and the initial rate is thought to follow Michaelis-
Menten kinetics (e.g. Humphrey and Toh, 1954).
b) In contrast, passive uptake or diffusion is not dependent on
cellular energy, but is the dominant uptake process at high
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external concentrations of serotonin (Born and Bricknell, 1959).
Passive uptake is temperature dependent, the rate declining with
decreased temperature (Pletscher, et_ al_., 1966).
Once internalised, serotonin is transported into the dense
granules for storage. This process is unaffected by metabolic
inhibitors, but can be blocked by reserpine (see Da Prada, et al.,
1978). Osim and Wylie (1983) showed that stored platelet serotonin
may be released and accumulated by other tissues. These workers
labelled the platelet membranes with Indium, and the platelet
stores of serotonin with [-serotonin; they found in certain
organs (notably the thyroid, skin and the adrenals) an increase in
1 u 11 1 1 u
the C/ In ratio, suggesting preferential uptake of [ C]-
serotonin by these organs.
Serotonin is released from the platelet following stimulation
by e.g. thrombin, which results in >90% of the total platelet
serotonin being released (Grette, 1962). This is clearly seen in
the clotting reaction (i.e. thrombin production and fibrin formation)
of whole blood; the thrombin produced (Figure 1.6; for a review, see
Vermylen, 1978) results in the release of platelet serotonin into the
surrounding fluid, thus producing the serum-specific vasoconstrictor
sought for and isolated by Rapport, et al., (1947). Plasma prepared
by centrifugation of anticoagulated blood contains only a fraction of
the serotonin concentration of serum, since thrombin formation is a
calcium-dependent process, and anticoagulation of blood by calcium-
chelating agents (e.g. EDTA, citrate) inhibits thrombin production,




Ca^+ + Blood factor V
•Thrombin
Fibrinogen. •Fibrin
Figure 1.6 Production of thrombin during clotting of blood.
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serum is rich in serotonin, whereas plasma is relatively serotonin-
free. Release of serotonin from the dense granules occurs after the
platelet has responded in other ways, e.g. by a shape change, or
aggregation. In general, depending on the concentration and the
strength of the stimulating agent, one or more of the platelet
responses may be observed, but they always proceed in the order of:
1) shape change, 2) aggregation, and finally, 3) the release reaction
(for a review, see Holmsen, 1979). It is thought that in the
circulation in vivo, there are significant levels of released
("free") serotonin, which may contribute to various pathological
states (see Gershon and Tamir, 1985); whether "free" serotonin is of
biological importance, or whether it is an artifact of sample
collection and processing remains to be conclusively established.
1.5 Measurement of Serotonin
Several different techniques have been used to measure serotonin
in biological tissues and fluids, the most common of which are
1) bioassay, 2) fluorimetry, 3) radioenzymatic assay (REA), 4) high-
pressure liquid chromatography (HPLC), and 5) radioimmunoassay (RIA).
The approximate detection limits for these different assays are shown
in Table 1.1.
1.5.1 Bioassay
Bioassays for serotonin rely on the ability of serotonin to
produce a contractile response in smooth muscle cells (e.g. rat
colon; Feldberg and Toh, 1953), and the degree of contraction is










Table 1.1 Relative detection limit of different assays
for serotonin (after Smythe, 1979).
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sensitive method, but not specific, since other* compounds present in
the sample may also cause contraction of smooth muscle (e.g.
histamine). Consequently, this type of assay is now rarely used to
measure serotonin.
1.5.2 Fluorimetry
Serotonin fluoresces in strong acid with an emission at 550 nm
(Udenfriend, et al., 1955) and this property has been used to measure
serotonin concentration in e.g. brain tissue (Bogdanski, et al.,
1956). The sensitivity of this method can be improved by
derivatisation of serotonin with, for example, o-phthalaldehyde (OPT;
Maickel and Miller, 1966). Other 5-hydroxyindoles also fluoresce
however, and to improve the specificity of the method, serotonin
should be extracted, for example by means of a cation-exchange resin
(e.g. Amberlite CG-50), followed by washing and elution with acid or
buffer (Awapara, et al., 1960).
1.5.3 Radioenzymatie Assay
Saavedra, et_ al_., (1973) described the method of measuring
serotonin after derivatisation into [%]-melatonin. The
derivatisation as originally described was performed in two steps:
i) serotonin was N-acetylated by incubation with N-acetyltransferase
(purified from rat liver) and acetyl coenzyme A; this was followed by
ii) [^H]-methylation of the 5-hydroxy group of the N-acetylated
serotonin (N-acetylserotonin) using hydroxyindole-O-methyltransferase
(purified from bovine pineal) and [^H-methyll-S-adenosyl-L-methionine
as the substrate. The C^H]-melatonin produced in this way was
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extracted into toluene, and counted directly in a liquid
scintillation counter. The recovered count rate was directly
proportional to the original concentration of serotonin and
endogenous fl-acetylserotonin in the sample. Hence in order to
measure the serotonin concentration in tissues or fluids which
contain appreciable amounts of _N-acetylserotonin (e.g. the pineal
gland; Pang and Tang, 1983), the endogenous N-acetylserotonin
concentration must also be measured by including blanks which contain
no acetylating enzyme. The true value for serotonin is then
calculated by subtracting the unacetylated blank from the apparent
total concentration of serotonin (Saavedra, et_ al_., 1973).
A major disadvantage with this assay is that the enzyme required
for the acetylation step degrades rapidly, and also contains some
decarboxylase activity (Saavedra, 1977), which may result in
production of serotonin from endogenous 5HTP in the sample, leading
to falsely elevated results. To circumvent this problem, other
workers have used N-acetyltransferase purified from the fruit fly,
Drosophila melanogaster, since this enzyme is reported to be more
stable, and lacks decarboxylase activity (Walker, et al., 1983).
Alternatively, chemical N-acetylation using acetic anhydride has been
described (Hammel, et_ £l., 1978; Hindberg, 1984). Although the REA
is a sensitive technique (detection limit typically 100 fmol/tube;
Hammel, et_ al_., 1978), the tritiated substrate is expensive, the
methyltransferase enzyme is not readily available, and a multi-step
procedure followed by liquid scintillation counting precludes
throughput of large numbers of samples.
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1.5.4 High-pressure Liquid Chromatography
The basic principle of reversed-phase HPLC is that a low-volume
sample of analyte (5-500 pi) is injected into a stream of a carrier
liquid (mobile phase) which is being pumped under high-pressure (1-
4,000 psi) and at a constant flow rate through a steel column packed
with silica particles (stationary phase). Covalently linked to
these particles are hydrophobic aliphatic carbon chains, usually Cg
or Ci0 in length, and the greater the length of the carbon chain, the
greater is the degree of hydrophobicity (Mefford, 1985). These
carbon chains will interact with analytes dissolved in the mobile
phase, the extent of interaction depending on hydrophobic strength of
the analyte molecule. This is an intinsic property of the analyte,
and different molecular species are thus retained to different
degrees, i.e. have different characteristic retention times.
In reversed-phase chromatography, polar (hydrophilic) compounds
elute from the column fastest, and non-polar (hydrophobic) compounds
are retained longer. The separation can be made more selective by
use of an ion-pairing agent (Horvath, et_ al_., 1977), an amphipathic
compound (e.g. octane-1-sulphonic acid) with a hydrophobic "head",
and hydrophilic electrically charged "tail" (octane-1-sulphonic acid
has an overall negative charge when ionised). The "head" of the
molecule interacts with the C-jg groups bonded to the silica, leaving
the charged "tail" free to interact with compounds dissolved in the
mobile phase. The addition of octane-1-sulphonic acid therefore
effectively creates a cation-exchange column, which retards the
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elution of hydrophilic cations (e.g. serotonin, which has a
positively charged amino group at and below physiological pH (Sakurai
and Ishimitsu, 1975)) and thereby increases their retention time.
After the compound of interest have been separated by the
chromatographic column, they must be detected as they elute. The
fact that serotonin can readily be oxidised (see Garattini and
Valzelli, 1965) is utilised in the electrochemical detector (ECD): as
the serotonin molecules elute from the column, they flow through a
cell across which a fixed voltage is continuously being applied.
The potential difference causes electrons to be removed from the
serotonin molecules, changing them to quinone-imine structures
(Mefford, 1981), and the resulting flow of electrons per unit time
(i.e. current) is directly proportional to the number of serotonin
molecules passing through the cell. This current is amplified and
recorded as a peak, the area and height of which is proportional to
the mass of oxidised analyte. Since different compounds oxidise to
varying extents at different applied potentials, this can be used to
increase post-separation selectivity. Furthermore, comparison of
the oxidation profiles obtained by injection of a fixed mass of
standard compounds or unknown material at different applied
potentials under otherwise fixed chromatographic conditions
(oxidative voltammetry) can be used to further identify unknown peaks
(see also section 3.2.4).
After standardising the HPLC-ECD system with a known mass of
serotonin, unknowns can be injected and concentrations calculated
from simple comparision of peak heights or areas. The former is
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more commonly used, as the height can be measured directly; the
latter method necessitates the inclusion of an integrator into the
HPLC system, increasing the capital outlay.
In summary, HPLC-ECD can be used to identify and quantitate an
unknown peak by comparision, with a pure standard, of retention
times, peak heights for a constant injected mass at different applied
voltages (oxidative voltammetry), and co-elution of the unknown and
standard peaks on co-injection.
1.5.5 Radioimmunoassay
The underlying principle of a competitive RIA is that antibodies
raised against an analyte will bind that analyte, or a radioactive
derivative (i.e. tracer). This tracer will compete with the
unlabelled ("cold") analyte for the available antibody binding sites,
and consequently will be displaced from the antibody in a dose-
dependent manner, by increasing concentrations of "cold" analyte
(assuming a fixed mass of tracer, and fixed concentration of antibody
are present). The proportion of bound or unbound (free) tracer to
the total amount of tracer added is constant for a given mass of cold
analyte under identical experimental conditions. At equilibrium,
the relationship obeys the law of mass action (Ekins, 197*0:
k1
Ag + Ab Ag.Ab
k2
where Ag is the analyte, Ab the antibody, and Ag.Ab the
analyte/antibody complex (it is assumed that the tracer behaves in a
similar manner to the native analyte). The forward reaction rate
(association rate) is k-j, and the backward reaction (dissociation
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rate) is k^. The affinity constant of the reaction (Ka) is given by
the ratio of to kj; thus the greater the association rate, the
greater the affinity constant, i.e. the greater the avidity of the
antibody. The dissociation constant (K^) is the ratio of k2 to k-|,
i.e. the reciprocal of Ka. The displacement of bound tracer
resulting from the incubation of unknown samples of analyte with a
fixed mass of tracer and antibody is compared with that given by
several standard masses of pure analyte under the same conditions,
hence the mass of analyte in the unknown can be calculated. Thus
for an RIA system there are four basic requirements:
i) an antibody raised against the compound to be studied
which has a high specificity and avidity for (i.e. binds
strongly) the analyte,
ii) a tracer of high specific activity which can be bound by the
antibody, but displaced by cold analyte,
iii) a pure standard analyte, and
iv) a means of separating the bound tracer from the free without
perturbing the established equilibrium.
1.5.5.1 Production of Antibody Containing Plasma or Serum
Immunisation of experimental animals with serotonin itself
will not evoke an immune response, since i) serotonin is present in
the blood of the animal as an endogenous substance, and therefore
will not be seen as "foreign" by the host's immune system, and
ii) it is too small (molecular weight 176) to elicit an immune
response, the smallest immunogens having molecular weights >1000.
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These two problems are classically solved by conjugation of several
molecules of the analyte to a large carrier protein molecule from an
animal species different to that used for raising the antibodies (for
a review, see Erlanger, 1980). This conjugation effectively
increases the size of the analyte (or hapten, as the conjugated form
of the analyte is termed) and also renders it "foreign"; antibodies
will be directed against antigenic regions (epitopes) of the
conjugate, some of which will include the hapten-protein complexes
and the bridge structures linking the two molecules. Antibodies
directed against these epitopes retain a degree of avidity for the
unconjugated analyte, and it is this property which enables these
antibodies to be used for immunoassay.
Antibodies to serotonin for RIA were raised some fourteen years
ago by Peskar and Spector (1973). These workers conjugated
serotonin through the 6 position of the indole ring by diazotisation
of D,L-£-aminophenylalanine conjugated to bovine serum albumin, and
used rabbits for immunisation. The antibodies were harvested in
platelet-poor plasma (PPP), since rabbit platelets have a high
serotonin content (Garattini and Valzelli, 1965), most of which is
released from platelets during clotting, and would otherwise
interfere in the assay by saturation of the antibody binding sites.
Even after taking such precautions, the antibodies obtained from PPP
could only be used at a dilution of 1/50 (this gave 30j binding of
total added tracer), compared with 1/10 for serum. The antibodies
were also found to cross-react strongly (93%) with 5-methoxy-
tryptamine (5MT).
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Other groups (Kellum and Jaffe, 1976, Engbaek and Voldby, 1982)
used the same methodology for the preparation of the immunogen, and
collected the antibodies from rabbits either as PPP (Kellum and
Jaffe, 1976) or serum, which was then dialysed against activated
charcoal to remove endogenous serotonin prior to use (Engbaek and
Voldby, 1982). Again, the working dilutions of "antiserum" used
were low (<1/500), and there was a high cross-reaction with 5MT
(>25$). However, since the levels of 5MT in plasma are normally low
relative to platelet serotonin (Franzen and Gross, 1965), this cross-
reaction may only interfer with the assay significantly when
measuring non-platelet-bound serotonin. The tracer used by all the
above groups was tritiated serotonin.
A different approach was used by Delaage and Puizillout in 1981
(with later modification (Geffard, et_ al., 1982)). It had already
been demonstrated that antibodies raised against cyclic adenosine
monophosphate (cAMP) using a 2'-£-succinyl-cAMP-serum albumin
conjugate had greater avidity for 2'-O-succinyl-cAMP than for cAMP
itself (Cailla, et_ a2., 1973). Fransden and Krishna (1976) later
showed that the 2'-O-succinylation step could be replaced by 2'-0-
acetylation for cAMP. This principle of chemically modifying the
analyte to resemble the original immunogen more closely (Figure 1.7)
was used by Delaage and Puizillout in their RIA for serotonin: these
workers raised antibodies to the N-succinamyl derivative of serotonin
conjugated to human serum albumin (HSA), and samples/standards were
succinylated at the 5-hydroxy group and N-terminal by treatment with
succinic anhydride. Prior to assay, the 5-0-succinyl group was
-22-
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Figure 1.7 Immunogen, tracer and modified analyte as used in the
serotonin RIA of Delaage and Puizillout (1981).
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hydrolysed back to a hydroxy group by brief exposure to alkali, since
the disuccinyl form would be expected to be bound less well by the
antibody than the N-succinamyl derivative (Cailla, et al., 1973).
In the modified assay (Geffard, et al., 1982) antibodies were raised
against 5-methoxy-N-succinamyltryptamine-HSA, and the samples of
serotonin were chemically acetylated and methylated to 5-methoxy-N-
acetyltryptamine (melatonin) prior to assay. Since the 5-hydroxy
group is methylated, it is protected from acetylation, and
consequently no alkali hydrolysis step is required. This assay
required an organic extraction step, but did illustrate that the
N-acetyl derivative of serotonin could be used instead of the
N-succinamyl form to displace tracer bound to the antibody. In both
these acylation assays, the working dilution of antibody was
>1/10,000, and an [^^I]-tracer was used. The antibody was
collected as serum, since unmodified serotonin was ineffective in
displacing the tracer, and therefore need not be removed.
1.5.5.2 Tracers Used in Serotonin Radioimmunoassays
Tritiated serotonin (Figure 1.8) has been used extensively as
a tracer in serotonin RIAs (Peskar and Spector, 1973; Kellum and
Jaffe, 1976; Engbaek and Voldby, 1982). This /3-emitting nuclide is
chosen in preference to due to its higher specific activity (29
14
Ci/mmol compared with 0.062 Ci/mmol respectively for the C form),
i.e. the count rate of tritium is approximately 500 times that of
^C, mol/mol. Pure (>95$) tritiated serotonin is readily available
commercially, and, due to the longer half-life (12.3 years compared
















* = site of substitution
Figure 1.8 Radioactive derivatives of serotonin.
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the [ ^^I]-labelled derivative of serotonin, but the latter has a
higher specific activity (and therefore count rate) compared with
the tritiated tracer (2,200 Ci/mmol, and 29 Ci/mmol respectively,
assuming 100# isotopic abundance and one radioactive atom per
12Rmolecule). Furthermore, JI tracers may have variable effects on
assay parameters, but careful attention to the chemistry of the
tracer and assay design can often lead to enhanced performance over
that available from tracers (Corrie and Hunter, 1981).
1 ?5
The gamma emissions from the decay of can be detected
directly (i.e. without sample pre-treatment), unlike /3 -emitting
tracers, which require an addition of liquid scintillant, which is
time consuming, costly, and may introduce further errors into the
assay. A y-emmitting tracer is therefore highly desirable for an
assay intended for routine use, with a throughput of large numbers of
samples.
Unlike tritium or ^C, ^^1 cannot be substituted for an existing
stable atom in most biological molecules, the exception being
the thyroid hormones, where iodine is an intrinsic component of the
125
hormone. Consequently, a method of coupling JI to the analyte
must be found. With large molecules (e.g. angiotensin II, All),
125
yI can be substituted for a hydrogen in tyrosine, histamine, or
tyramine groups with little loss (e.g. 25#) in biological activity,
as has been demonstrated by specific binding of [^-'ij-AII to
cellular All receptors (Lin and Goodfriend, 1970). Smaller
molecules which do not contain any of these groups can be conjugated
to histamine, tyramine, or their derivatives in a manner similar to
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the preparation of the immunogen, and then iodinated (e.g. Geffard,
et al., 1982). Alternatively, to minimise damage to the analyte by
the oxidising and reducing agents used during the iodination and
1 PS
avoid inclusion of the large atom in the analyte molecule with
subsequent loss of immunoreactivity, the histamine or tyramine
derivative can be iodinated and then conjugated to the analyte (Nars
and Hunter, 1973). Similarly, analytes containing free amino groups
can be iodinated by the elegant technique of Bolton and Hunter
(1972): these workers used IJ-succinimidyl-[ ^^I]-(3-iodo-4-
hydroxyphenyl)-propionate to specifically acylate amino groups in
proteins, but the technique is equally applicable to any compound
that contains a free amino group. In the serotonin RIAs which used
125 r125
JI-tracers, [ JI]-glycyl tyrosine was conjugated to either
N-succinamylserotonin (Delaage and Puizillout, 1981), or 5-methoxy-N-
succinamylserotonin (Geffard, et al., 1982). In the former method,
the glycyl tyrosine was iodinated prior to conjugation, which avoided
the destruction of the 5-hydroxyindole nucleus by the oxidising agent
(chloramine T) used to introduce "^I into the tyrosine ring. The
second method was a direct iodination of the tracer molecule, since
the methoxy group at the 5 position on the indole ring prevented
oxidation. The tracers prepared by both these methods are reported
to have high specific activities (approximately 2,000 Ci/mmol), and




Standard serotonin is usually prepared commercially as either
the creatinine sulphate, or the hydrochloride salt. The creatinine
sulphate salt is most widely used, since it is cheaper, and reputedly
more stable than the hydrochloride (Garattini and Valzelli, 1965).
The purity of commercially available serotonin is >99%.
1.5.5.4 Methods of Separation
Three methods of separating free tracer from the bound
fraction have been used in previous RIAs for serotonin:
1) precipitation with 50% saturated ammonium sulphate (Peskar and
Spector, (1973), Kellum and Jaffe, (1976)),
2) equilibrium dialysis (Delaage and Puizillout, (1981), Geffard,
et al_., (1982)), and
3) liquid-phase second-antibody precipitation (Engbaek and Voldby,
1982).
1. Ammonium Sulphate Precipitation
Precipitation by ammonium sulphate is based on the principle that
immunoglobulins have low solubilities, and will therefore precipitate
out at concentrations of precipitating reagents that should leave
other polypeptides in solution (Thorell and Larson, 1978). This
method is markedly affected by the protein concentration in the
plasma/serum sample, as the immunoglobulins contained therein will
also be precipitated, thus increasing the bulk of the pellet, and




As a method of separating free analyte from bound, equilibrium
dialysis is not widely used; indeed, it appears to be restricted to a
single research group (i.e. Delaage and Puizillout, 1981; Geffard, et_
al., 1982). Separation is achieved as follows: the incubation of
antibody, analyte, and tracer is carried out in a cuvette which is
bisected by a semi-permeable membrane, with all the reagents in
buffer on one side, and buffer only on the other. A membrane is
used with a pore size which will only allow the passage of tracer
which is not bound to the antibody; at equilibrium, equal aliquots
are removed from both sides of the cuvette and counted. The aliquot
from the side with all the reagents corresponds to the bound and free
fractions, whereas the aliquot from the buffer side is a measurement
of the free only; the relative ratios of bound to free ligand can
then be calculated. This system allows only small numbers of
samples to be assayed, which negates one of the fundamental
advantages of radioimmunoassay, namely the throughput of large
numbers of samples (Ratcliffe, 1974). Perhaps the only advantage of
equilibrium dialysis is that no centrifugation step is required, and
hence no significant perturbation of the equilibrium should occur.
3. Liquid-phase Second Antibody Separation
This separation system uses an antiserum ("second" antibody)
raised against antibodies from the same species in which the anti-
analyte antibodies (i.e. "first", or primary antibody) were raised
(Morgan and Lazarow, 1963). Generally, the second antibody is added
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to the pre-incubated first antibody/antigen/labelled antigen mixture,
followed by a period of further incubation and centrifugation of the
resulting immunoprecipitate, thus leaving the bound fraction of
tracer in the pellet, and the unbound, or free fraction in the
supernatant, which can easily be decanted or aspirated to waste.
Carrier serum from an animal (the same species as the first antibody)
which has not been immunised is added prior to the second antibody to
provide sufficient immunoreactive material to form a lattice which
can be centrifuged down (Hunter, 1978). The optimum concentrations
of first antibody, second antibody, and carrier serum which provide
maximal recovery of specifically bound tracer in the bound fraction
are determined by incubating a fixed dilution of first antibody with
varying dilutions of second antibody and carrier serum (Hunter and
Ganguli, 1971). Alternative methods of second antibody (also known
as double antibody) separation exist, e.g. where the first antibody,
carrier serum, and second antibody are pre-incubated to form a pre-
precipitate, which after washing to remove remaining free first
antibody, can be added directly to the analyte/tracer mixture (e.g.
Gray, et al., 1983). Addition of a single aliquot of a pre-
precipitate avoids inclusion of imprecision resulting from the
addition of first antibody, carrier serum, and second antibody as
single aliquots.
Charcoal separation, although not used previously in other RIAs
for serotonin, has been used successfully for other hapten RIAs (e.g
aldosterone; Al-Dujaili and Edwards, 1981). Unlike second antibody
separation, however, charcoal separation can be sensitive to time,
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temperature, pH and serum protein concentration (Ratcliffe, 1974;
Thorell and Larson, 1978; Binoux and Odell, 1973), and can sometimes
result in a significant misclassification of "free" vs. bound
radioligand.
1.6 Serotonin in Pathological Situations
Abnormal blood levels of serotonin have been described in many-
diseases including a) depression, b) migraine, c) essential
hypertension, and d) the carcinoid syndrome.
a) Depression. It has been suggested that the diminished levels of
serotonin and decreased uptake into platelets of patients with
depression (Tuomisto and Tukiainen, 1976) may indicate a defect in
neurotransmission. The similarity between platelets and
synaptosomes is reflected in the effectiveness of tricyclic
antidepressants as inhibitors of the active transport of serotonin
into platelets, and platelets therefore offer a practical way to
monitor the efficacy of such drugs (Tuomisto, 1976). Also, lithium,
which is used prophylactically in depression, has been shown to
normalise the uptake of serotonin into the platelets of depressed
patients iri vitro (Murphy, et_ al., 1969).
b) Migraine. Migraine sufferers are known to exhibit several
serotonin-associated disorders during, and for several hours after an
attack: the blood content of serotonin is reduced (e.g. Hilton and
Cumings, 1972), the platelets show an impaired ability to take up
serotonin when incubated in endogenous plasma, but not when incubated
in a plasma-free medium, or in plasma from a normal volunteer
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(Launay, et al., 1982; Pradalier and Launay, 1982). Furthermore,
the excretion of the serotonin metabolite 5HIAA increases during an
attack (Gawel, et_ al., 1979), and plasma prepared from migraineurs
during an attack markedly stimulates the release reaction of normal
platelets compared with plasma from the same patients outwith an
attack, or plasma from normal volunteers (Muck-Seler, et_ al., 1982).
Although it seems clear that serotonin and platelets are involved in
the pathology of migraine, much is unknown about the mechanisms which
result in the observed abnormalities of serotonin biochemistry and
platelet function. Hence clarification of the role of serotonin in
migraine may ultimately lead to better management of this disease.
c) Essential hypertension. Decreased levels of blood serotonin have
been reported in patients with essential hypertension, and the uptake
of serotonin into platelets from patients with essential hypertension
is also reduced (e.g. Bhargava, et al., 1979; Kamal, et al., 1984a).
Also, the release of [■%]-serotonin from platelets prepared from
patients with essential hypertension can be induced with lower
concentrations of thrombin compared with platelets taken from
normotensive controls (Valtier, et al., 1986). Bhargava, et al.
(1979) suggested that the impairment of platelet serotonin uptake in
patients with essential hypertension reflected a neural control
defect, which becomes expressed as an elevation of blood pressure.
However, it would seem that the overall view of platelet function in
patients with essential hypertension suggests enhanced platelet
activation in_ vivo, which would explain many of the reported effects
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(for a review, see De Clerck, 1986). It should be borne in mind
that some controversy still exists in this area, and some groups
(e.g. Ahtee, et al., 1974; Feltkamp, et_ al., 1984) have found no
differences in platelet serotonin content or platelet serotonin
uptake kinetics between patients with essential hypertension and
normal controls.
The effectiveness of the serotonin antagonist ketanserin in
lowering blood pressure in patients with essential hypertension (De
Cree, et_ al., 1981; Wenting, et al., 1984) suggests that serotonin
may be an important factor at least in the maintenance, if not the
development of the disease. Thus an understanding of the role of
serotonin in this disease may ultimately be important in establishing
better clinical management of these patients.
d) The carcinoid syndrome. This disease is possibly unique,
in that it is the only situation where measurement of blood levels of
serotonin, or urinary levels of the metabolite 5HIAA are used as part
of the clinical diagnosis (Gitlow, et al., 1972). In the carcinoid
syndrome, blood levels of serotonin are elevated (Pernow and
ft
Waldenstrom, 1957), and there is an increase in the urinary excretion
of the serotonin metabolite 5HIAA (Page, et al., 1955), due to
overproduction of serotonin by a tumour which synthesises serotonin
from dietary tryptophan, via 5HTP. Up to 60% of dietary tryptophan
can be metabolised in this way in the carcinoid syndrome, compared
with the normal convertion ratio of \% (Udenfriend, et al., 1956);
this in turn may lead to diseases associated with a deficiency of
dietary tryptophan, such as pellagra-type skin diseases (Zarafonetis,
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et al_., 1958), or mental disorders (Lehmann, 1966). The carcinoid
tumour which gives rise to the syndrome typically occurs in the small
intestine, and derives from the enterochromaffin cells of the gut
(for a review, see Grahame-Smith, 1977).
A patient with the carcinoid syndrome usually has the clinical
features of facial flushing, breathlessness, diarrhoea, and heart
lesions (Thorsen, 1958). These symptoms only present when either
the primary tumour is in the liver and drains directly into the
bloodstream, or if liver metastases are present, since otherwise the
active compounds secreted by the tumour (e.g. serotonin or
kallikrein) are inactivated by a normal liver (see Grahame-Smith,
1977). It seems likely that the elevated circulating levels of
serotonin present in the carcinoid syndrome may cause the diarrhoea,
since treatment with serotonin antagonists (e.g. methysergide or
ketanserin; Peart and Robertson, 1961; Ahlman, et al., 1984) or
an inhibitor of serotonin synthesis (i.e. PCPA; Engelman, et_ al.,
1967) have some beneficial effect in the loss of water and
electrolytes. The high blood levels of serotonin may also be
responsible for the cardiac lesions, since these usually occur on the
side of the heart exposed to the highest concentrations of serotonin
(i.e. the right side), and the left side is protected to some extent
by metabolism of serotonin during passage of the blood through the
lungs (Gillis, et_ al., 1979).
In summary, although serotonin was characterised nearly half a
century ago, very little is known about its role in physiology or
pathophysiology. This may be attributed partly to the intrinsic
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instability of the molecule, and also partly due to the lack of
assays suitable for screening studies, or for throughput of large
numbers of experimental samples. The aim of this thesis, therefore,
was to develop and validate assays for serotonin, and show that these
assays could be applied to the study of serotonin in various
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Polypropylene syringe (1 ml)
Scintran "Cocktail T"
(liquid scintillant)
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2.1.8 Assay Separation Systems
Ammonium sulphate (Grade I)
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M6000A solvent delivery system
U6K injector unit
LC-4A amperometric detector
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Glass chromatography tank
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Development of Assay Methods for Serotonin
3.1 Introduction
As outlined in the general introduction, serotonin can be
measured by high-pressure liquid chromatography with electrochemical
detection (HPLC-ECD), radioenzymatic assay (REA), or radioimmunoassay
(RIA); HPLC-ECD is currently the most common method in use, having
been applied to a wide range of biological materials, including whole
blood (Korpi, 1984), serum (Sasa, et al., 1978), plasma (Tagari, et_
al., 1984), cerebrospinal fluid (Petrucelli, et_ al_., 1982), brain
tissue (Falkowski and Wei, 1981), platelets (Fujimori, et_ al_., 1982)
and adrenals (Verhofstad and Jonsson, 1983). Many published methods
exist for the measurement of serotonin by HPLC, but most are similar
with respect to the chromatographic and detection systems used.
Several radioimmunoassay (RIA) methods have been published, but
only one was validated against an established reference method
(Kellum and Jaffe, 1976); this assay suffered from two major
disadvantages: firstly, only a low dilution of antibody could be used
(<1/500), and secondly, tritiated serotonin was used as the tracer.
In this thesis, an HPLC-ECD method was established, and used
a) during the development and b) for the validation of an improved
RIA technique for serotonin.
3.2 Development and Validation of an HPLC-ECD assay for Serotonin
3.2.1 Chromatographic Conditions for HPLC-ECD
The HPLC-ECD system used in this thesis was optimised to
separate (in order of elution) 5-hydroxytryptophan, 5-hydroxy-
indoleacetic acid, N-acetylserotonin, serotonin, and -methyl-
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serotonin. Several basio experiments were carried out to
validate the HPLC-ECD system:
a) elution profile of freshly supplied radioactive serotonin,
b) detector response to a range of analyte concentrations with
constant chromatographic conditions, and
c) detector response to fixed masses of different analytes, at
different applied potentials, under otherwise constant
chromatographic conditions.
The chromatographic conditions used were (unless otherwise stated)
as follows: the mobile phase (pH 4.8) consisted of sodium di-hydrogen
phosphate (5.4 g/1), octane-1-sulphonic acid (60-75 mg/1), EDTA (380
mg/1), methanol (15-20$ v/v), and water (85-80$ v/v). Prior to use,
the mobile phase was filtered under reduced pressure through a
0.22 pm Durapore filter. Chromatographic columns used were
stainless steel packed with octadecyl silica, and were either 30 cm x
3.9 mm with 10 pm particle size, or 10 cm x 3.9 mm with 5 pm particle
size. The analytical column was protected by a pre-column of
stainless steel (2 cm x 3.9 mm) packed with 37-50 pm diameter
octadecyl silica. Analysis was performed at room temperature.
Unless otherwise stated, the electrochemical detector was set at an
applied potential of +0.60 V, with a sensitivity of 5 nA full scale
deflection. The analytical electrode was polished glassy carbon,
and the reference electrode was silver/silver chloride. Flow rate
was 0.5-2.0 ml/min, and injection volumes were 10-1,000 pi, into a 2
ml sample loop. Stock standards were made up in a solution of
perchloric acid/cysteine, pH 1.8 (150 and 0.2 mmol/1 respectively),
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and stored in glass in the dark at 4°C. The concentration of each
standard was confirmed by UV analysis, using the formula:
A=£.c.l
where A is the absorbance, ^is the extinction coefficient
(1/mol.cm), c the concentration (mol/1), and 1 the path length (cm).
The standard was used if the UV concentration was within 5% of the
value calculated by weight. The extinction coefficient was taken to
be 5740 1/mol.cm for each 5-hydroxyindoleamine, at a wavelength of
approximately 275 nm, which was an absorption maximum for serotonin
(Figure 3.1).
Serotonin was found to be acceptably stable when stored as
described. When compared by HPLC-ECD analysis with a freshly
prepared solution of serotonin, a solution which had been prepared
and used over a period of nine months was found to contain 93.0% of
the original serotonin concentration. The separation given by the
system for a test mixture of (in order of elution) 5-hydroxy-
tryptophan, 5-hydroxyindoleacetic acid, N-acetylserotonin, serotonin,
and N_q-methylserotonin is shown in Figure 3.2. Each compound was
well resolved, and serotonin was separated from its immediate
precursor (5-hydroxytryptophan) and the major serotonin metabolite
(5-hydroxyindoleacetic acid).
3.2.2 Elution Profile of a Pure Radioactive Standard
Freshly supplied [side-chain %]-serotonin (quoted purity >95?)
was diluted 1/1,000 in a solution of perchloric acid/cysteine and an
















Figure 3.1 Ultra-violet absorption spectrum of serotonin creatinine










Figure 3.2 Typical elution profile of serotonin and related
indoleamines obtained using the HPLC-ECD system a3
described in the text:
1 = 5-hydroxytryptophan (5HTP)
2 = 5-hydroxyindoleacetic acid (5HIAA)
3 = N-aeetylserotonin
4 = serotonin
5 = Noj-methylserotonin (internal standard).
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solution of standard serotonin in perchloric acid/cysteine (1 pmol/1).
After passing through the detector, fractions (1 ml) of the eluate
from the column were collected every minute into polypropylene liquid
scintillation vials. Total counts (in duplicate) consisted of
mobile phase (1 ml) and tracer (50 pi); duplicate background samples
were mobile phase only (1 ml). After the final fraction had been
collected, liquid scintillant (10 ml) was added to each vial, the
vials were capped, shaken vigorously for 30 s and then counted. The
percentage radioactivity in each fraction was calculated as follows:
[Sample - background] x 100
[Total - background]
A typical elution profile of [%]-serotonin from the HPLC-ECD is
shown in Figure 3.3. As can be seen in comparison with the trace
from the HPLC-ECD recorder, the peak of radioactivity was isographic
with a peak of electrochemically active material eluting from the
column.
3.2.3 Detector Response to Different Masses of Serotonin
A solution of standard serotonin was made up in acid/cysteine,
and diluted to give a range of concentrations from 16 nmol/1 to
50,000 nmol/1, in steps of five-fold increases in concentration.
These solutions were stored at 4°C, and aliquots (50 pi) injected
into the HPLC, each concentration being analysed three times. To
avoid injection carry-over, the series of solutions was assayed





















Figure 3.3 Elution profile of radioactivity from a) an injection
of [^H]-serotonin compared with b) the HPLC-ECD trace of
a standard, non-radioactive solution.
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concentrated. The sensitivity of the detector was initially 1 nA
full scale, but was adjusted when necessary to keep peaks within the
range of the chart recorder.
For calculation of results, peak heights (mm) were measured
directly from the chart with a ruler, and the heights expressed
relative to a sensitivity of 1 nA full-scale deflection. The
detector response (as measured by peak height) to increasing
serotonin concentration (Figure 3.4) was linear over the range tested
(16-50,000 nmol/1), which is much greater than the range expected in
most samples.
3.2.4 Detector Response to Different 5-Hydroxyindoleamine Derivatives
at Different Applied Potentials
A mixture of 5-hydroxytryptophan, 5-hydroxyindoleacetic acid,
N-acetylserotonin, serotonin, and Ny-methylserotonin in acid/cysteine
was analysed by HPLC-ECD with the detector set at different oxidation
potentials. Flow rate was 1 ml/min, sensitivity was 5 nA full-scale
deflection, and the volume injected was 25 pi each time. Three
separate injections of the mixture were made at an initial applied
voltage of +0.70 V, and the mean peak heights for each compound at
this potential were assigned the value of 100?. The potential was
decreased by 0.05 V prior to each subsequent injection (25 pi) of the
mixture, which was stored at 4°C between injections. At the end of
the experiment, the potential was returned to +0.70 V, and an
injection of the mixture made, to confirm that the observed decreases

















Figure 3.4 Detector response (as measured by peak height) to
injection of different masses of standard serotonin;
mean value + SD of triplicate injections.
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during the course of the experiment. Peak heights were measured,
and expressed as percentages of the original injections at +0.70 V.
Oxidative voltammograms were constructed by plotting applied
potential vs_. percentage peak height for each compound.
The response of the detector to different indoleamines at
different applied potentials is shown in Figure 3.5. All the tested
indoleamines gave an oxidation profile different to that obtained
with standard serotonin, indicating that this technique may be used
to confirm the identity of sample peaks eluting from the HPLC-ECD.
3.2.5 Preparation of Human Platelet-rich and Platelet-poor Plasma
(PHP and PPP) for Serotonin Assays
Whole blood was taken from the antecubital vein (after applying
a tourniquet) using a 19 gauge needle, and added to the anti¬
coagulant, which was acid/citrate/dextrose, ACD, (citric acid (8
g/1), trisodium citrate (22 g/1), glucose (20 g/1) in 10 ml plain
polystyrene tubes; 9 vol blood:1 vol anticoagulant). The citrated
whole blood was then used to prepare either citrated PRP or PPP:
a) PRP. The blood was centrifuged immediately at room
temperature for 10 min at 121 x g, and the upper three-quarters
of the supernatant (PRP) harvested with a disposable transfer
pipette. An aliquot (500 |il) was added to a standard potassium EDTA
tube (5 ml) and sent to the Haematology Department, Western General
Hospital, for platelet counts; the remainder was stored frozen at
-20°C.
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Figure 3-5 Detector response to different indoleamines at different
applied oxidation potentials:
• = 5-hydroxytryptophan (5HTP)
0 = 5-hydroxyindoleacetic acid (5HIAA)
* = N-acetylserotonin
X = serotonin
A = Npp-methylserotonin (internal standard).
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b) PPP. The blood was oentrifuged immediately at 4°C for 1 h at
1,720 x g, and to avoid inclusion of platelets trapped in the floating
lipid layer or from the plasma/red cell interface, the middle third
of the supernatant (PPP) was removed and stored frozen at -20°C.
For normal male subjects (n=12), mean PRP platelet count (_+ SD)
was 480.3 _+ 150.2 x 10^/1 (Table 3.1). For PRP prepared from the
same individual (male) over a period of several months, the platelet
counts were reproducible (mean _+ SD, 437.9 _+ 55.5 x 10^/1, n=8).
Mean percentage contamination by white blood cells and red blood
cells was 0.1% and 6.2% for a given individual, and 0.2% and 6.2%
between volunteers respectively (calculated as a percentage of the
mean number of platelets). The corresponding values for white and
red cell contamination calculated as a percentage of the mean normal
whole blood ranges were 6.7% and 0.5% for a given individual, and
10.7% and 0.5% between volunteers respectively.
3.2.6 Preparation of Rat Serum for HPLC-ECD Serotonin Assay
Two methods were used to prepare rat serum:
a) Neat serum.
Whole blood (1-5 ml) was obtained from ether-anaesthetised rats by
cardiac puncture using a 19 gauge needle and dispensed into a plain
polystyrene tube (10 ml). The blood was allowed to clot at 4°C for
2-4 h, before being centrifuged at 1,720 x g for 1 h at 4°C, the















































Table 3.1 PRP parameters compared with normal whole
blood values in normal males.
MPV = mean platelet volume
WBC = white blood cell count
RBC = red blood cell count
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b) Diluted serum.
Whole blood (100 pi) was either collected as above, or via an
indwelling arterial cannula from conscious rats. The blood was
added to a saline solution (900 pi) which contained thrombin
(1 unit), chlorimipramine (1 nmol), and pargyline (10 nmol). The
diluted sample was mixed by inversion, and left to clot for 2-4 hr at
4°C, before centrifugation for 30 min at 20,000 x g and 4°C. The
supernatant was frozen at -20°C prior to assay.
3.2.7 Acid Deproteinisation of PRP/Serum Samples for HPLC-ECD Assay
3.2.7.1 Purification of [^H]-Serotonin for Recovery
Although the tritiated tracer as received from Amersham was
usually >95$ pure, once the vial had been opened, the purity (as
measured by HPLC-ECD analysis) rapidly decreased over a period of
weeks (Figure 3.6). Thus it was necessary to re-purify the tracer
by use of Amberlite ion-exchange resin. Amberlite CG-50 (0.15 g)
was prepared by packing as a slurry (in 0.1 mol/1 hydrochloric acid)
into a 1 ml polypropylene syringe, the exit being blocked by a glass
wool plug. The column was washed with 0.1 mol/1 phosphate:1 mmol/1
EDTA buffer (10-15 ml), pH 7, until the eluate was neutral, followed
by distilled water (15 ml) until the pH of the eluate was constant
(pH 5-6). Tritiated serotonin (10 pi; 10 pCi) was diluted in 0.1
mol/1 pH 5 sodium acetate buffer (2 ml), applied to the column, and
allowed to drain through; this was followed by a water wash (10 ml).
The eluting buffer (0.2 mol/1 sodium acetate, pH 4) was preceded by































Figure 3.6 Decrease in purity of [^H]-serotonin
tracer as determined by HPLC analysis
at intervals of a) 4 , b) 8, c) 12,
and d) 16 weeks after opening the sealed
vial. Value is % injected radioactivity
recovered in the serotonin peak.
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(10 ml). The eluate was collected in fractions (1 ml) and aliquots
(100 pi) used for scintillation counting, and HPLC-ECD analysis.
An elution profile of tritiated serotonin from the Amberlite is
shown in Figure 3.7. Analysis of fractions 27-28 by HPLC-ECD from
four experiments showed that the tracer was 94 +_ 1.6$ pure (mean +_
SD; n = 4j immediately after purification.
3-2.7.2 Recovery of [%] Serotonin From Plasma After Acid
Deproteinisation as an Internal Standard for Serotonin
Freshly purified C^H]-serotonin in assay buffer (50 pi;
30,000 dpm) was added to prp (400 pi), vortexed, and left to
equilibrate (15 min at room temperature) before being deproteinised:
an aliquot (50 pi) of perchloric acid/cysteine (1.5 mol/1 and 2.0
mmol/1 respectively) was added to the sample (450 pi) in a conical
polypropylene microcentrifuge tube (1.5 ml). The tube was vortexed,
left for 15 min at 4°C, and then centrifuged at 10,000 x g for 15 min
at 4°C. Duplicate aliquots (2 x 50 pi) of the protein-free
supernatant were then removed for liquid scintillation counting.
Totals consisted of aliquots (50 pi) taken from plasma which had been
deproteinised and then spiked with purified tracer at the same
dilution as for the recovery samples. Backgrounds were
deproteinised platelet-poor plasma (50 pi) only.
Recovery of purified [%]-serotonin after deproteinisation from
PRP was (mean _+ SD) 92.0 _+ 2.9$ for samples of the same plasma (n = 7),
and 91.5 _+ 1.8$ for plasma from different normal volunteers (n=7).
There was no significant difference between these two values as
calculated by the Student's t_ test.
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FRACTION NUMBER
Figure 3.7 Elution profile of [^H]-serotonin
from the Amberlite column.
1 = 0.1 mol/1 acetate, pH 4.5
2 = 0.2 mol/1 acetate, pH 4.0
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In order to see if significant degradation of serotonin would
occur in human plasma, a sample of PRP (400 pi) was spiked with
[^H]-serotonin, left to equilibrate at room temperature for 15 min,
then incubated for 1 h at 37°C. The sample was then frozen and
thawed to disrupt the platelets, and analysed by HPLC-ECD. The
elution profile (Figure 3.8) showed that 99.7 % of the original
[%1-serotonin (tracer co-injected with deproteinised PRP) was still
present. No distinct peak corresponding to 5HIAA was seen. Thus
it was concluded that no appreciable degradation of PRP serotonin
should occur during normal sample processing, which is in good
agreement with previous work (Born and Gillson, 1959).
3.2.7.3 Recovery of -Methylserotonin from Human Plasma and Rat
Serum After Acid Deproteinisation as an Internal Standard
for Serotonin
Human PRP or rat serum (400 pi) was spiked with 1.25 nmol
N_W-methylserotonin diluted in saline (50 pi) and was deproteinised
as described above. Aliquots (25 pi) of supernatant were assayed
for recovery by HPLC, which had previously been calibrated with
N_o>-methylserotonin. This internal standard was used for all
subsequent analytical runs with the HPLC-ECD.
Recovery of N_w -methylserotonin from samples of the same human
plasma was (mean +_ SD) 80.4 _+ 3-7% (n=7), and from different
plasmas, 83.3 +_ 7-9% (n=31). There was no significant difference
between these two figures (Student's t_ test), but they were both
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Figure 3.8 Effect of incubating human PRP at 37°C on the elution
profile of [^H]-serotonin from the HPLC-ECD:
a) PRP incubated for Ih at 37°C, freeze-thawed,
then deproteinised and co-injected with tracer
b) PRP spiked with [^Hj-serotonin, incubated for
1 h at 37 °C, freeze-thawed, then deproteinised
and injected
1 = position of 5HIAA peak, 2 = position of serotonin peak.
Figure in brackets = % of injected radioactivity
recovered in the serotonin peak.
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serotonin (p<0.001). Once deproteinised and stored at 4°C, the
serotonin in the PRP samples was stable for at least 6 h (Table 3.2).
A lower mean recovery of internal standard was seen with neat rat
serum when prepared directly from cardiac puncture (mean +_ SD, 71-3 _+
18.055, n=84); also, many of the samples were distinctly haemolysed.
The mean recovery of HPLC-ECD internal standard from rat serum
prepared from rat blood collected into the "coagulant" mixture was
(mean +_ SD) 89.1 _+ 19-0% (n=73). This was significantly higher than
the recovery from neat serum (p<0.005, Student's t_ test). Serotonin
was acceptably stable in these samples: diluted serum incubated in
triplicate at 37°C for up to two hours prior to HPLC-ECD analysis
showed no significant decrease in serotonin concentration (Table
3.3).
3.2.8 Oxidative Voltammograms of the Putative Serotonin Peak
from Human PHP and Rat Serum
PRP was prepared and deproteinised, and aliquots (25 pi)
analysed alternately with a standard solution (25 pi) of serotonin in
acid/cysteine (1 pmol serotonin/1), the applied potential being
decreased after each injection of standard, as described above
(3.2.4), to allow the construction of oxidative voltammograms. In a
separate experiment, rat serum was prepared and deproteinised, and
alternate injections (25 pi) made with a standard serotonin solution
in acid/cysteine (4 pmol serotonin/1) as described above for human
PRP.
The oxidative voltammograms for standard serotonin and human PRP are














Table 3-2 Stability of serotonin in
deproteinised PRP at 4°C.
Time at Serotonin Concentration p Value
37°C (mean _+ SD, (Student's
(min) nmol/1) t Test)
0 14,066 + 596 —
30 13,804 + 523 NS
60 14,980 + 232 NS
90 12,982 + 1381 NS
120 13,326 + 1538 NS
Table 3.3 Effect of incubating diluted rat serum at 37°C.
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Figure 3.9 Oxidative voltammogram for standard serotonin
and human PRP serotonin.
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identically to authentic serotonin under the same conditions for
oxidation. The retention times (mean +_ SD) of the standard
serotonin peak, and the putative PRP serotonin peak were 8.95 +_ 0.01
min and 8.86 +_ 0.31 min respectively (n=6). These values were not
significantly different when compared by Student's t_ test. On co-
injection of standard serotonin with human PRP, the height of the
resulting peak was 101.2% of the arithmetic sura of the two individual
peak heights.
The oxidative voltammograms constructed from the rat serum and
standard serotonin injections were superimposable (Figure 3.10).
The retention times (mean +_ SD) for six consecutive injections each
of deproteiriised rat serum and standard serotonin were not
significantly different (10.82 _+ 0.12 min, and 10.87 _+ 0.27 min
respectively, Student's t_ test). Furthermore, co-injection of a
standard serotonin solution and a deproteinised rat serum sample gave
a peak which was 97.5% of the arithmetic sum of the two individual
peak heights.
3.3 Development of a Radioimmunoassay for Serotonin
3.3.1 Synthesis of N-Succinamylserotonin and Immunogen
tJ-Succinamylserotonin was synthesised and conjugated to bovine
serum albumin by Dr. John Corrie, (MRC Clinical and Population
Cytogenetics Unit, Western General Hospital) using methods modified
from those of Delaage and Puizillout (1981): serotonin creatinine
sulphate (61 mg) and succinic anhydride (91 mg) were stirred under
nitrogen for 10 min with 0.68 mol/1 potassium hydroxide (2.16 ml).
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Figure 3-10 Oxidative voltammogram for standard serotonin
and rat serum serotonin.
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A solution of hydroxylamine hydrochloride (21 mg) in water (0.5 ml)
was added, followed by 0.68 mol/1 potassium hydroxide (1.55 ml), and
the solution was stirred for a further 5 min, then adjusted to pH 4
by addition of 1 mol/1 hydrochloric acid. The solution was rapidly
applied to a column of Amberlite XAD-2 (25 ml; previously freed of
UV-absorbing contaminants by exhaustive washing with ethanol) in
water, and the column was then washed with water (approximately 200
ml) until the eluate showed no UV absorption. The column was eluted
with ethanol (150 ml), and the yield of N-succinamylserotonin
determined by its UV absorption at 278 nm (£278 = 5,740 1/mol.cm).
The ethanolic solution was evaporated under reduced pressure, the
residue redissolved in water (10 ml), and lyophilised to leave the
product as a pale foam, which was either used directly for
conjugation to bovine serum albumin, or redissolved in dry dimethyl-
formamide (DMF) at 2.8 mg/ml. Aliquots of this solution were sealed
under nitrogen in glass ampoules to avoid oxidation and stored at
-20°C for use in the preparation of the radioiodinated tracer.
For the preparation of the immunogen, a solution of N-succinamyl¬
serotonin (38 mg) in dry dioxan (2.14 ml) was cooled to 10-12°C, and
treated with tri-n-butylamine (62 pi), and isobutyl chloroformate (15
pi). After 20 min this solution was added under nitrogen to an ice-
cold solution of bovine serum albumin (332 mg) in water (8.8 ml), 1
mol/1 sodium hydroxide (0.33 ml) and dioxan (5.7 ml). This solution
was stirred in an ice bath for 1 h, then treated with 0.25 mol/1
sodium phosphate, pH 6 (1.4 ml), and dialysed for 1 h against 0.05
mol/1 sodium phosphate, pH 6 (5 1). The dialysate was subjected to
-70-
gel filtration on Sephadex G-50 (40 x 3 cm), eluting with 0.05 mol/1
sodium phosphate, pH 6. The fraction eluted in the void volume was
analysed by UV spectroscopy and Lowry protein estimation, which
showed a conjugation ratio of 24 serotonin residues per protein
molecule. The eluate was lyophilised and the conjugate stored at
-20°C.
3-3.2 Production of Antisera
Initially, six guinea pigs (Western General Hospital Animal
Unit stock) were used, then later, four rabbits (New Zealand White):
the guinea pigs were injected with conjugate at either 4 sites sub¬
cutaneous ly, or 1 site intra-peritoneally, and for the rabbits,
immunisation was always at 4 sites sub-cutaneous ly. The dose was
100 pg/animal in each case, in 1:1 Freund's complete adjuvant:saline
for the primary, and in 1:1 Freund's incomplete adjuvant:saline for
the boosts. Boosts were given six weeks after the primary
immunisation, and thereafter at intervals of six weeks; bleeds were
taken ten days after boosting, the first bleed being taken after the
first boost. Blood was collected as heparinised plasma for the
early bleeds, centrifuged at 1,720 x g for 60 minutes at 4°C, and the
platelet-poor plasma harvested; serum was prepared from later bleeds.
The plasma or serum was stored neat, or in a 1/10 dilution in assay
buffer (0.1 mol/1 citric acid, 0.3 mol/1 sodium hydroxide, 1 mmol/1
EDTA, 0.1$ gelatine, final pH 6.2) at -20°C.
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3-3.3 Synthesis of Radioactive Tracers
3-3-3-1 Synthesis of a Succinylated [^H]-Serotonin Tracer
Tritiated serotonin (10 pi; 10 pCi) was diluted from an
Amersham stock into pH 7.4, 0.05 mol/1 phosphate buffer (10 ml). An
aliquot of this (1 ml) was added to succinic anhydride (5 mg) in a
small glass tube, vortexed to dissolve the anhydride, a volume of
triethylamine added (20 pi), and the tube vortexed again. The tube
was then incubated at 4°C overnight, and the putative tracer purified
by injecting a sample (750 pi) onto the HPLC-ECD (previously
calibrated with authentic N-succinamylserotonin), and the fractions
corresponding to the N-succinamylserotonin peak collected
(approximately 2 ml). The tracer was diluted before use in assay
buffer (0.1 mol/1 citric acid, 0.3 mol/1 sodium hydroxide, 1 mmol/1
EDTA, 0.1% gelatine, final pH 6.2).
A profile of tritiated material eluting from the HPLC-ECD is shown
before, and after succinylation (Figure 3.11). This tracer was used
for studying immunoreactivity of the early bleeds, prior to synthesis
of a gamma-emitting tracer.
3-3-3-2 Synthesis of a Gamma Emitting Tracer: Using N-Succinamyl-
12S
serotonin Conjugated to [ 3I]-Iodinated Glycyl Tyrosine
The procedure used was similar to that already described
(Delaage and Puizillout, 1981). All solutions were freshly prepared
on the day of the iodination. An aliquot (50 pi) of N-succinamyl
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Figure 3.11 Elution profile of [^H]-serotonin from the HPLC-ECD
system a) before and b) after succinylation.





and dispensed into a conical polypropylene microcentrifuge tube.
For activation of the N-succinamylserotonin prior to conjugation, a
solution (10 pi) of tri-n-butylamine in DMF (17 pi/ml) was added,
followed by a solution (10 pi) of isobutyl chloroformate diluted in
DMF (45 pl/8.5 ml). The tube was vortexed and incubated for 20 min
at 10-12°C. Glycyl tyrosine (476 ng) in 0.25 mol/1 pH 7.5 phosphate
buffer (10 pi) was added to a 1 mCi solution (10 pi) of Na[^^I]
(specific activity 1,650 - 2,157 Ci/mmol) and mixed. Chloramine T
(10 pg) dissolved in the same phosphate buffer (10 pi) was added to
1 PS
the [ 3I]-iodine/glycyl tyrosine solution, mixed, and left at room
temperature for 1 min. The reaction was stopped by the addition of
sodium metabisulphite (12 pg) in 0.05 mol/1 phosphate buffer, pH 7.5
(20 pi). An aliquot of activated N-succinamylserotonin solution (50
pi) was added to the [ ^-^I]-iodinated glycyl tyrosine, the solutions
mixed, and left at 4°C for 5 min. The reaction mixture was diluted
with 500 pi of the eluting buffer (0.1 mol/1 citric acid, 0.1 mol/1
sodium chloride, 3 mmol/1 ascorbic acid, final pH 6.2) before being
applied to a Sephadex G-25 column (49 x 1 cm). The buffer was
pumped through the column at 1 ml/min, and fractions (6 ml) collected
in plain polystyrene tubes (10 ml). Aliquots (10 pi) of the
fractions were counted in a multiwell gamma-counter to locate the
peaks. The immunoreactive fractions of a single peak (typically
fractions 25-30) were pooled, diluted 1+1 with assay buffer, and
stored at -20°C as aliquots (2 ml) in stoppered polystyrene tubes.
Each aliquot was thawed once only, after which it was stored in the
dark at 4°C and discarded after 1 week.
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The gamma-emitting material eluting from the Sephadex column after
the application of the iodination mixture shows two distinct peaks
(Figure 3.12). When an aliquot of pooled material from the later
eluting peak was incubated with excess antiserum, >90$ of the added
tracer was recovered in the bound fraction. Analysis of pooled
fractions from this peak showed that the specific activity was
2,011 Ci/mmol, and the yield of tracer was 28.3 +_ 8.5$ (mean +_ SD,
n=5). If the mass of tracer added was kept constant from assay to
assay, the tracer was usable for up to five months after iodination,
with no apparent loss in immunoreactivity. This method of
iodination was used to prepare all subsequent gamma-emitting tracers
for use in the studies described in this thesis.
3-3.3-3 Synthesis of a Gamma Emitting Tracers Conjugation of
Serotonin to N-Succinimidyl-[^-*1]-(3-iodo-4-hydroxyphenyl)-
propionate, (C^^I]-NSHPP, [^^I]-Bolton-Hunter Reagent)
The NSHPP ester was iodinated as previously described (Bolton
and Hunter, 1972), and extracted with toluene (200 pi) by vortexing
for 1 min. The organic layer was removed to a clean, glass
centrifuge tube, and the iodination tube given four toluene washes (4
x 200 pi), which were also added to the centrifuge tube. The toluene
was evaporated under vacuum, whilst gently warming the tube in a warm
water-bath. The residue was washed down to the tube tip with
toluene (200 pi), which was evaporated as before; this step was
repeated once more before the addition of serotonin (10 pi of 900
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Figure 3.12 Elution of gamma-emitting material from the




incubated at 0°C in an ice/water slurry for 30 min before the
addition of glycine (300 pi of 0.1 mol/1), after which the tube was
left a further 5 min. The putative tracer was extracted by
adding ethyl acetate (300 pi) and vortexing for 1 min, after which
the organic layer was removed, evaporated under reduced pressure, and
reconstituted in a smaller volume of ethyl acetate (50 pi). This
was spotted onto a silica TLC plate (200 x 200 x 0.25 mm), and
developed in ethyl acetatesmethanol (9:1). The plate was allowed to
dry in air, and the peaks located after a 30 min exposure to X-ray
film. The major peak was scraped off the plate into ethanol (5 ml)
in a glass tube (10 ml). After vortexing for 30 s and centrifuging
down the silica, an aliquot was taken for testing in an antibody
dilution curve, and the remainder stored at -20°C.
Three bands of radioactivity were obtained (Figure 3.13), with R^
0.09, 0.11, and 0.36. Only the major peak (R^. 0.36) was tested, but
less than 15$ of added activity was bound in the presence of excess
antibody, previously shown to bind approximately 90$ of tritiated
tracer. This tracer was not studied further.
3.3.4 Testing of Antisera
Varying dilutions of immune plasma/serum (or non-immune plasma
or serum for non-specific binding, NSB) were made in assay buffer,
and added (100 pi) to tubes containing buffer (200 pi) and a fixed
dilution of tracer (100 pi). The tubes were vortexed, and incubated
overnight at 4°C. Separation was by one of the following methods:
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Figure 3.13 Distribution of radioactivity on the TLC plate after
the purification of serotonin-[ ^-*I]-NHSPP.
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a) Ammonium Sulphate Precipitation
To each incubate (400 pi) was added a cold (4°C), saturated
solution of ammonium sulphate (400 pi), the tube vortexed, and left
at 4°C for 1 h. The tubes were centrifuged at 1,720 x g for 1 h at
4°C, the supernatant removed by aspiration, the pellet washed with
saturated ammonium sulphate (400 pi), then centrifuged for a further
1 h under the same conditions. The supernatant was aspirated, the
pellet redissolved in water (1 ml) and then decanted into
polypropylene scintillation vials, followed by scintillant (10 ml).
Each vial was vortexed (1 min) and counted. This separation system
was used only for the tritiated tracer.
b) Dextran Coated Charcoal (DCC)
DCC was prepared by suspending charcoal powder (1g) in a solution
of dextran T-70 (0.1g) in assay buffer (1 1). The stirred charcoal
solution (1 ml) was added cold (4°C) to each incubation tube (400
pi), and the tubes centrifuged immediately at 1,720 x g for 20 min at
4°C. For tritiated tracers, the supernatants (bound fraction) were
decanted directly into scintillation vials for counting, and for the
C125l] tracers, the supernatant was aspirated, and the charcoal
pellet (free fraction) counted. This system was only used to
monitor activity of early bleeds.
c) Second Antibody Precipitation
The ratio of first antibody:second antibody:non-immune serum was
optimised for both guinea pigs and rabbits as follows: incubates were
set up as normal for three concentrations of first antibody
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(approximately 1/1,000, 1/5,000, 1/15,000 final dilution in primary
incubate) and incubated for 4 h at room temperature. This was
followed by the addition of non-immune serum (100 pi) in the range
1/50-1/1,600 initial dilution in assay buffer, and then by the second
antibody solution (100 pi) in the range 1/5-1/160 initial dilution in
buffer; the tubes were vortexed, and incubated overnight at 4°C. An
assay buffer prewash (1 ml) was added cold (4°C), and the tubes
centrifuged at 1,720 x g for 20 minutes at 4°C. The supernatants
were aspirated and the pellets (bound fraction) were counted in a
multiwell gamma-counter.
All animals which were immunised gave sera or plasma which bound
tracer, and could be displaced by authentic N-acetylserotonin. No
difference was seen when blood was collected as either heparinised
PPP, or as serum (Figure 3.14). A typical antiserum dilution curve
is shown using either the tritiated tracer, or the gamma-emitting
tracer (Figure 3.15). Approximately 80-90$ of the tritiated N-
succinamylserotonin could be bound by an excess of antiserum, and
non-specific binding (NSB) was less than 5$. Using the gamma-
emitting tracer, specific binding was >90$, NSB was <5$.
The rise in titre over the period of immunisation is shown for one
of the rabbits, No. R16 (Figure 3.16). Results from an optimisation
of second antibody (Table 3.4) show that with these batches of
reagents, optimal precipitation of first antibody (1/28,000 final
dilution) was achieved using final dilutions of 1/240 for the second
antibody, and 1/4,800 for the non-immune carrier serum.
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Figure 3.14 Antibody-dilution curve constructed using either
heparinised plasma (• • ), or serum (+- - -+)
prepared simultaneously from a rabbit immunised
with the N-succinamylserotonin-BSA conjugate.
Points represent means of duplicate estimations.
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FINAL DILUTION FACTOR
0 0 - 250 fmol tracer/tube
+ + - 1 fmol tracer/tube
Figure 3.15 Antibody dilution curves constructed using the same
bleed of guinea pig plasma with either [%] (0 0)
or [ ■'I] (+ +) as the radioactive molecule.
Points represent means of duplicate estimations.
-82-
Figure 3.16 The rise in antibody titre in rabbit No. 16:







300 600 1,200 2,400 4,800 9,600
30 28.5 30.8 30.5 28.5 24.0 19.6
60 32.1 37.5 37.7 37.4 35.1 28.6
DARS final 120 4.7 39.4 42.8 44.6 42.0 33.5
dilution
factor 240 3.8 6.1 42.8 46.8 45.1 41.7
480 3.3 4.6 5.6 44.2 45.7 42.4
960 3.6 4.9 5.2 6.1 40.3 41.5
Table 3.4 Typical second-antibody optimisation assay
it total tracer added recovered in the bound
fraction)
NIBS = Non-immune rabbit serum
DARS = donkey anti-rabbit serum.
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3.3.5 Standards and Cross-reactants
Standard serotonin, tJ-aeetylserotonin, and putative cross-
reactants were prepared in acid/oysteine as for the HPLC, and stored
in the dark at 4°C. Concentrations were checked by UV absorption.
Standards for the preliminary RIA standard curves were prepared fresh
from N-acetylserotonin stock solution for each assay, in the range
1-1,000 nmol/1. A standard curve was set up by incubating the
standards (200 pi) with tracer (100 pi), and first antibody solution
(100 pi) at a dilution which was expected to give a zero standard
binding (Bq) of approximately 50$.
Figure 3.17 shows standard curves using authentic N-acetyl-
serotonin with guinea pig and rabbit antisera. One guinea pig serum
(animal 17, bleed 6, GP17B6) and finally one rabbit serum (animal 16,
bleed 4, R16B4) were selected on the basis of an acceptable titre
coupled with good sensitivity. Both animals gave similar curves,
with 50$ B/Bq being approximately 30 nmol/1, but the rabbit antiserum
was usable at a higher dilution than the guinea pig serum.
3-3.5.1 Effect of Tracer Mas3 on the Standard Curve
Standard curves using N-acetylserotonin with guinea pig
antiserum (GP17B6) were incubated with increasing masses of
1 PR
N-succinamylserotonin-[ 3I]-glycyl tyrosine (approximately 0.6, 3.6,
and 6.0 fmol/tube). Incubation and separation was by second
antibody as above.
Increasing the mass of tracer added to the incubates did not
result in a discernible shift or distortion of the standard curves
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N-ACETYLSEROTONIN CONCENTRATION (nmol/1)
Figure 3.17 Standard curves constructed using standard N-acetyl-
serotonin and either guinea pig (0 0; final
dilution 1/10,500) or rabbit (+— - —+; final dilution
1/28,000) antisera. Points represent means of
duplicate estimations; Bq = mean ■+ SD of triplicates.
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when plotted relative to the zero binding, Bq, (Figure 3.18),
although a drop in Bq was observed.
3.3.5.2 The Effect of pH on the Standard Curve
The effect of pH on standard curves with the guinea pig and
rabbit sera was investigated by diluting all reagents in citrate
buffers of differing pH values (4, 5, and 6.2). Incubation was as
above, and separation was by second antibody. Lowering the pH
markedly inhibited binding of tracer with the guinea pig antiserum
from 60% tracer bound at pH 6.2, to 6% at pH 4.0 (Figure 3.19a).
With the rabbit serum, there was a comparatively small drop, from 61%
at pH 6.2, to 53% at pH 4 (Figure 3.19b). In view of this, the
rabbit antiserum was used exclusively, so that any slight variations
in pH would have a minimal effect on the standard curve.
3.3.5.3 Effect on the Standard Curve of Adding Antisera Separately,
Pre-mixed, or as a Pre-precipitate
Standard curves were set up as described above using the
rabbit antiserum, except that the primary antiserum, non-immune rabbit
serum (NIRS), and donkey anti-rabbit serum (BARS), were added as:
a) individual aliquots of 100 pi each, after a 4 h pre-incubation
at room temperature with the primary antiserum,
b) as a single aliquot of 300 pi, which was freshly mixed, or
c) as a single aliquot of 300 pi, from a resuspended mixture of
the three sera (i.e. primary, NIRS, and DARS) which had been
incubated overnight at 4°C to form a precipitate.
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N-ACETYLSEROTONIN CONCENTRATION (nmol/1)
Figure 3-18 Effect of increasing tracer mass on the standard
curve using guinea pig antiserum. Points
represent means of duplicate estimations;
Bq = mean +_ SD of triplicates.
X X = 0.6 fmol tracer/tube (Bq = 64.9 + 1.5%)
0 0 = 3.6 " " " (B0 = 54.7 + 1.5%)
A- • -A = 6.0 " " » (B0 = 43.9 + 1.3%)
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N-ACETYLSEROTONIN CONCENTRATION (nmol/1)
Figure 3-19 Effect of pH on the standard curve using
a) guinea pig antiserum, or b) rabbit
antiserum. Bq = mean +_ SD of triplicate
estimations.
A A = PH 4
0 0 = pH 5
• • = pH 6.2
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The tubes and contents were incubated at 4°C overnight either (a)
after the addition of the NIRS and DARS, or (b and c) immediately
after the addition of the mixture of primary antiserum, NIRS, and
DARS; separation was as described above (3.3.4c).
There were no differences between the standard curves obtained
under any of these conditions (Figure 3.20), and thereafter the sera
were added as a single aliquot of a freshly prepared pre-mixture.
3.3.6 Acylation of Serotonin
3.3.6.1 Succinylation
In order to determine the appropriate amount of potassium
hydroxide (KOH) to add to the succinylation mixture so that the final
pH would be in the range 5-7, which would avoid oxidation of
serotonin, but still enable hydrolysis of the 5-0-succinyl moiety
(Means and Feeny, 1971), a fresh solution (500 pi) of serotonin (880
nmol/1) in 0.05 mol/1 pH 7.4 buffer was added to succinic anhydride
(20 and 30 mg) in glass tubes, and vortexed until the anhydride
dissolved. Increasing volumes (0-90 pi) of KOH (4 mol/1) were added
and the pH measured after vortexing. Initial results (Figure 3.21)
indicated that with 20 mg of succinic anhydride, approximately 50 pi
of 4 mol/1 KOH were required to take the reaction mixture to pH 6,
and so in a second experiment, a fresh solution of serotonin (440
pmol) in 0.05 mol/1 pH 7.4 buffer (500 pi) was added to succinic
anhydride (20 mg) in a glass tube, vortexed, and followed by the
addition of 50 pi of KOH (4 mol/1). The tube was incubated
overnight at 4°C, and analysed the following day. The yield of
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N-ACETYLSEROTONIN CONCENTRATION (nmol/1)
Figure 3.20 Effect of adding anti3era separately (• • ),
or as a pre-mix (0 0), or as a pre-
precipitate (3F»—*—3C). Bq = mean +_ SD
of triplicates.
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Figure 3.21 Effect of adding potassium hydroxide on the
final pH of succinylated serotonin:
§ = succinylation with 20 mg anhydride
0 = succinylation with 30 mg anhydride.
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N-succinamylserotonin as measured by HPLC, was 68.2%. There was no
remaining unmodified serotonin.
3.3.6.2 Acetylation by Acetic Anhydride
Serotonin (2.88 nmol) in protein-free assay buffer (500 pi)
was acetylated by adding triethylamine (10 pi) followed by acetic
anhydride (5 pi), and incubation at room temperature for 40 and 90
min. Analysis by HPLC with UV detection at 254 nm showed that under
these conditions, nearly all (91.150 of the serotonin was converted
into £,N_,-diacetylserotonin, with no reversion to the N-acetyl form,
even after 90 min at room temperature (Table 3.5).
3.3.6.3 Acetylation by N-Acetoxysuccinimide, (NAS)
NAS was prepared by the method of Treadway and Schultz
(1976). For acetylation, NAS was dissolved in methanol (127.6
pmol/ml), and an aliquot (20 pi) dried down under nitrogen in a glass
tube while warming gently (45°C). To this was added serotonin (2.88
nmol) in protein-free assay buffer (500 pi), the tube vortexed, and
incubated at room temperature. Analysis by HPLC-ECD of samples
withdrawn at varying times showed that a) the acetylation was
complete after 40 min, and b) the N-acetylserotonin produced was
stable for at least 3 h at room temperature (Figure 3.22). There
was virtually no (D,N_,-diacetyl-serotonin produced using NAS (<5.1$;
Table 3.5). Acetylation of 10 samples of serotonin by NAS as above
resulted in a recovery of 80.0 +_ 2.7$ (mean _+ SD) of the original




















Table 3.5 Production of 0,N-diacetylserotonin with acetic




Figure 3.22 Time course of N-acetylation of serotonin by
N-acetoxysuceinimide (NAS).
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3.3-6.4. Neutralisation of Deproteinised Plasma
PRP was deproteinised as described for the HPLC-ECD assay
(3.2.7) except no internal standard for recovery was used. Aliquots
(600 p,l) of the deproteinised PRP were dispensed into plain
polystyrene tubes (10 ml), potassium hydroxide (0, 37.5, 75, 93.75,
or 112.5 pmol) in water (150 jj.1 ) added, the tubes vortexed, and the
pH measured.
The rise in pH which occurred after the addition of the potassium
hydroxide is shown in Figure 3.23. The final pH was between 6 and
7.5 when 93.75 and 112.5 pmol respectively of KOH were added.
3.3.6.5 Acetylation by HAS after Deproteinisation and Neutralisation
PPP was spiked with serotonin (4 prnol/1 final concentration),
deproteinised as above (3.3.6.4), and aliquots (200 p,l) of the
supernatant added to NAS (1.59 |omol) dried down under nitrogen in
glass tubes as above from a fresh methanolic stock (31.9 pmol/ml).
The tubes were vortexed until the NAS was dissolved, an aliquot (50
p.1) of the potassium hydroxide solutions (0, 12.5, 25, 31 .25, or 37.5
pmol) added, the tubes vortexed, and left an hour at room
temperature. The acetylated samples were assayed by HPLC-ECD for
serotonin and N-acetylserotonin.
The maximum yield (85.2%) of IJ-acetylserotonin was obtained when
37.5 pmol of KOH were added to the acetylation mixture (Figure 3.24).
With no added acetylating agent, 95.8% of the original mass of
serotonin was recovered unmodified, and no peak corresponding to N-
acetylserotonin was seen. When no KOH was added, the pH after 40
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Figure 3.24 Acetylation of serotonin in PPP by NAS after
deproteinisation and neutralisation with
potassium hydroxide (value in brackets = pmol
KOH added).
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the original mass of serotonin used was recovered as N-acetyl-
serotonin, and 91.755 was unmodified serotonin. When 37.5 pmol KOH
were added in 0.5 mol/1 protein-free assay buffer (pH 6.2), the final
pH was 6.44 +_ 0.08 (n=3). This mass of KOH (or the molar equivalent
of NaOH) was subsequently used (diluted in 0.5 mol/1 protein-free
assay buffer, initial pH 6.2) to neutralise acidified, deproteinised
plasma for acetylation.
3-3.7 Preparation of Charcoal-stripped PPP (CSPPP)
PPP was prepared from normal volunteers as above, and pooled.
For charcoal stripping, the pooled PPP was spiked with purified [%]-
serotonin and stirred for 4 h at 4°C with dextran coated charcoal
(previously washed with 0.05 mol/1 phosphate buffer, pH 7.4) in the
ratio of plasma:charcoal:dextran of 100:10:1. The plasma was
centrifuged at 1,720 x g for 30 min at 4°C to remove the bulk of the
charcoal, and the supernatant filtered through a 0.22 pm filter to
remove charcoal fines. An aliquot (100 pi) was taken for
scintillation counting, and the remaining charcoal-stripped PPP
(CSPPP) stored as aliquots of 20 ml at -20°C. The CSPPP was
rendered 95.5 +_ 3.3$ free of added tracer after treatment as
described (n=5).
3.3.8 RIA of Standard Curves with Acetylation of Serotonin by NAS
after Deproteinisation and Neutralisation
Authentic serotonin was diluted either in assay buffer, or
PPP/assay buffer (1/20), or CSPPP/assay buffer (1/20), to give a
series of standards over the range 0-1,000 nmol/1. Each batch of PPP
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was routinely checked for serotonin, and used only if the apparent
concentration was <20 nmol/1, since this would be undetectable in the
RIA after dilution. The standards (450 pi) were deproteinised as
above (3.3.6.4), duplicate aliquots (2 x 200 pi) added to NAS (1.59
pmol) previously dried down in glass tubes, and vortexed. The
solutions were neutralised with KOH (37.5 pmol) in 0.5 mol/1 protein-
free assay buffer (50 pi), vortexed, and incubated at room
temperature for 60 min. Glycine (8.3 pmol) in assay buffer (50 pi)
was added, the tube vortexed, and left a further 30 min. The
standards were assayed by adding tracer (1 fmol, approximately 5,000
dpm) in assay buffer (100 pi), followed by a fresh mixture of primary
antiserum, NIRS, and DARS in assay buffer (300 pi), at dilutions
which would give final concentrations of 1/28,000, 1/4,800, and 1/240
respectively in the incubate (700 pi). Incubation was overnight at
4°C, followed by separation.
When plotted as percent tracer bound/percent tracer bound in the
zero standard (i.e.% B/Bq), there was no apparent difference either
between buffer and CSPPP curves, or between buffer and PPP standard
curves (e.g. Figure 3.25a and b). A drop in the absolute value of
the zero binding was observed with plasma, although this was not
significant (Student's t_ test); if the mean zero binding in buffer
was expressed as 100%, the corresponding values for CSPPP and PPP
were 95.2 +_ 11.6%, and 78.0 +_ 20.2% respectively (n=4). Since there
was no difference in the overall curve shape, but there was
appreciable difference in the zero binding in the presence of plasma,
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Figure 3.25 Comparison of buffer standard curve (0- -0) with:
a) 1/20 PPP in buffer (• •), or b) 1/20 CSPPP
in buffer (X- - -X). Points represent means of
duplicate estimates; Bq and NSB = means SD
of triplicates.
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human PRP were always constructed using serotonin prepared in normal
PPP diluted 1/20 in assay buffer.
3.3.9 Analysis of Human PRP Samples by HPLC-ECD and RIA
For the HPLC-ECD assay, samples of PRP (400 pi) were
deproteinised as above (3.2.7), then assayed by HPLC, previously
calibrated with fresh dilutions of serotonin and internal standard.
PRP samples for analysis by RIA were diluted in assay buffer (1/20),
deproteinised, neutralised, acetylated and assayed as described above
(3.3.8). The standards for the standard curve consisted of
serotonin freshly diluted in a solution of PPP in assay buffer
(1/20), to give a range of concentrations of 0-1,000 nmol/1. The
standards were deproteinised, acetylated and assayed in parallel with
the unknown samples during each RIA. The results obtained by HPLC-
ECD and RIA were compared by linear regression analysis.
A representative standard curve and precision profile (Raab and
McKenzie, 1981) derived from the mean data for eight consecutive PRP
assays is shown in Figure 3.26. With incubation conditions as
described above, mean zero binding from eight standard curves was
48.8 _+ 6.1% of the total added radioactivity. The formal sensitivity
of the standard curve (2.5 SD from the zero standard) was 2.0 nmol/1,
or 0.40 pmol/tube (70.4 pg/tube), which after correcting for
dilution, corresponds to a serotonin concentration in PRP of 40
nmol/1. Figure 3.27 shows the regression equation for comparison of
serotonin values measured by HPLC-ECD and RIA. Of the normal



















Figure 3.26 Standard serotonin curve for human PRP RIA
(mean value ——), with the associated
precision profile (mean value and
SD - - -) for eight consecutive assays.
Mean Bq was 48.1 +_ 6.1% of total














Concentration by HPLC (nmol/l)
3000
gure 3.27 Correlation of PRP serotonin concentration as
determined by HPLC and RIA. Standard error of
slope = +. 0.061, standard error of intercept =
± 82.9. Fitted regression line not significantly
different from y = x.
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1548 +_ 541 nmol/1 for females (n=5), and 1404 +_ 827 for males (n=6).
This difference was not significant (Student's t_ test). No
difference was seen between a standard curve which was assayed
immediately after the acetylation had been performed, and the same
standards when assayed after freezing for two days at -20°C (Figure
3.28).
Scatchard analysis of the standard curve (Scatchard, 1949)
demonstrated that there was a population of antibodies in antiserum
R16B4 with an affinity of 1.62 x 10® 1/mol (Figure 3-29). This was
taken to be the affinity constant of the antiserum.
3.3.10 Cross-reactivities
These studies were performed with the test indoleamines and
standard serotonin diluted in assay buffer prior to deproteinisation.
Cross-reactions were measured for the test compounds themselves, and,
where appropriate, after N-acetylation as above (3.3.8). Percentage
cross-reactivity was calculated from the ratio of the mass N-acetyl-
serotonin at 50% B/Bq: mass of cross-reactant at 50$ B/Bq.
The major (0.12$) formal cross-reactant (see Table 3.6) was
unacetylated serotonin. N-Acetylation increased the cross-reactivity
of the other indoleamines tested, but methylation of the 5-hydroxyl
group of N-acetylserotonin reduced cross-reactivity from 100$ to
<0.02$.
3.3.11 Precision Studies Using PPP Spiked with Standard Serotonin
Serotonin was added to PPP prepared from normal volunteers, at
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Figure 3.28 Plasma standard standard curves assayed either
immediately (• •), or after storage at -20°C
for 48 h (0- - -0). Points represent means of
duplicate estimations; Bq and NSB = means +_ SD
of triplicates.
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CONCENTRATION OF SEROTONIN BOUND (nmol/1)
Figure 3-29 Seatehard analysis of the serotonin standard
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Table 3.6 Cross-reactivities of the R16 antiserum.
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(845 |il) frozen at -20°C in polypropylene microcentrifuge tubes.
These recovery pools were assayed by HPLC-ECD and RIA over a period
of 8 weeks to determine intra- and inter-assay precision.
Intra- and inter-assay variation as calculated from repeat
analyses of the spiked pools are shown in Table 3.7. Intra- and
inter-assay variations in the HPLC-ECD assay were lower than in the
RIA at all the tested concentrations, but the analytical recoveries
of serotonin were similar for both assays. No decrease in the
values obtained from the spiked pools was seen in either the RIA or
HPLC-ECD assay over a period of two months.
3.3.12 Validation of RIA for Rat Serum
Comparative assay of serotonin standards prepared either in
charcoal-stripped rat serum (prepared from neat serum diluted 1/10 in
saline), normal human PPP, or charcoal-stripped rat "coagulant"
serum, all diluted 1/20 in buffer, showed that the rat serum prepared
by collection into saline alone shifted the lower concentrations of
the standards the curve to the right (Figure 3.30). This indicated
that the serotonin in the untreated rat serum curves may have been
becoming degraded, and unable to displace the tracer bound to the
antibodies. This effect was abolished by preparation of serum in
"coagulant". Thus rat serum was prepared by diluting whole blood in
a "coagulant" as described for the HPLC-ECD assay. The supernatant
was assayed by HPLC-ECD and RIA and the results compared by linear
regression analysis. The regression equation for samples measured
both by HPLC-ECD and the RIA is shown in Figure 3.31.
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Recovery HPLC n ftIA n
Pool
(nmol/1) X + SD ?CV X + SD JCV
Intra- 250 252.0 + 5.2 2.1 5 214.8 + 22.5 10.5 10
assay 750 884.2 + 5.7 0.6 5 773.6 +_ 79.6 10.4 10
variation 2,500 2,,579.0 + 79.1 3.1 5 2,296.8 + 131.1 5.7 10
Inter- 250 259.3 + 14.8 5.7 12 242.4 + 36.6 21.2 12
assay 750 836.9 + 46.9 5.6 12 885.0 + 106.6 12.0 12
variation 2,500 2,,432.0 + 158.8 8.2 12 2,465.5 + 364.8 14.8 12
Inter- 250 103.8 + 5.9 — 97.0 + 20.6
assay 750 111.6 + 6.2 118.0 + 14.2
% recovery 2,500 97.3 + 8.0 — 98.6 + 14.6
Table 3.7 Intra- and inter-assay variation for the RIA
and HPLC-ECD assay.
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CORRECTED SEROTONIN CONCENTRATION (nmol/1)
Figure 3-30 Effect of normal rat serum (• •) or rat
serum collected into the coagulant (X- - -X)
on the RIA standard curve (normal human curve
0 0). Points represent means of duplicate
estimations; Bq and NSB = means +_ SD of
triplicates.
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Figure 3-31 Correlation between rat serum serotonin concentration
as determined by RIA and HPLC-ECD assay.
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3.3.13 Validation of the RIA for in vitro Experiments
Samples of PRP (100 pi) were diluted in a mixture (900 pi) of
Medium 199/ACD (1:9, pH 7.4), and 0.2 mol/1 protein-free assay buffer
(1 ml, containing 2 pmol/1 chlorimipramine) was added to each of the
diluted samples. Standards were made up in PPP diluted 1/10 in
Medium 199/ACD (pH 7.4), followed by a 1/2 dilution with 0.2 mol/1
protein-free assay buffer, which also contained 2 pmol/1 chlor¬
imipramine. Standards and diluted samples were assayed by RIA as
described above, and the neat PRP samples were also assayed for
serotonin by HPLC. The results obtained by the RIA and the HPLC-ECD
as analysed by linear regression analysis are shown in Figure 3-32a,
together with a typical in vitro standard curve (Figure 3.32b).
3-3-14 Analysis of PRP from a Patient with the Carcinoid Syndrome
Blood was collected from a patient diagnosed as suffering
from the carcinoid syndrome, and PRP prepared as described (3.2.5).
The PRP was assayed by RIA after a twenty-fold dilution in assay
buffer, and a further two dilutions in PPP/assay buffer (1 part
PPP/19 parts buffer).
The diluted PRP from the carcinoid patient was parallel to the
standard curve (Figure 3.33), indicating that even plasma which
contains grossly elevated levels of indoleamines has no detrimental
effect on the assay.
-113-
"i 10 100 iToocS NSB
SEROTONIN CONCENTRATION (nmol/1)
Figure 3.32 a) Correlation between in vitro RIA results and
HPLC-ECD assay; fitted regression line not
significantly different from y = x. b) A
representative standard curve for use with in
vitro experiments. Points represent means of
duplicate estimations; BQ + NSB represent means +
SD of triplicates.
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* = Diluted carcinoid PRP
Figure 3-33 Dilution of carcinoid PRP compared with standard curve.
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3-3.15 Effect of 5-Hydroxytryptophan or p-Chlorophenylalanine
on the Serotonin content of Rat Serum.
Male Wistar rats (200-250 g) which had been cannulated via
the carotid artery were injected intra-peritoneally on the third and
fourth days after cannulation with either a) 1 ml normal saline,
b) 1 ml saline containing 5-hydroxytryptophan (5HTP; 4 mg/ml), or, in
a separate experiment, c) 1 ml saline containing ja-chlorophenyl-
alanine (PCPA; 80 mg/ml). On day 5, serum was prepared as described
(section 3.2.6b), and analysed for serotonin by RIA.
Treatment with 5HTP significantly (p<0.001; Student's _t test)
raised the serum level of serotonin from (mean _+ SD) 6.6 _+ 3.5 pmol/1
in the control group (n=15) to 13.6 +_ 6.3 pmol/1 in the experimental
group (n=l6; Figure 3.34a); conversely, the serum concentration of
serotonin in the rats treated with PCPA fell significantly (p<0.05;
Student's t_ test) from 9.2 _+ 4.3 pmol/1 in the control (n=17) to
6.6 +_ 5.4 pmol/1 in the experimental animals (n=17; Figure 3-34b).
3-3.16 Release of Serotonin from Human Platelets by
Thrombin Stimulation.
PRP was prepared from a normal volunteer, diluted 1/5 in
Medium 199/ACD, and aliquots (400 pi) incubated in triplicate in
conical polypropylene microcentrifuge tubes for 20 min at 37°C in a
shaking water bath (200 strokes/min), in the presence of thrombin
dissolved in saline (200 pi) at final concentrations of 0, 0.05, 0.5,
5.0, and 50.0 units/tube. A set of "Total" tubes was also included,
containing PRP (400 pi) and saline (200 pi). The tubes were removed






















Figure 3-34 Effect of a) 5HTP and b) PCPA on rat serum serotonin
(p value from Student's t test).
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assay buffer, which also contained 2 pmol chlorimipramine/1. Then,
except for the "Totals", which remained in the slurry throughout, the
tubes were centrifuged for 60 s at 5,000 x g and 4°C. Aliquots (450
pi) of the supernatant from each tube (including 450 pi from the
totals) were deproteinised, and assayed by RIA.
Incubation with 0.5, 5.0, and 50.0 units thrombin/tube resulted in
a significant (Student's t_ test) dose-dependent rise in the serotonin
concentration recovered from the supernatant (Figure 3-35).
3.4 Discussion
Although HPLC-ECD is currently the method of choice for analysis
of serotonin, its major disadvantage is that comparatively few
samples (<20) can be processed in a working day compared with the
large throughput (>100 samples/day) of an established RIA, which
would be necessary for a screening programme, or in vitro studies,
where large numbers of samples may be generated in one experiment.
The in-house HPLC-ECD system described in this thesis was developed
and validated for serotonin a) to be used as an assay in its own
right, b) to be used as a reference method for validation of the RIA,
and c) to aid in the development of the RIA methodology (e.g. by
monitoring the progress of the acylation experiments). The
chromatographic conditions are similar to those used by other groups
(e.g. Kamal, et_a_l., 1 984a; Tagari, ej^a^., 1984), i.e. a reversed-
phase ODS column, with a buffered mobile phase containing a small
percentage of organic modifier, and a ion-pairing agent.
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Figure 3-35 Effect of incubating PRP diluted in 199/ACD,
with increasing doses of thrombin (mean values
_+ SD from triplicates, p values from Student's _t
test.
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The experiments with the HPLC-ECD described demonstrate that:
a) the peak given by a pure standard solution of serotonin co-
elutes with >90% of injected radioactivity from a fresh tritiated
standard in which >90% of the activity is due to [^Hl-serotonin.
b) the response of the detector is linear over the tested range of
standard serotonin concentrations (16-50,000 nmol/1), thus, since the
regression line will pass through the origin (zero mass injected
gives zero peak height), it can be expressed as the equation of a
straight line:
y=mx + c
where y is peak height, x is mass of serotonin injected, m is the
gradient of the line, and c is the intercept, which is zero.
Therefore, a single injection of a known mass of pure standard can be
used to calculate unknown masses by comparison of peak heights, since







where hg and mg are standard peak height and mass, and hu and are
peak height and mass of the unknown respectively. The height of the
internal standard is used in the same way to calculate the recovered
mass, and therefore the recovery after deproteinisation.
c) Related indoleamines, although structurally similar to
serotonin, exhibit different, characteristic retention times and
oxidative voltammograms, when compared with serotonin. Unknown
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peaks can therefore be identified as serotonin if they have the same
retention time and oxidative voltammogram as a pure, standard
solution.
Differential centrifugation is widely used in the isolation of
platelets from whole blood (e.g. Sasa, et al., 1978; Tang and
Frojmovic, 1980; Mezzano, et al., 1982; Kamal, et al., 1984a). Other
methods have been used, whereby whole blood is spun through a density
gradient of dextran (Launay, et al., 1982) or Percoll (Ding, et al.,
1985a), and the platelets harvested. To separate the platelets from
the gradient material, further centrifugation and washing steps would
be required; the disadvantage of this is that the platelets are
subjected to manipulation for longer than they are during a single
centrifugation step, and this has been shown to result in release of
platelet constituents (Parker, et al., 1984), or decreased platelet
cAMP levels, possibly indicating an increase in platelet activation
or aggregation (Gorman, et al., 1977), which could adversely affect
any subsequent tests of function. Furthermore, release of platelet
constituents during excessive centrifugation and washing would result
in falsely depressed levels of serotonin, which is secreted during
the platelet release reaction (Grette, 1962).
No attempts were made to use PPP in the assays to measure "free",
or non-platelet bound serotonin, for several reasons. Firstly, PPP
by definition is not devoid of platelet contamination; assuming a
O
platelet serotonin concentration of approximately 300 pmol/10
platelets, and assuming 400 x 10° platelets/ml whole blood, a
contamination of 1.0% after centrifugation would leave 4 x 10^
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platelets/ml PPP, which would correspond to an apparent serotonin
level of 12 nmol/1. Only ultra-centrifugation is thought to be
effective in removing residual, small platelets (Wolf, 1967).
Contamination of PPP with platelets may arise from inefficient
centrifugation, resuspension of platelets from the plasma/red cell
interface, or from platelets becoming trapped in the layer of lipid
floating on the top of the plasma (Rasi, 1979). Secondly, it is
evident from studies of other products of platelet release (e.g.
y3-thromboglobulin, BTG), that the protocols used for blood sampling,
centrifugation and storage are critical to avoid release of these
platelet constituents (Ludlam and Cash, 1976; Levine, et al., 1981),
whereas most published methods for production of PPP do not seem to
take extensive precautions to avoid platelet activation during
sampling. It has been suggested that the platelet <=* -granules which
store BTG liberate their constituents more readily than the dense
granules which store serotonin (Witte, et al., 1978), at least when
stimulated by thrombin, hence it would seem that the precautions
required when sampling for BTG are unnecessary for preparation of PPP
for "free" serotonin analysis. Thirdly, the expected levels of
"free" serotonin in carefully prepared PPP would seem to be <10
nmol/1, which approaches the cut-off limits for the working range
both for HPLC-ECD and the RIA, making accurate and precise
determinations difficult without prior sample concentration. It is
presumably because of such difficulties that a large variation in
"free" serotonin levels have been reported (Table 3.8).






87 Kellum and Jaffe, 1976
<7 Demet, et_ al., 1978
40 Frattini, et al., 1979
19 Koch and Kissinger, 1980
9 Engbaek and Voldby, 1982
72 Petrucelli, et_ a^L., 1982
17 Emson, et al., 1984
3.3-20.5 Hindberg, 1984
<10 Kamal, et al., 1984a
44 Tagari, et_ al_., 1984
15 Artigas, et al., 1985
<1 Molyneux and Clarke, 1985
Table 3.8 Reported levels of serotonin in normal human PPP.
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oxyhaemoglobin is liberated from the red cells during
deproteinisation with perchloric acid, resulting in the rapid
oxidation of serotonin, unless the blood is saturated with carbon
monoxide prior to deproteinisation (Korpi, 1984). Also, when
corrected for platelet count, no difference was seen in the serotonin
content (on a per platelet basis) between whole blood and PRP (Kellum
and Jaffe, 1 976).
Serotonin is unstable at alkaline pH, and rapidly undergoes auto-
oxidation in the presence of atmospheric oxygen (Garattini and
Valzelli, 1965; Falkowski and Wei, 1981). Consequently, the monoamine
is usually stored in acid, in the presence of an anti-oxidant, at 4°C
(e.g. Sasa, et al., 1978; Fujimori, et al., 1982; Patthy and Gyenge,
1984; Tagari, et al., 1984). Under the conditions described above
(3.2.1), standard serotonin is stable over a period of several
months, and serotonin in deproteinised PRP samples stored at 4°C is
stable throughout the course of an analytical run (3-4 h), which
agrees well with published results (Guicheney, £t_ al., 1985).
Serotonin in plasma is also acceptably stable when stored as sealed
aliquots frozen at -20°C, as demonstrated by the spiked PPP samples
which were analysed over a period of two months. These spiked
samples were not truly representative of PRP samples, as they did not
contain platelets in appreciable concentrations, and platelets do
contain a monoamine oxidase (MAO); however, the platelet MAO, MAO B,
does not readily metabolise serotonin (Glover, 1977).
In the undiluted rat serum, there was a large variation in
individual recoveries as measured by height of the internal standard
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peak, and it was thought that this may have been due to either MAO
activity, or a non-specific oxidation of serotonin by free
oxyhaemoglobin in the serum (Korpi, 1984). When prepared using the
"coagulant" containing a serotonin releasing agent (thrombin), a
serotonin re-uptake inhibitor (chlorimipramine), and an inhibitor of
monoamine-oxidase (pargyline), rat serum serotonin was stable for up
to 2 h at 37°C, (Table 3.3) suggesting the degradation was due
enzymatic activity rather than non-specific oxidation, since no anti¬
oxidant was added.
Acid deproteinisation is commonly used to remove proteins from
plasma prior to analysis for serotonin (Rao, et al., 1976; Koch and
Kissinger, 1980; Mefford', 1981; Tagari, et al., 1984). This is
necessary both for the HPLC-ECD assay, and for the RIA; in the
former, protein contamination of a column can rapidly lead to reduced
resolution, increased back pressure, and generally impaired
performance, and in the latter, free amino groups on the protein
would compete with serotonin for the acetylating agent. Perchloric
acid has been used in serotonin assays at final concentrations
ranging from 0.05 mol/1 (Meyer and Shoup, 1983) to 1 mol/1 (Delaage
and Puizillout, 1981). The concentration of perchloric acid used in
the RIA (0.15 mol/1) should remove >7555 of the protein (Blanchard,
1981). Acid deproteinisation has the added advantage that under
these conditions (i.e. pH<6), serotonin is stable at room temperature
(Garattini and Valzelli, 1965).
The significant difference between the recoveries of tritiated
serotonin and the HPLC-ECD internal standard (Ncu-methylserotonin)
-125-
from PRP may be due to impurities in the tracer, as it is not known
exactly how the residual (<10$) of radioactivity behaves, i.e.
whether it is distributed throughout the sample, or is concentrated
in the supernatant, which would result in a falsely elevated
recovery. Although it is assumed that the internal standard behaves
in exactly the same way as serotonin during the deproteinisation, the
fact that serotonin and the internal standard can be separated by
HPLC-ECD underlines the point that they are not identical, and may
possess different chemical properties.
Due to the intrinsic instability of serotonin at room temperature
in the presence of atmospheric oxygen, and at neutral or alkaline pH,
it was found necessary to synthesise the II-succinamyl serotonin under
nitrogen, as exposure to the alkaline hydroxylamine used to cleave
the 5-0-succinyl moiety back to a 5-hydroxy group (Means and Feeny,
1971) otherwise resulted in the destruction of the indole nucleus.
Similarly, the preparation of the immunogen had to be conducted in an
inert atmosphere. The structures of serotonin and the acylated
derivatives used in the RIA are shown in figure 3.36.
In attempting to produce a gamma-emitting tracer using the Bolton-
Hunter reagent, it was hoped a) to increase the sensitivity of the
assay by having a tracer with a bridge structure more similar to the
modified antigen than to the original iramunogen, (c.f. Corrie, et_ al.,
1981), and b) to simplify the preparation of the tracer, since
serotonin itself is used instead of the N-succinamyl derivative, and
is acylated by the [^^Ij-Bolton-Hunter reagent directly. This type
of iodination is technically straightforward, and there seems no
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v) II-succinamyl serotonin-[ ^^1]-
glycyl-tyrosine
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obvious reason why virtually no binding of the tracer was seen, since
a recent publication describes the preparation of such a tracer (Manz
et al., 1985). It is possible that some auto-oxidation of serotonin
occurred during the acylation step (pH 8.5), or during the thin-layer
chromatography.
Separation of the bound fraction from the free was initially by
ammonium sulphate precipitation as described by Kellum and Jaffe
(1976), and after immunogenic activity was detected, dextran-coated
charcoal (Al-Dujaili and Edwards, 1981) was used. These two
separation systems were used to monitor activity in the bleeds, but
were not used for the routine assay for several reasons: the
precipitation of immunoglobulins by 50% saturated ammonium sulphate
was extremely time-consuming, since the ammonium sulphate was added
to each tube dropwise whilst vortexing; furthermore, the process had
to be repeated after the first centrifugation to wash the pellet,
otherwise the NSB was unacceptably high (>10?). Although separation
using dextran-coated charcoal is widely used, it is far from ideal.
Charcoal separation is sensitive to changes in pH, temperature and
time (Ratcliffe, 1974; Hunter, 1978), and the possibility exists that
the removal of the free tracer by the charcoal may alter the
equilibrium of the binding reaction during separation (Thorell and
Larson, 1978). Double-antibody separation has very little effect on
the binding of tracer to the first antibody (Thorell and Larson,
1978), but does involve the risk of adding external analyte contained
in the second antibody or carrier. With the serotonin RIA described
above, this problem does not exist as such, since the assay measures
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N-acetylated serotonin, and the acetylation reaction is completed
prior to the addition of any of the antisera. Circulating
^-acetylserotonin has been described in sera from rats, hamsters, and
rabbits, but all reported levels have been less than 100 nmol/1
(Pang, et_a_l., 1980; Pang, £t_a_l., 1981; Geffard, £t_a_]^., 1982; Pang
et al., 1983), which would not be detectable in the assay system
after dilution of the second antibody or carrier (typically 1/50 and
1/500 respective initial dilutions).
Immunisation of experimental animals with the N-succinamyl
derivative of serotonin led to the production of antisera with such a
high avidity for the bridge portion of the hapten, that the
unmodified molecule is nearly 1,000 times less effective at displacing
the tracer than the modified analyte. Similar effects have been
described in earlier derivatisation assays for serotonin (Delaage and
Puizillout, 1981; Geffard, et al., 1982), and also for the cyclic
nucleotides (Cailla, et al., 1973; Fransden and Krishna, 1976).
Substitution of the side-chain of serotonin has slight effects on
the stability of the molecule, as can be seen from the oxidative
voltammograms (Figure 3.6); the further the curve lies to the right,
the greater is the potential difference required to achieve oxidation
(i.e. the greater the stability). Substitution of the 5-0_ group of
serotonin markedly increases the stability of the molecule: 5-methoxy-
N-succinamylserotonin can be exposed to the oxidising agent
chloramine-T during an iodination, without the molecule undergoing
oxidation (Geffard, et al., 1982), whereas 5-hydroxy-N-succinamyl-
serotonin is rapidly degraded (Delaage and Puizillout, 1981). On
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the basis of this observation, it seemed unlikely that 5-methoxy-N-
acetyltryptamine (melatonin), or any of the 5-0-acyl derivatives would
be detected by the electrochemical detector under the oxidative
conditions used for serotonin and the other side-chain derivative
indoleamines, hence the need to use UV detection for analysis of the
diacetyl products of acetylation.
The lack of shift of the standard curve (when expressed as % B/Bq)
with increasing tracer mass confirms that the tracer is of high
specific activity (Hunter, 1983), therefore the decrease in zero
binding is not due increasing tracer mass, but rather to some non¬
specific effect. Both previous publications which use this method
of iodination (Delaage and Puizillout, 1981; Geffard, et al., 1982)
report the production of tracers with specific activities similar to
that of the original sodium "'^iodide, i.e. >2,000 Ci/mmol.
The succinylation conditions used were similar to those employed
in the original paper by Delaage and Puizillout (1981); the
acetylation (and, in the production of a tritiated tracer,
succinylation) conditions were essentially those used in cyclic
nucleotide assays (Cailla, et al., 1973; Fransden and Krishna, 1976).
Succinylation by succinic anhydride, or acetylation by acetic
anhydride were not pursued further, since both acylating agents
require alkaline conditions for acylation (Means and Feeny, 1971),
both result in the production of a 5-0-acyl group as well as the
N-acyl derivative, and (as in the original immunogen), the 5-0-acyl
group must be cleaved to avoid a loss in assay sensitivity (Cailla,
et al., 1973). Specific N-acetylation by N-acetoxysuccinimide
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obviates this step, and therefore reduces the risk of auto-oxidation,
since the pH is maintained below neutrality throughout. Others
(Treadway and Shultz, 1976; Baumann, et al., 1973) have used
N-acetoxysuccinimide as a specific N-acetylating agent, and the
present work confirms this.
The sensitivity of the RIA for human PRP is comparable both with
that of previously published RIAs (Table 3.9), which use either
tritiated serotonin or gamma-emitting tracers, and also with that of
HPLC-ECD, without extraction (approximately 2-5 nmol/1), although the
precision with the RIA is poorer than the HPLC-ECD at the tested
concentrations. This may be partly due to the use of an internal
standard as a recovery marker in the HPLC-ECD assay, since this
compensates for imprecision incorporated in sample preparation and
analysis.
As expected, the precision in the the RIA is poorest at the upper
and lower asymptotes, since at these flattening portions of the
curve, small deviations in the measured response will be transposed
into large variations in the apparent concentration (Ekins, 1974).
The agreement between the RIA and the HPLC-ECD reference method shows
that in human PRP, the endogenous concentration of N-acetylserotonin
is negligible compared with serotonin (the HPLC-ECD separates these
two compounds, allowing them to be measured independently). This
agrees with a previous observation (Hindberg, 1984), but other
workers (Manz, et al., 1985) have found apparent N-acetylserotonin
concentrations of 0-150 nmol/1 in human serum, which is approximately







































BSA = bovine serum albumin
HSA = human serum albumin




[3H]-5HT = tritiated serotonin
[^23I]GT = ^23Iodinated glycyl tyrosine
[123I]BH = ^23Iodinated Bolton-Hunter reagent
Table 3-9 Sensitivities of previous serotonin radioimmunoassays
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regression equation (29.3 nmol/1) is approximately Z% of the mean
normal PRP serotonin levels, and may reflect true background
N-acetylserotonin, or general "noise" due to assay imprecision. On
the basis of the observed correlation, it has been assumed that
compared with the levels of serotonin in human PRP, the circulating
levels of N-acetylserotonin are negligible; this assumption is also
tacitly implied in most descriptions of radioenzymatic assays
(Walker, et al., 1983; Hammel, et al., 1978), and two other RIAs
(Delaage and Puizillout, 1981; Geffard, et al., 1982). The rat
serum RIA correlates well with HPLC-ECD analysis, although our levels
of serotonin in normal rats are higher than other previous reports
(Table 3.10). It is possible that our method of sample processing
is less detrimental to endogenous serotonin than published methods,
which use no enzyme inhibitors, and collect the blood neat (e.g. Ho,
et al., 1975; Halvey, et al., 1980). The extra dilution step used
in the collection of the serum will almost certainly introduce
precision errors, and this may explain the large scatter seen on the
regression plot. The increase in rat serum serotonin after
injection with the serotonin precursor 5HTP, and the corresponding
decrease following administration of the tryptophan hydroxylase
inhibitor PCPA, demonstrate the expected physiological changes in
serotonin levels can be detected by the RIA.
The correlation between the RIA using _in vitro reagents suggest
that the incubation medium (199/ACD) and chlorimipramine have no
effect on the assay. The release experiment shows that serotonin




242 Halvey, et al., 1980
443 Geffard, et_ al., 1982
4,000 Ho, et al., 1985
1,200 Marcenac and Blanche, 1985
Table 3.10 Reported serotonin levels in normal rat serum.
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detected using the RIA, and that this release follows a dose-
dependent pattern. Previous studies of the release of platelet
serotonin in vitro have used a) platelets pre-loaded with either
[3H] or [^^C]-serotonin (e.g. Grant and Zucker, 1979), b) a complex,
direct electrochemical detection method (Marcenac and Blache, 1985),
or c) detection of released serotonin by HPLC analysis (e.g.
Fujimori, et al., 1982; Ingebretsen, et al., 1985). All these
methods have major disadvantages: the isotope method (a) requires
pre-labelling of the platelets followed by liquid scintillation
counting with its inherent disadvantages; furthermore, given that
serotonin tracers may be nearer 50% than 100% pure for radioactive
serotonin (see Section 3.2.7.1), the results may become difficult to
interpret. Direct electrochemical detection or conventional HPLC (b
and c respectively) both require expensive equipment, and the rapid
throughput of large numbers of samples is not possible. The RIA,
however, provides a relatively simple and cheap method for the rapid
analysis of large numbers of in vitro samples.
The values obtained from normal volunteers are in good agreement
with published serotonin levels (Table 3.11), and although the
difference between the males and females was not significant as tested
by the Student's t_ test, similar findings have been reported in the






284 Born and Gillson, 1959
1,158 190 Kellum and Jaffe, 1976
690* — Demet, et al», 1978
809** — Sasa, et al., 1978
689 260 Frattini, et al., 1979
280 Ahtee, et_ a^., 1981
1,136* — Anderson, et al., 1981
634* — Emson, £t al., 1984
360 Hindberg, 1984
165 Kamal, et_ a]^., 1984a
500-1,700* — Korpi, 1984
1,160 — Le Quan-Bui, et_ al_., 1984
300 Artigas, et al., 1985
320 Ingebretson, et al., 1985
190-3,430 — Manz, et_ al_., 1985
259 Sharma, et al., 1985
* = whole blood
** = serum
Remainder are PRP






The preceding chapter has dealt with the development of an HPLC
assay and an RIA for serotonin; this chapter describes the
development of two tests of platelet function used in this thesis,
viz. the uptake of [%]-serotonin by platelets, and platelet
aggregation. By necessity, the former function test required
detailed investigation, since, mainly due to the diversity of methods
described in the literature and the apparent lack of standard
conditions used, there is a wide variation in the magnitude of uptake
parameters reported. In contrast, the technique of in vitro
platelet aggregation is relatively simple, and the methodology has
remained largely unchanged since the original description 25 years
ago (Born, 1962).
4.2 Development of an in vitro Serotonin Uptake System
4.2.1 Collection of Blood
Platelet-rich plasma (PRP) was prepared from whole blood
collected into acid/citrate/dextrose using a 19 gauge needle with
minimal stasis as described earlier (section 3.2.5). Unless
otherwise stated, blood was collected between 0900 h and 1000 h
from a seated subject who had not received any drugs with known anti¬
platelet activity within the preceding seven days. Platelet numbers
were estimated in a preliminary experiment either by diluting PRP
1/50 In a solution (1$) of ammonium oxalate in water, and counting in
a haemocytometer, or by sending an aliquot of PRP (500 pi) in a
standard (5 ml) potassium EDTA tube to the Haematology Department,
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Western General Hospital, for analysis by Coulter counter.
Figure 4.1 shows a) the distribution of platelets in a sample of
citrated whole blood, compared with b) the distribution of platelets
in citrated PRP. The precision of counting platelets visually in a
haemocytometer was poorer than by electronic particle (Coulter)
counting (% coefficient of variation 15.2 and 1.2 respectively; Table
4.1); furthermore, the values obtained from the visual counts were
higher than those obtained from the Coulter counter, but the
difference was not significant (p>0.05, Student's _t test). In all
subsequent studies, platelet counts were determined by Coulter
counter.
4.2.2 Optimisation of Centrifugation Conditions Required to Pellet
Platelets
Fresh PRP (5 ml) was incubated with [%]-serotonin
(approximately 30 pmol freshly diluted in saline (1.25 ml)), for 1 h
at 37°C. Aliquots of this labelled PRP (300 pi) were dispensed into
polypropylene microcentrifuge tubes, followed by 1 ml cold (4°C)
chlorimipramine in saline (1 pmol/1). Triplicate sets of tubes were
centrifuged for either 40, 90, or 180 seconds at 200, 500, 1,000,
2,000, 5,000, 10,000, or 20,000 x g, all at 4°C. The supernatant
was aspirated from each tube, and the platelet pellet digested with a
solution (500 pi) of ammonia in water (3f v/v) overnight at room
temperature. An aliquot (200 pi) was taken from each tube for
scintillation counting, and the mean recovered radioactivity for each
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Figure 4.1 Comparison of profiles of platelet volume a3
determined by Coulter counter using platelets from
either a) citrated whole blood or b) PRP prepared
from citrated whole blood from a normal
human volunteer (male).
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Parameter Visual Count Coulter Count
Platelet Count
( x 109/1) 736 + 112 610 + 7
CV (?) 15.2 1.2
NS
Table 4.1 Comparision of platelet count as determined from
triplicate estimations of the same sample of PRP either
by haemocytometer, or by Coulter Counter (mean value +
SD, p value from Student's t^ test).
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The results (Figure 4.2) indicate that for all the tested
centrifugation times, maximal recovery of radioactivity was achieved
at RCF values of >2,000 x g. The centrifugation conditions used
hereafter for serotonin uptake experiments were 1 min at 5,000 x g
and 4°C.
4.2.3 Optimisation of Time Taken to Digest Platelet Pellet
Fresh human platelets were incubated with [^H]-serotonin as
described above, and six aliquots (6 x 300 pi) pipetted into separate
polypropylene microcentrifuge tubes, followed by 1 ml of a cold (4°C)
solution of chlorimipramine in saline (1 pmol/1). The tubes were
centrifuged for 1 min at 5,000 x g and 4°C, and the supernatants
aspirated. A solution (500 pi) of ammonia in water (3$ v/v) was
added to each tube, and after vortexing, each tube was left for
either 0, 10, 20, 40, 60, or 80 min at room temperature before
removal of a single aliquot of 200 pi for liquid scintillation
counting.
As can be seen from Figure 4.3, maximal recovery of radioactivity
was achieved after 40 min digestion, with no increase at up to 80 min
at room temperature. Consequently, in all further uptake
experiments, platelet pellets were digested for at least 40 min at
room temperature prior to sampling for liquid scintillation counting.
4.2.4 Effect of Tracer Purity on Uptake
As demonstrated earlier (see 3.2.7.1), the [^Hl-serotonin is
unstable once opened, and purity rapidly declines over a period of


































Figure U.2 Effect of increasing both the duration of
centrifugation and the relative centrifugal
force (RCF) on the recovery of radioactivity
from the platelet pellet.
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Time (mins) —»
Figure 4.3 Effect of increasing the time allowed for digestion
of the platelet pellet produced by centrifugation.
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the uptake mechanism, impure [^H]-serotonin was fractionated and used
in uptake studies as follows: 200 pi (200 pCi) of stock [%]-
serotonin was injected onto the HPLC (previously calibrated with
authentic standard serotonin), and the major peaks of radioactivity
which did not correspond to [^H]-serotonin (Figure 4.4) were
collected and pooled. Similarly, the peak of [%]-serotonin was
collected, and then diluted in mobile phase to give the same count
rate as the pooled impurity peaks. This was to ensure that any
observed differences would be due to tracer purity, and not because
of different amounts of mobile phase in the incubates. Finally, the
purified serotonin tracer and the combined impurities were diluted
1/100 in saline and used immediately in an uptake experiment. The
same activity (approximately 2 nCi of [%]) of purified serotonin
tracer or the combined impurities was added per tube for the
respective experiments.
For the uptake experiments, standard serotonin was diluted in
saline spiked with a low concentration of radioactivity (i.e. the
purified serotonin tracer or the combined impurities) to give
initial concentrations ranging from approximately 600 nmol/1 to 6,000
nmol/1, in dilution steps of 1/3, 1/5, 1/7, and 1/9. PRP was
prepared from a normal volunteer, and aliquots (600 pi) pre-incubated
in glass tubes for 10 min at 37°C with either normal saline (150 pi)
for the active uptake tubes, or chlorimipramine (900 pmol) in normal
saline (150 pi) for the passive uptake tubes. After this period,
duplicate volumes (2 x 250 pi) of pre-incubated plasma/saline (active














1 + 2 = IMPURITIES (11.5 % TOTAL)
3 = SEROTONIN PEAK (63.5 % TOTAL)
Figure 4.4 Profile of radioactivity eluted from the HPLC after
injection of impure [%]-serotonin.
-145-
to aliquots (50 p,l) of the non-radioactive serotonin spiked with
purified serotonin tracer or the combined impurities, in conical
polypropylene microcentrifuge tubes (1.5 ml), which had been pre-
warmed for 1 min at 37°C. The tubes were incubated for 1 min each
at 37°C, after which time 1 ml of cold (4°C) chlorimipramine in
saline (1 pmol/1) was added, the tubes centrifuged as described
above, and the supernatant aspirated. The pellets were digested for
1 h at room temperature, and an aliquot from each (200 pi) taken for
liquid scintillation counting. To enable accurate timing of the 1
min incubation of PRP at 37°C, each uptake run was staggered, i.e. at
each concentration of serotonin being used, the duplicate active and
passive uptake tubes were always incubated together, but there was a
difference of 15 s between additions to each tube. Active uptake
was calculated by subtracting the amount of tracer taken up in the
"passive" tube, from the uptake in the "active" tube, and expressing
this as a percentage of the total counts added. Final serotonin
concentrations were always corrected for the mass of tracer included
(approximately 1.25 pmol/tube).
Figure 4.5 shows that there was essentially no active uptake of
radioactivity when platelets were incubated with the impurity peak,
while there was extensive active uptake of purified tracer into the
platelets in the corresponding experiment. Therefore, since the
impurity did not contribute to the amount of radioactivity taken up,
it was assumed that all the radioactivity actively taken up into the
platelets was due to [%]-serotonin. Hence, for all subsequent












852.5 284.2 170.5 121.8 94.7
Serotonin concentration (nmol/l)
Figure 4.5 Uptake experiments performed with radioactive material
collected from either the pooled [^H]-impurity peaks, or
from the [-^Hi-serotonin peak (means of duplicate
determinations, values corrected for passive
diffusion).
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used to spike varying concentrations of non-radioactive serotonin,
the range of final concentrations used being approximately 100 -
1,000 nmol/1, in dilution steps of 1/3, 1/5, 1/7, and 1/9. The
total counts were always corrected for the purity as determined by
HPLC (e.g. if only 75$ of the activity of the tracer was associated
with the serotonin peak, then uptake was calculated as a percentage
of 75$ of the total counts). In order to monitor tracer purity,
each batch of [^H]-serotonin was analysed by HPLC at intervals of
four weeks, and was no longer used for uptake studies once the purity
had fallen below 60$.
4.2.5 The Effect of Diluting Platelets on Uptake
For these experiments, Krebs-Henseleit saline (KHS) was
prepared as described (Krebs, 1950), but using NaCl to replace the
sodium salts of the amino acids originally used (Table 4.2 and 4.3).
The KHS was diluted with ACD (the anticoagulant used for blood
collection) in the ratio of 9 parts KHS:1 part ACD (the KHS had been
gassed with 95$ 02:5$ COg for 1 h prior to dilution). Fresh PRP was
prepared from a normal volunteer, and uptake studies carried out as
described above, either with neat PRP, or PRP diluted 1/5 in KHS/ACD.
The percentage uptake in the diluted samples were significantly
lower than those obtained with the undiluted PRP (p<0.05, Student's t_
test), but comparison of the results by linear regression analysis
(Figure 4.6) showed a good correlation (r = 0.976) between uptake
after 1 min in the undiluted samples compared with uptake (corrected
for platelet number) in samples diluted in KHS/ACD. Thus any
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Component Formula Stock Volume Mass Cone. Mass Cone
weight (mmol/1) added added (mmol/1) added (mg/1)
(ml) (mmol) (mg)
NaCl 58.4 154 100 15.4 118.5 899.4 6920
KC1 75.6 154 3 0.5 3.6 34.5 265
CaCl2 147.0 110 3 0.3 2.54 48.5 373
kh2po4 136.1 154 1 0.2 1.2 0.02 163
MgS04.7H20 246.5 155 1 0.2 1.2 0.04 294
NaHC03 84.0 154 21 3.2 24.8 271 .4 2087
Glucose 180.2 1 500 1 1.5 11.5 2.7 210
Table 4.2 Composition of The Krebs--Henseleit saline used










Na 143.3 161.4 143.3 161.5 138-148 157-166
K 4.72 4.26 5.36 4.82 3.84-5.12 3.46-4.61
Ca 2.54 2.29 1.81 1.63 2.50-2.74 2.25-2.47
Mg 1.19 1.07 0.81 0.73 0.65-1.05 0.59-1.45
CI 127.1 114.4 125.2 112.7 101.6-106.6 91.4-95.9
po4 1.18 1.06 1.01 0.91 0.65-1.61 0.54-0.95
so4 1.19 1.06 0.81 0.73 0.15-0.50 0.14-0.15
HC03 24.8 22.4 26.2 23.6 21.3-28.5 19.2-25.7
Glucose 11.54 21.5 5.55 16.1 6.30-8.90 16.8-19.1
Table 4.3 Comparison of the composition of Krebs-Henseleit
saline (KHS), Medium 199 with Earle's balanced salt
solution (199/EBSS), and normal human plasma, before and
after dilution with acid-citrate-dextrose anticoagulant
(ACD).
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Figure 4.6 Correlation between the uptake of [•%]-serotonin
by normal human platelets determined either in undiluted
PRP, or in PRP Diluted 1/5 in KHS (means of duplicate
determinations, values corrected for passive diffusion).
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Ghanges in the extent of uptake seen using undiluted PRP should also
be seen using the diluted samples. For all further uptake
experiments, PRP was diluted 1/5 in fresh KHS/ACD, which had been
gassed with 95# 02:5# CO2 for 1 h.
4.2.6 Effect of Storing Diluted PRP at Room Temperature
Prior to Uptake
Aliquots (750 pi) of fresh PRP were diluted 1/5 in KHS/ACD,
dispensed into glass test tubes, and left uncapped at room
temperature for 0, 30, 60, 90, or 120 min prior to a portion (700 pi)
being dispensed into clean, glass tubes. These were pre-incubated
either with saline, or saline/chlorimipramine (175 pi), followed by-
incubation in triplicate with [%]-serotonin/non-radioactive
serotonin for 1 min at 37°C as desribed above, except that only one
concentration of tracer/cold serotonin was used (approximately 100
nmol/1 final concentration). Uptake was halted by the addition of 1
ml ice-cold chlorimipramine in saline (1 pmol/1), the tubes
centrifuged, the supernatant aspirated, and the pellet digested.
The results (Figure 4.7) show a significant decrease (p<0.05,
Student's t_ test) in the active uptake when diluted PRP was left for
>30 min at room temperature, but no significant change in passive
diffusion for up to two hours from the start of the experiment. To
try and minimise this apparent decrease in function, in all later
uptake experiments, PRP or diluted PRP was prepared and stored in
stoppered polystyrene tube, with the air above the PRP/diluted PRP
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Figure 4.7 Effect of leaving diluted PRP at room temperature and
exposed to the atmosphere, on the accumulation of [ H]-
serotonin by human platelets (mean + SD of triplicate
determinations, active uptake corrected for passive
diffusion, p values determined by Student's t test).
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4.2.7 Calculation of Maximum Velocity (7maY), and Michaelis Constant
(Kjjj) of Uptake of [%]-serotonin
To calculate the paramaters of uptake, Vmax, and K^, a program
(Appendix 1) was written to run in Microsoft BASIC on an IBM-PC or
compatible microcomputer. The program was based on the direct
linear plot, a non-parametric analysis, as described by Eisenthal and
Cornish-Bowden (1974), with later modifications (Cornish-Bowden and
Eisenthal, 1978). This plot constructs a line from each substrate
concentration and its related initial velocity; the points of
intersection of these lines represent estimates of Vmax and K^.
These values are ranked in ascending order, and the median values
taken to be the best estimates of the "true" Vmax and K^. The
computer program was used to calculate the equation of a line of best
fit for each uptake study, from a set of Lineweaver-Burk co-ordinates
derived from the experimental data (i.e. 1/initial velocity of
uptake, 1/v^, and 1 /serotonin concentration used, 1/S). The data
were plotted as a double reciprocal, from the equation
1 =_!_+ ^
vi ^max ^max,s
which results in a straight line. The uptake parameters Vmax and
were then calculated from the intercept on the v_axis C/V_„„),
» max
and the slope of the line (Km/Vmax) respectively.
Figure 4.8 shows a set of uptake data plotted using the revised
Eisenthal/Cornish-Bowden method, and Table 4.4 is the calculated Vmax
and Kjjj for each intersection after re-arranging into ascending order.
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Figure 4.8 Data from a typical uptake study plotted as a direct
linear plot (mean of duplicate estimations of VmaY>










-26.8 7.6 -0.385 0
100.0 34.8 0.281 0
128.6 38.5 0.330 0.902
163.2 42.4 0.372 1.355
174.1 46.4 0.375 1.383
175.4 46.5 0.380 1.440
180.0 47.3 0.381 1.458
220.0 53.5 0.397 1.540
248.2 53.9 0.413 1.560
260.0 61.0 0.432 1.560
275.2 63.8 0.433 1.574
277.2 63.9 0.434 1.829
291.9 64.7 0.450 1.863
363.9 66.6 0.461 2.090
372.1 68.8 0.533 2.103
397.7 69.2 0.575 2.169
415.9 71.8 0.581 2.180
433.3 72.8 0.604 2.337
650.0 105.8 0.615 2.631
-192.0 -16.4 1.000 2.922











Table 4.4 Calculation of parameters of uptake kinetics (?maY and
direct linear plot, or IBM computer program, from
an uptake experiment using platelets from a patient with
essential hypertension.
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used on the same data shows that both methods give comparable results
for the same original set of data.
The Michaelis-Menten parameters Vmax and for serotonin uptake
into platelets from normal volunteers are shown in Table 4.5,
together with the intra- and inter-volunteer variation.
4.3 Platelet Aggregation
Platelet aggregation was determined after the method of Born
(1962). Briefly, PRP was prepared as previously described, and
autologous PPP was obtained by further centrifugation (20 min at
3,025 x g at room temperature) of the red cell fraction which
remained after removal of the PRP. The PRP was stored under an
atmosphere of 95$ 0£:5$ CO2 as described for the C^H]-serotonin
uptake studies, and was used within an hour of preparation.
The aggregometer was calibrated by designating the amount of light
(wavelength 660 nm) transmitted through the PRP sample as 0$, and the
amount of light transmitted through the PPP sample as 100$. To
determine the extent of aggregation, an aliquot of fresh PRP (990 pi)
was dispensed into a disposable clear polystyrene tube, and pre-
incubated for 5 min at 37°C, whilst being stirred (1,100 rpm) by a
small (1x3 mm), polypropylene-coated magnetic stirring-rod.
Aggregation was induced by the addition of ADP in 199/ACD (10 pi, pH
7.4), to give final concentrations of up to 4 pmol ADP/1. The
extent of aggregation ($) was expressed as the maximum increase in
light transmission obtained with the aggregating agent, relative to
the reference points established with PRP (0$) and PPP (100$). When
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ymax — ^ nUptake (pmol/10 (nmol/1)
platelets/min)
Intra-individual 120.0 _+ 47.6 778.1 +_ 384.2 6
% CV 39.7 49.4
Inter-individual 133.6 +_ 87.0 570.3 +_ 207.5 8
% CV 65.0 36.4
Table 4.5 Intra- and Inter-individual variation of [%]-serotonin
uptake parameters in normal male volunteers.
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the effect of a drug was being investigated, the procedure was as
described above, except for the following changes:
1) the volume of PRP used was 890 pi,
2) the pre-incubation time was 3 min,
3) after pre-incubation, 50 ptl of 199/ACD (pH 7.4) was added,
followed by a further 1 min incubation, and
4) either 199/ACD (50 pi, pH 7.4), or the drug diluted in
199/ACD (50 pi) was added, incubated for 1 min, after which
aggregation was induced by addition of ADP as above.
In each case, aggregation was allowed to proceed for 4-5 min, and,
where aggregation was carried out on more than two samples, tubes for
pre-incubation were staggered at intervals of 3-4 min, in a manner
similar to that employed for the [-^Hi-serotonin uptake experiments.
The variation seen in induced aggregation in the same volunteer
within run, or between runs is shown in Table 4.6. Figure 4.9 shows
typical profiles obtained when platelets from a normal volunteer are
aggregated by ADP.
4.4 Discussion
Blood samples were collected from subjects at approximately the
same time of day to avoid any variations which may be due to
circadian fluctuations of uptake, but generally, no special
precautions were taken to ensure that subjects had fasted prior to
venesection. Apparent rhythms of uptake have been reported in
normals (Arora, et al., 1984) and in depressed patients (Rausch,
et al, 1982). Also, nyctohemeral variations in serotonin
-159-
Parameter % Aggregation % CV n
(+ SD)
Intra-run 41.6 _+ 1.8 4.3 3
Inter-run 48.2+5.4 11.2 5
Table 4.6 Intra- and Inter-run variation in percentage
aggregation induced by ADP (4 pmol/l) in PHP
from a normal volunteer.
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Figure 4.9 Profiles of the ADP-indueed aggregation of plateletsfrom a normal volunteer.
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concentration have been described in the pineal gland of the rabbit,
with levels being highest during the day (Brainard, et_ al_., 1984);
rat serum serotonin has also been shown to fluctuate over a 24 h
period (Ho, et al., 1985), with maximal values occurring during the
light period. Whether these observed increases in serotonin
concentration are due to intrinsic rhythmic changes in the rate of
uptake of the indoleamine into platelets remains to be clarified, but
it has been suggested that the frequency of feeding is a stronger
entrainer of the rhythm of serum serotonin in the rat than the
light/dark cycle (Ho, et_ al_., 1985). A post-prandial increase in
blood serotonin has been reported in normal human volunteers (Kellum
and Jaffe, 1976); this effect may be due to release of serotonin from
the gut enterochromaffin cells due to direct stimulation of the
intestinal mucosa (Biber, et_ al_., 1974), or an increase in synthesis
of serotonin due to increased availability of the serotonin
precursor, tryptophan, from ingested food (Feltkamp, et_ al_., 1984),
since it has been suggested that the concentration of tryptophan is
the rate-limiting factor in serotonin synthesis (Lovenberg, et al.,
1967; Friedman, et al., 1972).
Slow-speed centrifugation of whole blood to prepare PRP has been
criticised since it is possible that the most dense platelets will be
spun down and lost from the PRP (Healy and Eagen, 1984). The
similarity between the profiles of platelet volume obtained from
citrated whole blood and from PRP prepared as described suggests that
the size distribution of platelets harvested from PRP as described in
this thesis is similar to that which exists in whole blood.
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Platelets isolated from whole blood for function tests should be
representative of the original total platelet population, otherwise
it would not be valid for iri vitro observations to be extrapolated to
the iri vivo situation. Although detailed investigation of this was
beyond the scope of this thesis, it should be emphasised that there
is much debate in the literature about the relationship between
platelet size, density, age, and function in PRP compared with whole
blood: Mezzano, et al., (1982) compared platelets recovered from PRP
(prepared by differential centrifugation of whole blood), with the
population of platelets trapped in the layer of packed red cells.
These workers found that 7-43$ of platelets in whole blood were
trapped in the red cell layer, but both populations of platelets had
the same mean volume, size distribution, and similar life-spans, as
determined by [-^Cr] labelling. The assumption here was that ageing
platelets would show a decrease in size and/or an increase in
density, and, if the most dense platelets were being trapped by the
red cells, there would therefore be an increase in radioactivity
recovered from the red cell layer as the population aged.
This was apparently contradicted by a later study (Mezzano, et
al., 1984), in which [^Cr] labelled low density human platelets
showed a decrease in specific activity compared with a high density
sub-population over a period of time, suggesting that newly-formed
platelets were low-density, effectively "diluting out" the original
labelled low-density cohorts, which would progressivly increase in
density as they aged, thus apparently maintaining the specific
activity of that high-density sub-population.
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Martin, et al., (1983) found virtually no difference in density
between platelet sub-populations, and suggested that density is
determined at the time of thrombocytopoeisis rather than by ageing;
others (Thompson, et al., 1984) showed the same size distribution
both in young (2 days post-infusion) and old (9 days post-infusion)
[^Se]-methionine-labelled baboon platelets, suggesting that platelet
size is age-independant. More recently, (Savage, et al., 1986)
showed that there was no difference in the in vivo survival time of
either low or high density [ ^^^In]-labelled baboon platelets; the
latter workers suggest that the great controversy in the literature
about the relationship between platelet size, volume, density, and
functionality may partly reflect the different methodologies
employed. Similar results had been found earlier by Healy and Eagen
(1984), who demonstrated that mean platelet volume and distribution
width could be affected by choice of anticoagulant, or the method of
preparation of PRP, with increasing g forces progressively depleting
PRP of the larger platelets.
In summary, it has been assumed in this thesis that platelets
harvested by low-speed centrifugation are a fair representation of
the total platelet population in whole blood, but it could be argued
that the distribution of platelets seen in whole blood ex vivo is a
misrepresentation of the in_ vivo situation, since it has been shown
that in the intact rabbit mesenteric artery, the red blood cells flow
predominantly in the centre of the vessel, whereas platelets are
distributed peripherally around the vessel walls (Tangelder, et al.,
1985). The net result is that there is a localised 30% increase
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in platelet concentration at the vessel walls compared with that in
isolated whole blood.
Visual estimation of platelet numbers by counting in a
haemocytometer is a common technique, but it is time consuming, and
requires a degree of skill and practice. Furthermore, unless strict
precautions are taken to avoid contamination by extrinsic particulate
matter (e.g. Born and Hume, 1967), falsely elevated counts will
result. For the visual estimations carried out in this thesis, the
platelets were not allowed to settle out in the haemocytometer, but
an attempt was made to include platelets distributed in different
planes by focusing up and down on the sample. Although this enabled
a rapid count to be made, it may also account for the poor precision
of the visual method. The higher count by the visual method is
almost certainly due to inclusion of extrinsic particulate material
in the count.
Centrifugal separation of the platelets from the incubation medium
after uptake was chosen, since this was rapid, and could easily be
performed at 4°C. Isolation of platelets by rapid filtration of the
incubate through a small-pore membrane (typically 0.45 pm or less),
followed by washing with cold buffer has been used by several other
groups to separate the bound and free fractions of [%]-serotonin
(see Table 4.6). This method suffers from the disadvantage that
bound tracer may be "washed out" into the filtrate from platelets
which lyse due to the washing procedure, and is consequently mis-
classified as free (Tuomisto, 1974). A similar criticism has been
made in a study of platelet [^H]-imipramine binding sites, in which
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either equilibrium dialysis or vacuum filtration was used to separate
the free radioisotope from the bound fraction (Lui, et al., 1984).
To date, there is no evidence in the literature that the effect of
tracer purity on the uptake of [%]-serotonin into platelets has been
critically evaluated. In light of the results obtained in this
thesis, this is surprising, since the purity of the stock tracer
decreased once the sealed vial had been opened, even though the
tracer was stored refrigerated as recommended by the manufacturers.
Thus, if no correction factor is applied, then as the purity of the
tracer decreases, the apparent uptake of serotonin will also
decrease. This may partly explain the variations in magnitude of
the uptake parameters Vmax and seen in platelets from normal
subjects (Table 4.5). Furthermore, if experiments are badly
designed (e.g. control group studied before experimental group),
significant differences may be observed due to poor methodology,
rather than any real biological difference.
The nature of the impure peaks was not investigated; it is
possible that some of the impurity was tritiated water, since this
highly polar molecule would not be retained by the hydrophobic column
and would elute in the void volume of the system (approximately 2
ml); such a peak is seen in Figure 4.4. It is also possible that
some of the impurity is an oxidised derivative of [%]-serotonin,
since the peak appeared after the tracer had been exposed to the
atmosphere.
The passive diffusion of [^H]-serotonin into platelets was
measured at 37°C using 1 pmol/1 chlorimipramine to block active
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uptake (Kamal, et al., 1984a) rather than incubating a parallel set of
tubes at 4°C. This was intended to reflect more accurately
diffusion at 37°C, since the rate of passive diffusion is known to
increase with increasing temperature (Arora and Meltzer, 1981).
Chlorimipramine was used since this is approximately 5 times more
potent than imipramine at blocking uptake, (Todrick and Tait, 1969).
PRP stored in an open container rapidly loses CO2 to the atmosphere
(Terres, et al., 1986), and becomes alkaline (Day, et al., 1975). This
rise in pH is accompanied by an apparent change in function, notably a
decrease in Vfflax (Lemmer, et al., 1977), increased responsiveness to
aggregating agents (Tang and Frojmovic, 1977), and an increase in the
rate of shape change (Malmgren, et al., 1985). Of the methods used
to try and minimise the loss of CO2, one of the most common is to
seal the PRP in a tube, after replacing the air above the PRP with a
mixture of 95$ air/5$ CO2 or similar; use of this method maintained
the pH of citrated PRP at approximately 7.3 for up to 3 h at 37°C
(Tang and Frojmovic, 1977), with no increase in function as measured
by the aggregation responses Tang and Frojmovic (1977) suggested that
the increase in PRP pH may somehow lead to an increased mobilisation
of calcium ions, which results in an enhanced aggregation response.
For the studies in this thesis, the PRP or diluted PRP used for
function studies was stored under 95$ 02/5$ CO2 and at room
temperature, in order to minimise alterations in platelet function
(Lemmer, et al., 1977; Tang and Frojmovic, 1977).
In the uptake studies, since only seven concentrations of [%]-
serotonin/cold serotonin were used for each uptake, the time interval
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between the start of the experiment and the last tube being pre-
incubated would be 30 min: this is calculated on the basis of a 10
min pre-incubation period for each concentration point, with tubes
set up for pre-incubation at intervals of 5 min. The time taken for
the uptake, centrifugation, and aspiration (which includes pipetting,
loading/unloading centrifuge, the acceleration or deceleration etc.),
can be estimated by allowing 2 min for the uptake procedure overall,
1 min 30 s for centrifugation, and 30 s for aspiration, total time
taken = 4 min, which leaves an interval of 1 min before the start of
the next incubation period. Thus even if the diluted PRP was left
exposed to the atmosphere, it is unlikely that significant decreases
in uptake would be seen.
There are several reasons why PRP was diluted prior to being used
in uptake studies: firstly, it enables uptakes to be performed over a
wide range of serotonin concentrations using a minimum volume of
PRP, and this was expected to result in a more accurate determination
of Vmax and K^. Secondly, dilution slows down the rate of uptake on
a "per tube" basis. This was necessary, since otherwise a large
proportion of free substrate (>25%) may be taken up by the platelets
after incubation for 1 min at 37°C (Malmgren, 1981); in such a
situation, it would not be valid to apply Michaelis-Menten kinetics
to the uptake process (Tuomisto, 1974), since a fundamental
assumption in the derivation of the Michaelis-Menten equation is that
there is no change in substrate concentration at initial velocity.
The uptake of serotonin by human platelets is linear with respect to
time for up to six minutes after the start of incubation (Arora and
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Meltzer, 1984), and the rate of uptake during the first minute is
taken to be the same as the initial velocity. This may explain the
observed differences in uptake between the diluted and undiluted PRP,
since in the undiluted samples, there will be a rapid substrate
depletion over the incubation period; thus in the two sets of tubes,
it is probable that the uptake process will be following two
different types of kinetics. As a method of reducing the rate of
[^H]-serotonin uptake per tube, dilution of PRP was more practical
than increasing the masses of substrate used, or decreasing the
incubation time to <1 min (Tuomisto, 1974; Malmgren, 1981).
Finally, it was hoped that dilution of PRP in a bicarbonate buffer
(i.e. KHS) we 11-saturated with CO2 would minimise the functional
changes associated with an increase in pH due to loss of CC>2 to the
atmosphere.
In serotonin uptake studies, it is common practice to calculate
r
the Vmax and ^ of the reaction from a straight line fitted by least-
squares linear regression to a Lineweaver-Burk plot of the
experimental data (e.g. Kamal, et al., 1984a; Lee and Chan, 1984;
Guicheny, et al., 1985). This technique has been criticised, since
unless proper attention is given to "weighting" of the data points
with the best precision, the least squares plot is unsatisfactory
(Nimmo and Atkins, 1979; Atkins and Nimmo, 1980).
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Furthermore, in the Lineweaver-Burk plot, the initial velocity (v^)
is plotted as:
_1_ = _1 +
vi ^max ^max's
where is the Michaelis constant, is initial velocity, Vmax is
maximum velocity, and s is substrate concentration; the result of
this is that undue emphasis is given to the smallest v^, which will
probably contain the largest errors (Dowds and Riggs, 1965). The
revised direct linear plot (Cornish-Bowden and Eisenthal, 1978) is a
distribution-free method of fitting a line to a set of points, and is
thought to be more robust and reliable than the Lineweaver-Burk plot
with linear regression (Dowd and Riggs, 1965; Nimmo and Atkins, 1979;
Atkins and Nimmo, 1980). The revised version of the plot is
equivalent to fitting a line to data for 1/v^ and 1/ (Nimmo and
Atkins, 1974), which was the method used in this thesis. Finally,
Nimmo and Atkins (1979) concluded that the direct linear plot
"...in general, appears to be superior to that of least squares...
Consequently, we believe the revised version of the plot should
become the standard method for estimating Michaelis constants."
In essence, the computer program calculates the equation of the
line between each data point, and every other data point; it has been
shown that for n_ co-ordinates, there are 0.5 x n_ x (n-1) possible
lines (Nimmo and Atkins, 1979). The gradients and intercepts of
these lines are then calculated algebraically (statements 270-340),
sorted into ascending order (statements 520-580), and the median values
-171-
taken as representing the line of best fit for those data (statements
740-860). In the revised plot (and as used by the computer
program), negative intercepts on the y-axis (i.e. negative 1/V )
are set to zero (statement 330), and their corresponding gradients
(Km/VmaX) set to 1 (statement 330), thus making Vmax and ^ very
large, as recommended in the modified original method (Cornish-Bowden
and Eisenthal 1978).
Platelet aggregation in vitro is a common test of platelet
function, and the methodology is well-established. However, as with
serotonin uptake studies, attention must be paid to the possibility
of spurious results resulting from technical rather than biological
differences. For example, after preparation, the PRP was stored at
room temperature sealed under an atmosphere of 5t C02> and
aggregation studies were completed within an hour of preparing the
PRP. The PRP was not diluted down with autologous PPP to give
constant counts for each experiment for two reasons: firstly, PPP is
known to contain "free" serotonin, the concentration of which may
depend on the degree of trauma during venesection, or the subsequent
processing of the blood/PRP. Serotonin itself can induce,
potentiate, or inhibit platelet aggregation (Baumgartner and Born,
1968), and it was felt that dilution with PPP which may contain
varying amounts of serotonin between experiments would be introducing
an unacceptable variable. Secondly, variations in the platelet
count do not appear to affect the aggregation response, unless the
concentration is <75 x 10^ platelets/1, at which point there is a
significant decrease in the extent of aggregation (Roper, et_ al.,
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1974; Levine, 1976).
Adenosine diphosphate (ADP) was used to induce aggregation, since
ADP may be released from injured blood vessels in vivo (Born, 1962),
or from damaged red cells (Born, 1962; Born, et al., 1976; Born,
1985). Therefore it was anticipated that the platelet response to




Serotonin, Angiotensin II, and Platelet Aggregation
5.1 Introduction
The steroid hormone aldosterone is known to be the major
inhibitor of natriuresis in higher mammals (see Fraser and Padfield,
1985). The increased production of aldosterone seen during sodium-
restriction results from increased stimulation of the zona
glomerulosa cells of the adrenal cortex by angiotensin II (All), the
circulating levels of which increase during sodium deprivation;
conversely, during sodium loading, All synthesis is reduced, which in
turn results in diminished aldosterone production (Figure 5.1).
Serotonin has also been shown to stimulate aldosterone production
from isolated zona glomerulosa cells in_ vitro (Haning, et al., 1970;
Williams, et al., 1984), and elevated plasma levels of aldosterone in
humans have been demonstrated after infusions of serotonin in man
(Mantero, et_ al., 1982). However, the relationship between
serotonin and sodium status in_ vivo remains to be clarified. It has
been demonstrated that All has a stimulatory effect in_ vitro on the
activity of tryptophan hydroxylase (possibly through its metabolite
AIII (Nahmod, et_ al., 1978)), which is the rate limiting step in
serotonin biosynthesis; thus it may be argued that increased levels
of All should lead to increased serotonin synthesis.
Angiotensin II is known to affect the response of platelets to
aggregating agents in_ vitro: high concentrations (10-^ mol/1) of All
inhibited the extent and velocity of adrenaline-induced platelet
aggregation (Ding, et_ al., 1985b), whereas low concentrations (10~^-
10"^ mol/1) of All potentiated the aggregation response (Poplawski,






































Figure 5.1 The relationship between sodium status and
the renin-angiotensin-aldosterone system
conversion
action at target site
negative feedback.
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have been shown to exist on human platelets, and the number of these
receptors was significantly reduced in normal human subjects during a
low salt diet (Ding, et_ al_., 1985a). Serotonin also affects in vitro
platelet aggregation in a pattern similar to that seen with All: high
doses of serotonin inhibit ADP-induced platelet aggregation, whereas
low doses cause potentiation of the aggregation response (Baumgartner
and Born, 1968). Receptors for serotonin have been shown to exist
on human platelets (Peters and Grahame-Smith, 1980), but it is not
yet known if these are affected by changes in dietary sodium intake.
This chapter describes experiments which were carried out to
investigate the effect of variations in sodium intake on serum
serotonin levels in rats, followed by further work in normal human
subjects.
5.2 Effect of Different Sodium Diets on Rat Serum Serotonin
Experiments were performed using normal female Wistar rats from
the Animal Unit, Western General Hospital. The rats (weights 175 —
250 g) were housed in the Animal Unit at a constant temperature of
19-21°C, with a day:night cycle of 12 h light:12 h dark. Three
separate experiments were performed, each with four groups of
five/six rats, maintained on either a standard diet (CRX rat chow),
low, normal or high sodium diet (Table 5.1) for 14 days. Blood was
collected on the morning of day 15 by cardiac puncture (following
ether anaesthesia of the rats), and serum prepared as described above
(3.2.6b). The serum was initially stored at -20°C, and was assayed
for serotonin by HPLC within a week of collection. The serum was










148.5 ■ 148.5 148.5
*Na (mg) 4.5 4.5 4.5
*K (mg) 534.6 534.6 534.6









Ad lib. Ad lib. Nil
Normal Nil Nil Ad lib.
saline
Table 5.1 Daily dietary allowance for rats
on varied sodium intake.
(* = from wholemeal flour)
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1981) by the staff of the routine RIA laboratory, Department of
Medicine, Western General Hospital, Edinburgh. Angiotensin II
levels were not measured, since the assay required approximately 5 ml
of plasma, and only 4-5 ml of whole blood could be obtained from each
rat. Results were analysed by the Student's t_ test, with p<0.05
being taken to represent a significant difference.
There was a significant (p<0.01) difference in serum serotonin
only when comparing rats on a low sodium diet with rats on a normal
sodium diet (Figure 5.2). The expected trends in serum aldosterone
levels were seen after the different sodium diets (Table 5.2). The
rats on the low sodium diet had significantly higher (p<0.001) serum
aldosterone levels than those on the standard diet, or normal or high
sodium intakes. Aldosterone levels in rats on high sodium intake
were not significantly depressed compared with the rats on the normal
sodium diet, but were lower (p<0.02) when compared with rats on the
standard Animal Unit diet. There was however, no significant
difference in serum aldosterone levels between the standard diet and
the normal sodium diets.
5.3 Effect of Different Sodium Diets on Angiotensin II, Serotonin,
and Aldosterone Levels in Normal Human Volunteers
Normal female volunteers (age 25-40 years) were studied during
the follicular phase of their menstrual cycle, first after a low
sodium diet, and then after a high sodium diet, with an intervening
period of at least 10 days on an ad_ libitum sodium intake. Each
subject was maintained on either a low sodium (10 mmol/day) or high












Figure 5.2 The effect of dietary sodium intake







Diet CRM Low Normal High
Na+ Na+ Na+
Mean (+ SD)
rat serum 2.3 12.1 1.8 1.7
aldosterone +0.7 +3.0 +0.6 +0.6
(nmol/1)
Table 5.2 Effect of varying sodium intake on
rat serum aldosterone levels.
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study. Potassium intake was constant at 80 mmol/day. A complete
urine collection was made during the 24 h preceding study to verify
that the subjects were in sodium balance. Blood was collected on the
morning of study, and PRP prepared (as described in section 3.2.5)
for aggregation studies and assay of serotonin by RIA; the PRP for
serotonin measurement was stored frozen (-20°C) until assayed, which
was within one month of the study day. Blood samples (9 ml) were also
taken into a solution (1 ml) of EDTA/o-phenanthroline (12.5 and
2.5 mmol/1 final concentrations respectively) for measurement of All
(Dusterdieck and McElwee, 1971; Morton and Webb, 1985) and into
lithium heparin tubes for analysis of aldosterone; plasma was
prepared by centrifugation of these samples for 20 min at 1,720 x g at
4°C. Angiotensin II and aldosterone levels were measured (RIA) by
the staff of the routine RIA laboratory, Department of Medicine,
Western General Hospital, Edinburgh: All was extracted from plasma
using C-]q "Sep-pak" cartridges (Morton and Webb, 1985), and measured
using antisera raised in rabbits against an All-bovine thyroglobulin
conjugate, using [1^I]-AII as the tracer. The aldosterone assay
was a direct RIA (Al-Dujaili and Edwards, 1981), using sheep antisera
raised against aldosterone-3-carboxymethyloxime, and the tracer was
[I]-histamine conjugated to the same oxime. Urinary electrolytes
were measured (flame photometry) by the staff of the Metabolic Unit,
Western General Hospital. Blood pressures for each subject (supine
for 30 min prior to the first reading) were the means of 5
consecutive readings taken using a "Copal" electronic sphygmo¬
manometer. Unless otherwise stated, statistical analyses were
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performed using Student's paired t_ test.
All subjects were in sodium balance on the day of study (see Table
5.3 for summarised results); there was no significant change in
urinary potassium excretion, and no change in either the systolic or
diastolic blood pressure between the two diets, but plasma levels of
both All and aldosterone fell significantly (p<0.01 and p<0.001
respectively) when the intake of sodium was increased. There was no
significant correlation between the concentration of serotonin and
aldosterone (Figure 5.3), or plasma All and serotonin (Figure 5.4).
Significant positive correlations were observed between plasma All
and aldosterone levels (Figure 5.5), and nmol serotonin/1 PRP and
g
pmol serotonin/10 platelets (Figure 5.6).
There was a significantly (p<0.01) greater number of platelets/ml
recovered in PRP from volunteers on a low sodium diet compared with a
high sodium intake (Figure 5.7); the mean platelet volumes (MPV) and
platelet distribution width (PDW) did not change (Figure 5.8).
Serotonin concentration (nmol/1 PRP) fell significantly (p<0.01) when
subjects changed from a low to a high sodium intake (Figure 5.9);
g
when expressed as pmol/10 platelets, the mean serotonin
concentration still fell, but this drop was not significant
(Figure 5.10).
5.4 Effect of Different Sodium Diets on ADP-induced Aggregation of
Platelets from Normal Human Volunteers
Aggregation studies were completed as described (section 4.3)
within 90 min of venesection using ADP as the aggregating agent at




High Na+ n p value
Diet
Systolic 102.7+5.9 102.7+8.7 12 NS
Pressure (mm Hg)
Diastolic 65.2_+8.0 62.3+5.0 12 NS
Pressure (mm Hg)
Plasma All 35.3+21.6 18.9+17.2 10 p<0.01
(pg/ml)
Plasma Aldosterone 1010.0_+343.4 362.9_+l86.6 12 p<0.001
(pmol/1)
Urinary Na+ <20 193.5^25.6 12
(mmol/24 h)
Urinary K+ 66.9+21.5 69.1+/17.5 12 NS
(mmol/24 h)
Platelets 449.0+19.5 370.0+17.5 11 p<0.01
(x 109/1PRP)
Serotonin 1642.0+548.4 1241.3+555.9 11 p<0.01
(nmol/1)
Serotonin 360.6+93.8 335.1+133.3 11 NS
(pmol/10° platelets)
Aggn. ADP 1 pmol/1 18.6+7.9 30.3+/12.6 10 p<0.05
ADP 4 pmol/1 49.9+7.2 68.6+9.3 10 p<0.001
Rate ADP 1 pmol/1 53.3+18.6 62.8+18.1 10 NS
ADP 4 pmol/1 113.0+28.2 116.7+11.5 10 NS
Table 5-3 Summary of results (mean jh SD) on the effect of
varying sodium intake in normal female volunteers.
Aggn. = t extent of aggregation




(Analysis by Spearman's rank correlation coefficient: NS)
Figure 5.3 Correlation between plasma serotonin and aldosterone
concentrations in normal females (pooled results
from low and high sodium diets).
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(Analysis by Spearman's rank correlation coefficient: NS)
Figure 5-4 Correlation between plasma All and serotonin
concentrations in normal females (pooled results




(Analysis by Spearman's rank correlation coefficient: p<0.01)
Figure 5.5 Correlation between plasma All and aldosterone
concentrations in normal females (pooled results




(Analysis by Spearman's rank correlation coefficient: p<0.001)
Figure 5.6 Correlation between pmol serotonin/10® platetlets
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Figure 5.7 Comparison of normal female platelet counts (PRP)




















Low Salt High Salt
Figure 5.8 Comparison of mean platelet volume (MPV),
and platelet distribution width (PDW) in














Low Salt High Salt
Figure 5.9 Comparison of PRP serotonin levels (nmol/l)
in normal female volunteers on a low
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O
Figure 5.10 Comparison of PRP serotonin levels (pmol/10 platelets)
in normal female volunteers on a low or high sodium diet.
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calculated by measuring the slope of the initial phase of
aggregation, and expressing this as % transmission/min, with
PPP = 100%, and PRP = 0%. Typical aggregation profiles using
platelets from a volunteer initially on a low sodium diet, followed
by a high sodium diet, are shown in Figure 5.11. Changing from a
low to a high salt intake resulted in irreversible aggregation with 4
p.mol/1 ADP (Table 5.4), and a significant increase in the extent of
aggregation in_ vitro using both 1 and 4 pmol/1 ADP (Figure 5.12 and
Table 5.3); there was no difference in the initial rate of
aggregation between the two salt diets (Figure 5.13 and Table 5.3).
A significant inverse correlation was seen between log serotonin
concentration (nmol/1 PRP) and the extent of aggregation induced by
4 pmol/1 ADP (Figure 5.14a). A similar but not significant trend
O
was seen between log serotonin concentration (pmol/10 platelets) and
the extent of aggregation induced by 4 pmol/1 ADP (Figure 5.14b).
There was no significant correlation between the measured levels of
plasma All and the extent of in_ vitro aggregation induced by 1 pmol/l
ADP (Figure 5.15), but there was a significant (p<0.02) correlation
between the extent of aggregation induced by 4 pmol/1 ADP, and plasma
All concentration (Figure 5.16).
5-5 Effect of adding Ketanserin or Saralasin in vitro on the ADP-
induced Aggregation of Platelets from Normal Human Volunteers
during Different Sodium Intakes
The effect of pre-incubating PRP for 1 min with either the






Figure 5.11 Typical platelet aggregation profile obtained using
4 mol/1 ADP with PRP from a normal female volunteer
on either a low or high sodium diet.
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Volunteer Low Na+ High Na+
1 Mjnol/1 4 pjnol/1 1 pmol/l 4 |j,mol/l
ADP ADP ADP ADP
1 N N N Y
2 N N N Y
3 N N N Y
4 N N N Y
6 N N N N
7 N N N Y
8 N N N N
9 N N N N
10 N N Y Y
11 N N N N
Table 5.4 Presence of irreversible aggregation in platelets
from normal female volunteers on varying sodium intakes:
N = no irreversible aggregation















Low salt High salt
4 pimol/l ADP
Figure 5.12 Effect of varying sodium intake on the extent
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1 pmol/l ADP 4 jjmol/l ADP
Figure 5.13 Effect of varying sodium intake on the rate
of ADP-induced aggregation in PRP from
normal female volunteers.
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Serotonin Concentration (log nmol/1)
(Analysis by Spearman's rank correlation coefficient: p<0.05)
Serotonin Concentration (log pmol/1 Gaplatelets)
(Analysis by Spearman's rank correlation coefficient: NS)
Figure 5.14 Correlation between serotonin concentration,
and extent of aggregation induced by 4 pmol/1 ADP
in PRP from normal female volunteers
(pooled results from low and high sodium diets):
a) % aggregation vs. log nmol serotonin/1
O
b) % aggregation vs. log pmol serotonin/10 platelets
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70 ~ y = -0.253x + 32.6
■ r - 0.411
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(Analysis by Spearman's rank correlation coefficient: p<0.02)
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Figure 5.15 Correlation between All concentration, and
extent of aggregation induced by 1 pmol/1 ADP
in PRP from normal female volunteers

















(Analysis by Spearman's rank correlation coefficient: p<0.02)
Figure 5.16 Correlation between All concentration, and
extent of aggregation induced by 4 pmol/1 ADP
in PRP from normal female volunteers
(pooled results from low and high sodium diets).
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the All antagonist saralasin (1 nmol/1) was studied as described in
section 4.3.
Ketanserin significantly decreased both the extent and initial
rate of aggregation induced by 4 p.mol/1 ADP in PRP prepared from
subjects after sodium loading : when the subjects were on a high
sodium intake, the extent of aggregation (%) fell from 64.2 +_ 7.9 to
55.3 _+ 4.4 (mean +_ SD; p<0.02, control and with ketanserin
respectively, n = 6) compared with 49.0 _+ 8.0 to 47-1 +_ 8.7 (mean +_ SD;
NS, control and with ketanserin respectively, n=7) using PRP taken
from the same subjects on a low sodium diet (see also Figure 5.17).
The rate of aggregation (%/mln) fell from 121.2 _+ 7.4 to 107.2 +_ 10.3
in PRP from subjects on a high sodium intake (mean _+ SD; p<0.05,
control and with ketanserin respectively, n=6), whereas on a
restricted sodium diet, the aggregation rates were 113.1 _+ 25.5 and
103.8 _+ 25.5 (mean _+ SD; NS, control and with ketanserin
respectively, n=7; see Figure 5.18). Saralasin had no significant
effect either on the extent or the initial rate of aggregation
(Figures 5.17 and 5.18), but it was noticed that addition of
saralasin in vitro caused a rapid decrease in light transmission of
the sample (e.g. Figure 5.19), which is usually attributed to the
platelets changing shape (Born, 1970). Ketanserin resulted in an
initial increase in light transmission, which is presumably due to a
dilution effect, since this was also observed when 199/ACD alone was
added (Figure 5.19).
-200-
n-7 n=7 n=6 n=6
1 i 1 i 1 i 1
+ Ketanserin Control + Saralasin Control + Ketanserin Control + Saralasin
(l|imoL'l) (Inmol'l) (ijrmol/l) (Inmol'l)
Effect of ketanserin (1 fimol/1) and saralasin
(1 nmol/1) on the extent of aggregation induced
by 4 mnol/1 ADP in PRP from normal female
volunteers on low or high sodium diets.
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Low Salt Intake High Salt Intake
Figure 5.18 Effect of ketanserin (1 pmol/1) and saralasin
(1 nmol/1) on the rate of aggregation induced
by 4 nmol/1 ADP in PRP from normal female















Figure 5.19 Effect of a) Medium 199/ACD, b) saralasin (1 nmol/1),
or c) ketanserin (1 pmol/1) on the light transmission
of PRP prepared from normal female volunteers on low
or high sodium diets.
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5.6 Discussion
In the rat model, there was a significant difference in serum
serotonin levels between the low and the medium salt diets; given
this difference, it was somewhat surprising that further suppression
of the renin-angiotensin system by increasing the sodium load
resulted in a slight but insignificant rise in serum serotonin; the
reason for this apparent anomaly remains unresolved. The
aldosterone results show the expected trend, i.e. gradual decrease
of serum aldosterone with increased sodium load.
Platelets from volunteers on low-sodium diets (i.e. high plasma
All levels, low platelet All receptor density) are known to exhibit
decreased aggregation in vitro when compared with a high sodium
intake (i.e. low plasma All levels, high platelet All receptor
density): groups studied included normal males, normal males
with a high risk of becoming hypertensive (Nara, et al., 1984), and a
sub-group of essential hypertensives (Ashida, et_ al_., 1985).
Similarly, in Bartter's Syndrome, a disease where blood All levels
are chronically elevated, induced platelet aggregation in vitro is
markedly reduced, and can be inhibited further by sodium deprivation
(Stoff, et al., 1980; Van Wersh and Pereira, 1983). The results
found in the study described here are in accordance with these
previous observations, and provide further evidence that All may
modulate platelet function, although the mechanism of the enhanced
platelet aggregation seen during a high salt intake remains to be
elucidated.
The slight decrease in platelet levels of serotonin between the
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low and high sodium diets may reflect an increase in platelet
responsiveness and release during a high sodium intake, as
suggested by the in vitro data, although the difference did not reach
statistical significance, possibly due to the small sample number.
Furthermore, it must be borne in mind that subtle differences in
platelet biochemistry may not have had the opportunity to express
themselves: the volunteers were either sodium restricted or sodium
loaded for 4 days prior to the study, therefore only approximately
half their total population of platelets could have been affected by
the diet, as the lifespan of a human platelet is thought to be
approximately 10 days (Aster and Jandel, 1964), and platelets once
formed have virtually no capacity to synthesise new proteins.
The possibility that an increase in platelet serotonin release
occurs during the high sodium state, which then enhances platelet
activation is an attractive hypothesis, since this could explain
1) the slight loss in platelet serotonin, 2) the increase in the
extent of aggregation, 3) the reduction of the enhanced aggregation
by the serotonin antagonist ketanserin, 4) the inverse relationship
between platelet serotonin content and induced aggregation, 5) the
inverse correlation between All levels and the extent of induced
aggregation (i.e. lowest All levels during sodium loading), and 6)
the lack of irreversible aggregation seen with platelets from most of
the low-sodium volunteers (a similar change in the aggregation
profile following sodium loading has already been described elsewhere
(Ashida, et_ al_., 1985)). Unfortunately, no other markers of
platelet release (e.g. Q -thromboglobulin, or platelet factor 4) were
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measured in this study; it would also have been useful to have
measured in vivo platelet activation and aggregation, possibly by the
method of Wu and Hoak (1974), as this may have indicated whether the
low platelet recoveries seen during sodium loading were due to loss
of platelets as aggregates during the centrifugation step.
The effects seen with the serotonin antagonist ketanserin and the
All antagonist saralasin are more difficult to interpret, since
ketanserin is also thought to have partial <s<-adrenoreceptor
antagonist activity (van Nueten et al., 1981; Marwood and Stokes,
1984), and platelets are known to have °<'2~a^renoreGeP^or's (Motulsky
and Insel, 1982; Bond and Salmon, 1985); however, it seems that
ketanserin acts via the o<-|- and not the o^-adrenoreceptor (Kalkman,
et al., 1982; Marwood and Stokes, 1984), thus it is anticipated that
the effects observed in this study are not due to blockade of
adrenaline, a potent inducer of platelet aggregation. Saralasin is
known to have a slight agonist activity at high concentrations, at
least during in vivo infusions in man (MacGregor and Dawes, 1976), so
whether the decrease in light transmission seen in PRP incubated with
saralasin is due to blockade of the All receptor or an All-agonist
effect is not known. However, it does suggest that All may be a
factor in regulation of platelet shape.
If, as has been suggested, All can stimulate the synthesis of
serotonin directly (Nahmod, 1978), the net effect during sodium
restriction may be twofold: firstly, an All-induced increase in
serotonin levels may result in direct inhibition of platelet
responsiveness due to saturation of the serotonin binding sites on
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the platelet membrane (Baumgartner and Born, 1968; Baumgartner and
Born, 1969). Secondly, if the platelets were less active in vivo,
then there would be diminished release of platelet-bound serotonin,
resulting in an apparent increase in platelet levels of serotonin.
However, there is no evidence in this study to suggest that All can
regulate serotonin production. The significant negative correlation
between All levels and in_ vitro aggregation induced by 4 pmol/l ADP
does not demonstrate that the level of All in vivo can affect in
vitro aggregation directly, although the observed trend is in
agreement with the findings of Ding, et_ al., (1985b), where high in
vitro levels of All were seen to inhibit the adrenaline-induced
aggregation of human platelets, whereas lower doses of All
potentiated the response. It then becomes difficult to explain the
report by Someya, et_ al., (1984), who demonstrated that chronic
therapy with the ACE inhibitor captopril significantly reduced in
vitro platelet aggregation in patients with essential hypertension
(the drug itself had no in vitro effect).
One possible explanation is that All may modulate platelet
function through prostaglandin production: it has been demonstrated
that All invoked the release of a compound with prostacyclin-like
activity from the canine kidney (Shebuski and Aiken, 1980), which
would be expected to decrease platelet activity in vivo. These
workers reported that the effect of the putative prostacyclin lasted
for 45 min after the All infusion, but since prostacyclin in man does
not circulate at levels which would be expected to have a biological
effect (Blair et al., 1982; Ritter, et_ ajL., 1983), and infusions of
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prostacyclin in humans (5-10 ng/kg) are reported to decrease ex vivo
platelet aggregation for up 30 min post-infusion (Szczeklik, et al.,
1978; FitzGerald, et al., 1979) the observed changes in platelet
function must be maintained by other, less transient mechanisms,
possibly a prostacyclin-induced elevation of platelet cAMP
(Szczeklik, et_ al_., 1978) which is known to inhibit the platelet
aggregation response by decreasing the available free cytosolic Ca^+
(Vermylen, 1978).
The stimulation of prostaglandin production by All may be
indirect: the enzyme (angiotensin converting enzyme, ACE) which
/ ff
produces All from angiotensin I (Al) also degrades bradykinin (Erdos,
1975), a peptide which stimulates prostaglandin synthesis (McGiff, et_
al., 1972); an increase in All production (e.g. in salt restriction,
or Bartter's Syndrome) may mean that the active site on the ACE
molecule is occupied by Al in preference to bradykinin. This would
lead to an increase in bradykinin, and hence prostaglandin
production, and possibly decreased platelet aggregation. Similarly,
captopril binds to the ACE molecule, thus blocking the production of
All, but also inhibiting the degradation of bradykinin (Mullane and
Moncada, 1980), therefore having the same effect on platelet function
as low salt or chronic elevation of All production.
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Chapter 6
Serotonin and Cadiovascular Diseases
6.1 Introduction
There have been many reported differences in biochemistry and
behaviour between platelets isolated from normal subjects and from
patients with essential hypertension (for a review, see De Clerck,
1986). There is also some evidence to suggest that serotonin may be
a factor involved in the pathogenesis of essential hypertension, both
in man and in experimental animals: in patients with essential
hypertension, treatment with the serotonin 5HT2-receptor antagonist
ketanserin resulted in a significant decrease in blood pressure (De
Cree, e_t al., 1981; Wenting, et_ al., 1984), while blood platelets
from patients with essential hypertension, or from spontaneously
hypertensive rats, have been reported to possess an impaired
serotonin uptake mechanism (Bhargava, et_ al_., 1979; Palmero, et al.,
1982; Kamal, et al., 1984a and 1984b; Sharma, et al., 1985),
decreased platelet levels of serotonin (Bhargava, et al., 1979;
Kamal, et al., 1984a and 1984b; Sharma, et al., 1985), and an
apparent increase in plasma "free" serotonin (Palmero, et al., 1982;
Sharma, et_ al., 1985). Also, when compared with normal platelets,
platelets from patients with essential hypertension have increased
free cytosolic calcium (Le Quan Sang and Devynck, 1986), and release
[%]-serotonin at lower doses of thrombin (Valtier, et_ al_., 1986).
It has been suggested (Bhargava, et al., 1979) that the observed
impaired uptake of a neurotransmitter (i.e. serotonin) into blood
platelets may reflect abnormalities in neuronal control of the
cardiovascular system, since platelets are thought to be a good model
of the adrenergic neurone (Abrams and Soloman, 1969) as both types of
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cell have many similar biochemical properties (see Table 6.1).
There are several studies which describe abnormal platelet
activity in heart disease; elevated levels of plasma /3-thrombo-
globulin (BTG), an indicator of platelet activation and release, have
been reported (Mehta and Mehta, 1982; Pumphrey and Dawes, 1982;
Pengo, et al., 1985); increased platelet aggregation and an elevation
of thromboxane A^ (TXA2) production have also been described
(Schwartz, et al., 1980; de Boer et al., 1982). Both TXA£ and
serotonin are released from platelets during aggregation, and both
are potent vasoactive compounds, so it is conceivable that these
compounds may play a role in the development, if not the initiation,
of cardiovascular disease. The relationship between plasma
serotonin levels and heart disease is not well documented, which is
surprising given the body of evidence for abnormal platelet behaviour
in this group of patients, and the potent vasoactive effects of
serotonin.
6.2 Comparison of Serotonin Levels and C^H]-Serotonin Uptake
in Patients with Essential Hypertension and Normal Controls.
PRP was prepared from males clinically diagnosed as suffering
from essential hypertension, or normal male controls. All patients
and controls had refrained from taking any medication with known or
suspected anti-platelet activity, for the preceding 7 days. Platelet
serotonin content was measured by HPLC, and blood pressure by a
"Copal" electronic sphygmomanometer (mean of 3 consecutive readings).
The uptake of [^Hj-serotonin was measured in the 7 hypertensive




Synthesis of serotonin No Yes
Limiting membrane Yes Yes
Mitochondra Yes Yes
Monoamine oxidase Yes Yes
Active transport of serotonin Yes Yes
" " " dopamine Yes Yes
" " " noradrenaline Yes Yes
Storage of biogenic amines Yes Yes
in granules
Release of stored amine Yes Yes
by reserpine
Table 6.1 Some similarities between platelets and synaptosomes
(after Sneddon, 1973).
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determined by Coulter counter in the Haematology Department, Western
General Hospital. All results were analysed initially by the
Student's _t test, and later by Wilcoxon's rank sum test.
The results of the study are summarised in Tables 6.2 and 6.3.
The systolic and diastolic blood pressures were elevated
significantly in the hypertensive group (p<0.001 for both, Student's
t_ test), and PRP serotonin concentration (nmol/1) in the hypertensive
group (n=7) was significantly lower (p<0.05; Student's t_ test) than
the control group (n=12). No other significant differences were
observed between the two groups studied using either the Student's t_
test, or Wilcoxon's rank sum test. When the control group was
reduced to n=8, although the trend was the same, no significant
difference was found in the serotonin levels between the two groups
(Table 6.3) using either of the statistical tests.
6.3 Serotonin Levels in Patients with Cardiac Failure Before and
After Captopril Therapy.
A group of patients (4 male, 1 female) with heart failure (New
York Heart Association Class III-IV) were selected for study. These
patients were diagnosed as suffering from cardiomyopathy on the basis
of clinical assessment and echocardiography, and had failed to
respond to conventional diuretic therapy (frusemide, 80 - 120 mg/day).
Patients were each studied on two separate days, and blood samples
were taken on each day for analysis of serotonin levels by RIA.
On the first day, blood was collected from the femoral vein via a




























Pressure (mm Hg) +11.5
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Table 6.2 Comparison of results (mean value _+ SD) from normal males,
























































Table 6.3 Comparison of results and parameters of serotonin
uptake (mean value +_ SD) from normal males, and
males with essential hypertension; p value from
Students t test.
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indwelling for <30 min. Samples were taken prior to, and 1 h
after administration of captopril (25 mg orally). The 1 h time
point was chosen for study since the maximum blood concentration of
captopril occurs 45 - 60 min after oral administration (Shaw, et_ al.,
1985). Thereafter, each patient received 25 mg captopril orally
three times daily, and continued with frusemide 40 - 80 mg/day as
maintenance therapy. Re-admission for the second study day was
after at least one month of therapy. On the second study day, blood
was taken from the antecubital vein using a 19 gauge needle as
described (3.2.5).
The results are summarised in Table 6.4. There was no
significant increase in plasma serotonin concentration within 1 h of
receiving captopril (Student's t_ test; Figures 6.1 and 6.2).
Chronic captopril therapy, however, resulted in an increase in total
serotonin (i.e. nmol/1 PRP; p<0.05, Student's _t test), but not in
O
platelet serotonin (pmol/10 platelets; Figures 6.1 and 6.2). There
was no change in PRP platelet count following captopril therapy.
Further analyses of these data by the Wilcoxon rank sum test failed
to reveal significant differences between any of the measured
parameters.
6.4 Discussion
Although there was no significant difference in age between the
controls and the patients with essential hypertension the two groups
were poorly age-matched, and may indeed be biologically different.
It is not clear whether this would affect the serotonin levels, since
little work has been done in this area; however, it is known that the
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Table 6.4 Paired mean (_+ SD) serotonin levels and PRP platelet
counts in heart failure patients before starting
captopril therapy, and after
a) 1 h, or














i 1 i 1
Pre Post Pre Post
captopril captopril captopril captopril
(1h) (> 1 month)
Figure 6.1 Effect of captopril therapy on serotonin levels












i 1 i 1
Pre Post Pre Post
captopril captopril captopril captopril
(1 h) (> 1 month)
Figure 6.2 Effect of captopril therapy on serotonin levels
(pmol/10 platelets) in patients with heart failure.
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plasma levels of ^3-thromboglobulin (BTG) an indicator of platelet
release, do increase with age (Ludlam, 1979). There was no
significant correlation between age and serotonin concentration
(nmol/1 PRP) in the control group (serotonin = 1971.9 - 9.0 x age;
NS; n=12), therefore it seems unlikely that any decrease in total
serotonin seen in these data would be due to an age-related increase
in the release reaction. Both systolic and diastolic blood pressure
are known to increase with age (Hamilton, et al., 1954), but the
group of patients studied here had already been selected on the basis
of having abnormally high blood pressure for their age group.
No significant differences were seen in the kinetics of
[^Hj-serotonin uptake between platelets from patients with essential
hypertension, and the normotensive control group. There may be
several reasons why the results obtained in this study differ from
those obtained by other workers (e.g. Bhargava, et al., 1979; Kamal,
et al., 1984a and 1984b). The sample size is small, so that a small
difference between the two populations may not be statistically
significant (Kamal, et al., (1984a) saw significant differences with
a sample size of 16-17 for the controls or patients). Also, it is
possible that the population of patients suffering from essential
hypertension is itself subdivided: Ashida, et al., (1985) demonstrated
that a group of essential hypertensives who changed from a high to a
low sodium diet could be divided into two types, namely those whose
blood pressure fell ("responders") and those whose blood pressure
remained unchanged ("non-responders"). In the "responders" there
was a significant increase in platelet "^-ad^enoreceptors during
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salt loading, but there was no such increase in the non-responders.
The methodology used to study platelet [^Hj-serotonin uptake in this
thesis may also have influenced the results: if the alteration in
uptake kinetics is due to an endogenous plasma factor rather than a
platelet defect, dilution of PRP in KHS may have reduced the
concentration of this putative inhibitor to such an extent that it
has no observable effect on uptake. Endogenous imipramine-like
factors have been described in human plasma (Angel and Paul, 1984;
Brusov, et al., 1985), and it is known that other plasma components
can reduce the uptake of serotonin into platelets (e.g. derivatives
of phenylethylamine (Richter and Smith, 1974), and derivatives of
tryptamine (Born, £t al., 1972; Baker, et al., 1980)). Furthermore,
in migraine, where, during an attack, platelet levels of serotonin
are decreased (Hilton and Cumings, 1971) and there is impaired
platelet serotonin uptake (Coppen, £t al., 1979), Launay and
Pradalier (1985) demonstrated that the inhibition of uptake is
probably due to an unidentified plasma factor rather than a platelet
defect. It is conceivable a similar situation may exist in
essential hypertension. It is unlikely that the reported inhibition
of uptake of radioactive serotonin into platelets is due entirely to
endogenous "free" serotonin in the samples, since this would not
result in a change in V_,.v, as the inhibition would be trulyIuctwC
competitive.
The difference in PRP serotonin concentration between the controls
and the patients with essential hypertension was not significant
after correcting for the platelet count; this may be due in part to
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inclusion of further errors (i.e. from platelet counting) affecting
overall precision, but it also reflects the higher platelet counts
seen in normal PRP compared with PRP prepared from patients with
essential hypertension. This probably does not reflect differences
in whole blood platelet numbers, since essential hypertension
patients are reported to have a normal whole-blood platelet count
(Mehta and Mehta, 1981). However, platelets from patients with
essential hypertension do show an increased tendency to aggregate
compared with normals (e.g. Someya, et al., 1984), and enhanced loss
of aggregates (formed either in vivo or ex_ vivo) during preparation
of citrated PRP would thus lead to a lower total platelet recovery.
Platelets from patients with essential hypertension may be generally
hyperactive, since they are known to contain elevated levels of
cytosolic free Ca^+ (Le Quan Sang and Devynck, 1986), which is
necessary for platelet shape change and aggregation (see Ardlie,
1982); also the dense granule release reaction can be induced with
lower doses of thrombin than are needed for normal platelets
(Valtier, et al., 1986). An enhanced release reaction would explain
the decrease in serotonin levels and the elevated levels of BTG
described in patients with essential hypertension (Kjeldesen, et_ al.,
1973). In summary, the observed trends between normals and patients
with essential hypertension are in agreement with those described by
other groups, particularly the significant changes in PRP serotonin
(e.g. Bhargava, et al., 1979; Kamal, et_ a_l., 1984a and 1984b),
whereas for the other measured parameters, the changes did not reach
statistical significance.
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The increase in platelet serotonin in the heart failure patients
receiving captopril, although not significant, may reflect a general
improvement in platelet function following chronic therapy. In
patients with essential hypertension, it is known that in_ vitro
aggregation is diminished after captopril therapy (Someya, at al.,
1984) compared with normals, and this was not due to a direct effect
of the drug on aggregation; it was suggested that, since captopril
also inhibits the degradation of bradykinin, which in turn may lead
to increased prostaglandin synthesis, the effect may be mediated
through a captopril-induced increase in prostacyclin, resulting in a
reduction in induced aggregation. However, as it is unlikely that
prostacyclin circulates in appreciable quantities, the observed
effect must be mediated by other mechanisms (see section 5.4).
Pumphrey and Dawes (1982) showed that patients with heart disease had
increased platelet activation in vivo as measured by BTG levels, so
the possibility exists that in the group of heart-failure patients
studied here, chronic captopril therapy has the same effect on
platelet activity as has been described in patients with essential
hypertension (Someya, et_ al., 1984).
Thus in the two groups of patients with cardiovascular disease,
the measured serotonin levels may reflect a) increased platelet
activation in patients with untreated essential hypertension, and
b) decreased platelet activation in patients with heart failure
following treatment with captopril and diuretics, possibly resulting




General Discussion and Conclusions
7.1 Assays for Serotonin
The serotonin assays developed in this thesis have been used to
determine serotonin status in various physiological and patho¬
physiological situations; the HPLC-ECD assay is simple, precise, and
can be used to measure several 5-hydroxyindoleamines (or other
electrochemically active compounds) in a single injection of sample;
the major disadvantage with this method is that few (<20) samples can
be processed within a working day, compared with up to 100/day by the
RIA. The sensitivity of the HPLC-ECD assay was not studied
formally, but it can be estimated by assuming that if the smallest
detectable peak is 3 times the height of the baseline noise
(approximately 5 mm deflection at sensitivity 0.2 nA full scale
deflection), then this corresponds to a serotonin concentration of
approximately 4 nmol/1, which is comparable with other published
HPLC-ECD methods (Table 7.1).
A radioimmunoassay method similar to that described in this thesis
has recently been published (Manz, et al., 1985). These workers
raised antisera to N-succinamylserotonin-BSA after the method of
Delaage and Puizillout (1981), but derivatised serotonin by
acetylation with acetic anhydride; this group also monitored the
acetylation by HPLC-UV, but, contrary to the results of this thesis,
they found that no diacetylserotonin was produced. This conclusion
was based on the observation that acetylation of serotonin followed
by HPLC analysis and RIA of the fractions elution from the HPLC both
yielded single peaks, but since no elution profile for diacetyl¬





2.3 Fujimori, et al., 1982
<4 Petruccelli, et al., 1982
5 Tagari, et al., 1984
1 Molyneux and Clark, 1985
Table 7.1 Sensitivities of other published HPLC-ECD methods
(assuming 25 pi injection).
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diacetylserotonin were isographic in their HPLC system. This group
did not validate their RIA with any reference method, whereas the RIA
developed in this thesis is currently the only RIA for serotonin
which has been validated against a reference method (HPLC-ECD). The
assay has been used to measure serotonin in a variety of matrices,
including human PRP, rat serum, and Medium 199 for in vitro platelet
release studies.
The only major disadvantage with the RIA developed in this thesis
is that serotonin is converted into N-acetylserotonin for
measurement; this molecule is present in many biological matrices,
and although the levels are low enough in plasma relative to
serotonin to enable any interference to be ignored, this may not be
the case in other biological fluids or tissues. This problem may be
circumvented in a derivative assay by creation of a derivative which
does not exist biologically. Such an assay has been described for
histamine, where the molecule is derivatised to 2-histamyl-1,4,-
benzoquinone (Guesdon, et al., 1986); this would presumably work with
serotonin (or any other monoamine), since the modification is carried
out at pH 4.5, which would not result in the destruction of the
indole nucleus.
7.2 Assay Application
Variations in sodium status in normal females significantly
altered the extent of ADP induced platelet aggregation in_ vitro, PRP
serotonin concentration (nmol/1), and the number of platelets
recovered in PRP. There was an inverse relationship between the
extent of induced aggregation, and the total serotonin concentration
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(nmol/1 PRP). Furthermore, salt loading resulted in a reduction
in the rate and extent of ADP-induced aggregation when the serotonin
antagonist ketanserin was added in vitro. Thus, high in_ vivo All
levels were accompanied by low levels of in_ vitro platelet
aggregation; the increase in the extent of aggregation seen on salt
loading may reflect an increase release of platelet constituents,
possibly including serotonin. This would explain the inhibitory
effect seen with the serotonin antagonist ketanserin, and also the
increase in aggregation, since serotonin is known to potentiate the
effect of other aggregating agents. Whether All affects aggregation
directly, or indirectly remains to be clarified, but it has been
suggested that All may stimulate the release of, or potentiate the
action of TXA£ (Ding, et al., 1985b).
In the patients with heart failure, chronic captopril therapy
(which is known to decrease circulating All levels) resulted in an
increase in total serotonin levels (nmol/1 PRP). It is possible
that this is mediated by a captopril-induced increase in bradykinin
levels (the enzyme producing All from AI also degrades bradykinin),
which may result in an increased production of prostaglandins (e.g.
prostacyclin), and ultimately a decrease in platelet activation.
The observed increase in serotonin concentration may therefore
reflect decreased platelet activation due to chronic captopril
therapy in these patients.
The patients with essential hypertension had lower total serotonin
(nmol/1 PRP) levels than the normotensive control group. No
significant difference was seen between the two groups with regard to
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the kinetics of serotonin uptake. Analysis of the [^H]-serotonin
used for the uptake studies by HPLC-ECD showed that the purity
decreases rapidly once the sealed vial is opened (<85% pure after 4
weeks, <60$ pure after 16 weeks), and only the remaining radioactive
serotonin is taken up into the platelets. Thus uptake values must
be corrected for tracer purity, otherwise the results will be falsely
depressed; this observation may partly explain reported discrepancies
in the literature for absolute values for the serotonin uptake
parameters, Vmax, and f^.
The application of the assays for serotonin in the physiological
and pathophysiological studies described in this thesis show that in
circumstances where platelet function increases, or is expected to
increase, there is a corresponding significant decrease in the
concentration of serotonin in PRP; conversely, with a decrease in
platelet activity (e.g. as shown by a decrease in the extent of
aggregation), there is an associated increase in PRP serotonin.
These findings are in good agreement with previous similar work
(Table 7.2).
It has been suggested that measurement of total plasma
serotonin is a useful indicator of platelet activation in_ vivo (e.g.
Parbtani, et_ ad^, 1980); therefore measurement of PRP serotonin
concentration may be preferential to e.g. the measurement of
(3 -thromboglobulin (BTG), since for the serotonin assay, as it is the
total concentration of PRP serotonin which is measured, no special
precautions need to be taken during venesection or subsequent sample
processing to minimise ex_ vivo degranulation, which would otherwise
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Situation Aggregation BTG Total References
serotonin
1 2 3
Essential k 1s Someya, et al. 1984
hypertension ' ' 1 2: Kjeldsen, et al.,
¥ 3: Kamal, et a_l, 1984a & b
Heart failure ? I ? 1: _
2s
3s
Pumphrey and Dawes, 1982
Post ♦ ♦ ? Is O'Brien, et al., 1966
myocardial ' 1 2s Pengo, et al., 1985
infarction 3s -
Migraine 4 I 1 1s Hilton and Cumings, 1971
(during ! 1 1 2s Gawel, et al., 1979
attack) ¥ 3s Hilton and Cumings, 1972
Diabetes f ♦ ? 1 s Kubisz, et al., 1984
1 1 2s
3s
Burrows, et al., 1978
Sodium | ? *f 1s Nara, et a^., 198restriction i 1 2s -
3s -
Table 7.2 The relationship between the extent of induced platelet
aggregation, in vivo platelet activation as measured by
BTG levels, and total plasma serotonin levels in various
pathological or non-pathological situations.
* = result obtained in PRP in this thesis
? = as yet unknown
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result in falsely elevated values with BTG assays.
In the studies carried out in this thesis, although significant
differences were seen when comparing the levels of serotonin in PRP
between two groups, these differences were not significant after
correcting for platelet numbers, indicating differences in platelet
counts in the groups studied. Figure 7.1a shows the correlation
obtained by linear regression analysis of PRP serotonin levels
(nmol/1), and the corresponding values after correcting for the PRP
platelet number for 162 consecutive samples from patients and normal
volunteers (nmol/1 = 4.67 x pmol/10® platelets - 14.2; n = 162;
r = 0.917); Figure 7.1b shows the correlation obtained by linear
regression analysis of the natural logarithm of both sets of data (In
nmol/1 = 0.865 x In pmol/10® platelets + 1.0; n = 162; r = 0.833).
In each case, the slope of the line is significantly different from
zero (p<0.0001 in both instances). These data suggest that when
Q
compared with platelet serotonin concentration (i.e. pmol/10
platelets), measurement of PRP serotonin (i.e. nmol/1 PRP) is an
equally reliable index of physiological changes in blood serotonin
concentration, suggesting that the significant differences found in
this thesis when comparing PRP serotonin levels between two groups
are real.
7.3 Future Prospects
As outlined above, the results obtained in this thesis and work
from other groups (Nara, et al., 1984; Ashida, et al., 1985) suggest






Figure 7.1 Correlations between
O
a) serotonin (pmol/10 platelets) and
serotonin (nmol/l PRP), and
O
b) serotonin (In pmol/10 platelets)
and serotonin (In nmol/l PRP).
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relationship is partly mediated by an increase in the release of
serotonin from platelets during sodium load, it should be possible to
detect both an increase in the release reaction itself in_ vitro and
at the same time an increase in the circulating levels of the
indicator of platelet release, BTG. If an enhanced release of
platelet constituents does occur during salt loading, then it is
anticipated that there would be an inverse correlation between PRP
serotonin concentration and the concentration of BTG present in PPP.
The release of serotonin from platelets can be measured directly by
the RIA developed in this thesis, obviating the need to pre-incubate
o 12i
platelets with either [°H]- or [ C]-serotonin, and subsequent
measurement of released serotonin by liquid scintillation counting.
Further study is required concerning the modulation of circulating
All levels by ACE inhibition; although published work (Someya, et_ al.,
1984) and the results presented in this thesis indicate that there
may be a decrease in platelet activity following captopril therapy,
it remains unclear how this is brought about. As discussed earlier
(section 5.6), it has been suggested that ACE inhibition may result
in elevation of prostacyclin due to an increase in bradykinin.
Consequently, blockade of prostaglandin synthesis e.g. by indo-
methacin or aspirin, with and without concomitant ACE inhibition may
help to indicate how prostaglandins contribute to the observed
effects, thus leading to a better understanding of the role of
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Appendix I Program to Fit Line Using Revised Direct Linear Plot
10 CLS
20 REM DISTRIBUTION FREE ANALYSIS
30 REM IDENTIFICATION!
40 INPUT " PATIENT NAME";P$
50 INPUT " EXPERIMENT DATE"jES
60 PR I NT'.PRINT: PR INT: PR I NT
70 PRINT " PAT IENT: ,PS
80 PRINT " DATE:-".ES
-90 PR INT:PR INT:PR I NT:PR I NT
100 DIM CRADC50) ,X(10) , YC10) , INTERCEPT(50 )
110 REM INPUT NUMBER OF DATA POINTS TO BE HANDLED
120 INPUT " NUMBER OF DATA POI NTS";POI NTS
130 REM CALCULATE NUMBER OF LINES JOINING ALL POINTS
140 LINES 5*P01NTS*(POINTS-1 )
150 REM INPUT DATA
160 FOR COUNT-1 TO POI NTS: INPUT " X VALUE";X:X(COUNT) = X
170 INPUT " Y VALUE";Y:Y(COUNT)-Y
180 NEXT COUNT
190 LPRI NT , , " PAT IENT:-", P$
200 LPR1 NT, , " DATE:-", E$
210 LPRINT:LPRINT:LPR1NT
220 FOR COUNT - 1 TO POINTS
230 LPRI NT " X "COUNT" - ";:LPRINT USING "####.###";X(COUNT);
240 LPRI NT " Y "COUNT" - ";:LPRINT USING "ft###.###";Y(COUNT)
250 NEXT COUNT
260 A-1:T-1
270 REM CALCULATE GRADIENTS
280 FOR C-A TO (POINTS-1)
290 REM NO DIVISION BY ZERO I I I II
300 IF X(A)-XCC-M) THEN GRAD (T )-9999 : I NTERCEPT (T )-9999 : GOTO 340
310 GRAD(T)-((Y(A)-YCC+1))/(X(A)-XCC+1)))
320 INTERCEPT(T)-(X(A)*Y(C+1)-X(C+1)»Y(A))/(X(A)-X(C+1))
330 IF INTERCEPT(T)< 0 THEN INTERCEPT(T)-.0001 :GRAD(T)-1
340 T-T+l:NEXT C: A-AM
350 REM CHECK ALL LINES DONE
360 IF T> L1NES THEN GOTO 390
370 REM IF NOT. THEN BACK TO LOOP
380 GOTO 280
390 REM PRINT RESULTS
400 PRINT:PRINT:PRINT
410 LPRI NT:LPRI NT:LPRINT:LPRI NT
420 FOR T»1 TO LINES
430 IF GRAD(T)-9999 THEN PRINT " GRADIENT - INFINITE ";
440 IF GRAD(T)-9999 THEN LPRI NT ." GRADIENT - INFINITE "; :GOTO 470
450 PRINT " GRADIENT - ",:PRJNT USING "ft###.###" ; GRAD (T) ,
460 LPRI NT ," GRADIENT - ", :LPRI NT USING "####.###";GRAD(T),
470 IF INTERCEPT (T)-9999 THEN PRINT " INTERCEPT - NONE"
480 IF INTERCEPT CT)-9999 THEN LPRI NT " INTERCEPT - NONE":GOTO 510
490 PRINT " INTERCEPT - ".: PRINT USING " (tfttt# . tttftt"'. I NTERCEPT (T )
500 LPR1 NT " INTERCEPT - ", :LPRI NT USING "####.###";INTERCEPT(T)
510 NEXT T
520 REM SORT ROUTINE
530 FOR N-LINES TO 1 STEP -1
540 FOR A-1 TO (N-l)
550 IF GRAD(A)>GRAD(A+1) THEN B-GRAD(A):GRAD(A)-GRAD(A+1):GRAD(A+1)=B





600 LPRI NT:LPRI NT:LPRI NT
610 PRINT." RESULTS ARRRANGED IN ASCENDING ORDER:-"
620 LPRINT," RESULTS ARRRANGED IN ASCENDING ORDER:-"
630 PR 1 NT:PR I NT
640 LPRI NT:LPRI NT
650 PR I NT:PR I NT:PR I NT:PR I NT
660 LPRI NT ." GRADIENTS". ."INTERCEPTS"
-270-
670 FOR COUNT-1 TO LINES
t*&0 PRINT. : PR I NT US I NO "####.###" ;GRAD( COUNT ) ,
600 LPRI NT. , :LPRI NT USING "####.###";GRAO(COUNT),
700 PR I NT, . ; :PR I NT USING "####.###" ; INTERCEPT(COUNT)
7 10 I.PR I NT , , ; :LPRI NT USING "####.###"; INTERCEPT(COUNT)
72'H NEXT COUNT
700 MEAN-LINES/2
740 REM CALCULATE IF LINES IS ODD OR EVEVN
750 IF MEAN-CI NT(MEAN ) *0 THEN GOTO 820
760 REM MEDIANS FOR ODD NUMBER OF LINES
770 PR I NT:PR I NT:PR I NT
780 LPRI NT:LPRI NT:LPRI NT
790 O-((LINES-1)/2)M:G-CRAD(G)
000 I-((LINES-I )/2 ) + 1 : I - INTERCEPT(I )
Hill GOTO 670
020 REM MEDIANS FOR EVEN NUMBER OF LINES
030 PR I NT:PR I NT:PR I NT
84 0 LPRI NT:LPRI NT:LPRI NT
H50 G-(GRAD(LINES/2)+GRAD((LINES/2)+l))».5
860 I »( I NTERCEPT (L 1 NES/2 ) + I NTERCEPT ((LI NES/2 ) + 1 ))«.5
870 PRINT," MEDIAN GRADIENT PRINT US ING"####.###" ;G
880 I.PRINT.," MEDIAN GRADIENT - " ; ;LPRI NT US ING"####.###";G
890 PRINT," MEDIAN INTERCEPT »";:PRINT US ING"####.###"; I
900 L.PR I NT , , " MEDIAN INTERCEPT -";:LPRJNT US I NG" #### . ###" ; I
910 PR I NT:PR I NT
920 LPRI NT:LPRI NT
930 PRINT," V MAX - " ; : PR I NT US I NG"#### .###"•, 1 00/1
940 LPRI NT, ," V MAX -";:LPRINT US ING"###0.###";100/1
950 PRINT," K M -";:PRINT US ING"####.###";1000*G/1
960 LPRI NT, ," K M -";:LPRINT US ING"####.###";1000*G/I




Appendix II New York Heart Association Classification
Class I - No limitation. Ordinary physical activity does not
cause undue fatigue, dyspnoea, or palpitation.
Class II - Slight limitation of physical activity. Comfortable at
rest. Ordinary physical activities result in fatigue,
palpitations, dyspnoea, or angina.
Class III - Marked limitation of physical activity. Comfortable at
rest. Less than ordinary activity will lead to symptoms
described in Class II.
Class IV - Inability to carry out any physical activity without
discomfort. Symptoms of congestive cardiac failure




Appendix III Preparation of N-Aeetoxysuccinimide
"...N-Acetoxysuooinimide. To N-hydroxysuccinimide (5 g, 43.5 mmol)
in 150 ml of acetone was added 4.1 ml (43.5 mmol) of acetic anhydride
dropwise at room temperature with stirring. After 160 min the
solvent was evaporated under vacuum, the residue redissolved in 150
ml of absolute ethanol at 45°C, and the solution cooled to 4°C,
yielding 5.39 g (88% yield) of product, mp 132-133°C (lit. mp 132-
133°C (Baumann et al., 1973))..."
Treadway and Schultz, 1976
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Appendix IV
Appendix IV Short Protocols
1. HPLC-ECD Serotonin Assay
To the sample (400 pi), add the internal standard (50 pi, 25 pmol/1
in saline), vortex, add 50 pi of a solution of perchloric acid/cysteine
(1.5 mol/1 and 2 mmol/1 respectively), vortex again, and leave at
least 15 min at 4°C. Sample is then centrifuged at 4°C for at least
15 min at 1,720 x g (or greater) to pellet precipitated protein.
Sample can then be injected directly, or removed to fresh tube and
stored at 4°C for at least 6 h.
2. RIA for Serotonin in Human PRP
Sample is diluted 1/20 in assay buffer; standards (1 - 1,000
nmol/1) are made up in PPP diluted 1/20 in assay buffer (PPP must
contain <20 nmol/1 serotonin). To the sample/standard (450 pi) add
50 pi perchloric acid/cysteine (1.5 mol/1 and 2 mmol/1 respectively),
and treat as above. Take duplicate aliquots (2 x 200 pi) of protein-
free supernatants, and add to N-acetoxysuccinimide (250 pg, dried down
from a 5 mg/ml methanolic stock) in glass tubes. Vortex, and add
50 pi of KOH or NaOH (37.5 pmol) in 0.5 mol/1 protein-free assay
buffer (original pH 6.2). Vortex, and leave for 60 min at room
temperature; add glycine (8.3 pmol) in assay buffer (50 pi), vortex,
and leave 30 min. Add tracer in assay buffer (100 pi), followed by a
freshly prepared mixture of NIRS, DARS, and primary antiserum in assay
buffer (300 pi). Vortex and incubate overnight at 4°C. Separate
by adding 1 ml cold (4°C) buffer prewash, and centrifuge at 4°C and









Only the intra-assay percentage coefficient of variation (%CV) is
given, since the samples from the studies which used the above assays
were run within a single assay.
-275-
Appendix VI
This paper is reproduced with the permission
of Clinica Chimica Acta, and also the co-authors




Development and validation of
an improved radioimmunoassay
for serotonin in platelet-rich plasma
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Summary
A radioimmunoassay (RIA) using a 125I-tracer is described for measurement of
serotonin (5-hydroxytryptamine, 5-HT) in human platelet-rich plasma (PRP). Anti-
sera were raised against 5-HT-succinamate conjugated to bovine albumin and, to
improve assay sensitivity, the analyte was made chemically similar to the immuno-
gen by conversion to A-acetylserotonin prior to assay, using the specific amino
reagent A-acetoxysuccinimide. The assay shows good correlation with a high-pres¬
sure liquid chromatography (HPLC) reference method (5-HTRIA = 1.007 X 5-
HThplc + 29.3, r = 0.936, p < 0.001, n = 40), indicating that no significant cross-re-
actions were detected. Samples of PRP are diluted 1/20 to fall within the working
range (80-15% B/B0) of the assay, which is 4.75-325 nmol/1, (0.95-65.0 pmol/
tube), corresponding to 95-6500 nmol/1 in PRP. Intra- and interassay coefficients
of variation were 5.0-10.5% and 12.0-21.2% respectively for serotonin concentra¬
tions of 250-2 500 nmol/1 added to platelet-poor plasma. With this improved assay,
it is possible to analyse up to 100 samples/day, compared with 10-20 samples/day
by HPLC.
Correspondence and reprint requests should be addressed to: Mr. I.F. Gow, University Department of
Medicine, Western General Hospital, Crewe Road, Edinburgh, EH4 2XU Scotland, UK.
0009-8981/87/$03.50 © 1987 Elsevier Science Publishers B.V. (Biomedical Division)
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Introduction
Abnormal concentrations of serotonin (5-hydroxytryptamine, 5-HT) in platelets
have been described in several pathological conditions, including essential hyperten¬
sion [1-3], migraine [4,5], depression [6], carcinoid syndrome [7], liver cirrhosis [8],
and pre-menstrual tension [9]. Despite this growing body of evidence implicating
serotonin as a possible biochemical marker in disease, the development and valida¬
tion of an assay capable of handling the large numbers of samples necessary for
comprehensive studies has been slow.
Serotonin is conventionally measured by high-pressure liquid chromatography
(HPLC) with electrochemical detection [10-12], radioenzymatic assay [13-16], or
radioimmunoassay (RIA, [17-21]). HPLC has the advantage that 5-HT, its pre¬
cursors and metabolites can be measured in the same injection, but few samples
(< 20) can readily be assayed in a working day. Radioenzymatic assays are
multi-step procedures, and ultimately involve extraction of a tritiated product
followed by liquid scintillation counting. Of the existing RIA methods for serotonin
only two use gamma-labelled tracers [20,21], which would make them more suitable
for use as a routine assay. The remainder use [3H]serotonin as the tracer, and low
working dilutions of rabbit antisera (typically 1/300), which show high cross-reac¬
tivity with 5-methoxytryptamine [17-19], although since the level of this in plasma
is normally low [19], interference would only be significant if 'free' (i.e. non-platelet
bound) concentrations of serotonin were being measured. Since rabbit serum
contains a high level of serotonin (approximately 20 jiimol/1 [22]), this must be
removed to avoid a decrease in sensitivity in the RIAs using [3H]serotonin as tracer.
This can be achieved either by dialysis of the antiserum [18], or by collecting plasma
instead of serum [19] and rendering it platelet-free by centrifugation (almost all














Fig. 1. Structure of serotonin, its acylated derivatives, and the acetylating agent iV-acetoxysuccinimide.
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The assays with gamma-labelled tracers [20,21] use antibodies raised to either
/V-succinamylserotonin or A-succinamyl-5-methoxytryptamine and avoid a loss in
sensitivity by chemically modifying the analyte into the A-succinamyl form [20], or
to A-acetyl-5-methoxytryptamine (melatonin [21]) prior to assay. Consequently,
unmodified serotonin is poorly recognised in these systems which avoids the need to
remove endogenous antigen from the antisera. A disadvantage with the first method
is that the succinylating agent used (succinic anhydride) reacts with 5-HT both at
the amino and the 5-hydroxyl group and the 5-O-hemisuccinyl moiety must then be
hydrolysed by alkali [24] to render the molecule fully immunoreactive. In the second
method, the 5-hydroxyl group is chemically methylated, and is therefore protected
from reaction with the acetylating agent (acetic anhydride). This assay still requires
a final organic extraction step, but it demonstrates that the chemically similar
/V-acetyl derivative (Fig. 1) can be recognised by an antiserum raised against the
A'-succinamyl derivative. A similar approach has been described for cyclic nucleo¬
tide assays [25]. Potential interference by endogenous A-acetylserotonin was not
fully considered in the original papers [20,21], and the assays were not validated by
a reference method. We have developed and validated by HPLC a radioimmunoas¬
say which broadly follows a published method [20], but which incorporates certain
improved features.
Materials and equipment
Serotonin creatinine sulphate, A-acetylserotonin, tryptamine, tryptophan, 5-hy-
droxytryptophan, 5-hydroxyindoleacetic acid, melatonin, cysteine hydrochloride,
isobutyl chloroformate and Amberlite XAD-2 were all purchased from Sigma,
Poole, Dorset, UK. Bovine serum albumin (BSA), dimethylformamide and dioxan
were from BDH, Poole, Dorset, UK. The perchloric acid was from May and Baker,
Dagenham, Essex, UK, the A'-methylserotonin and tri-n-butylamine were from
Aldrich, Gillingham, Dorset, UK. Tritiated serotonin was from Amersham Interna¬
tional, Amersham, Bucks, UK, and Sephadex G-50 was from Pharmacia, Milton
Keynes, Bucks, UK. Donkey anti-rabbit serum, and non-immune rabbit serum were
from the Scottish Antibody Production Unit, Law Hospital, Carluke, UK. Assay
buffer, pH 6.2, contained 0.1 mol/1 citric acid, 0.3 mol/1 sodium hydroxide, 1
mmol/1 EDTA, and 1 g/1 gelatin. The multi-well gamma counter with software was
supplied by Nuclear Enterprises, Sighthill, Edinburgh, UK. Glass assay tubes
(12x75 mm) were from Corning, New York, NY, USA, and polypropylene
microfuge tubes were from Macfarlane Robson, Glasgow, Scotland, UK. The HPLC
equipment (Waters/Millipore, Harrow, Middlesex, UK) comprised an M6000A
pump and U6K injector with a 2-ml sample loop, a precolumn (3.9 mm X 2 cm)
packed with Clg Corasil (37-50 /im diameter), and either a Waters 3.9 mm X 30 cm
Clg jiiBondapak column (particle diameter 10 /im), or a Capital HPLC (Edinburgh,
UK) column (4.9 mm X 10 cm) packed with Hypersil ODS (particle diameter 5 /xm).
Detectors used were a Bioanalytical Systems (West Lafayette, NJ, USA) LC-4A
electrochemical detector with a single glassy carbon electrode, or a Waters 441 UV
detector. Peaks were plotted on a Waters data module, and peak heights used for
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calculation of concentrations. Mobile phase was de-gassed with a Waters solvent
clarification kit, through a Millipore 'Durapore' filter (0.22 jam). Methanol and
water for HPLC were from Rathburn Chemicals, Walkerburn, Peebleshire, UK.
Non-HPLC organic solvents were redistilled prior to use. The remaining chem¬
icals were all of analytical grade.
Methods
Standards
Standard serotonin (serotonin creatinine sulphate) was stored as a concentrated
(4-5 mmol/1) stock dissolved in 0.15 mol/1 perchloric acid/0.2 mmol/1 cysteine
(pH 1.8); JV-acetylserotonin was dissolved first in ethanol (approximately 500 jal),
then diluted in acid/cysteine; both were then stored at 4°C in the dark. Concentra¬
tions were checked by UV absorption at 275 nm for serotonin, and 278 nm for
/V-acetylserotonin (the molar extinction coefficient, e, had previously been de¬
termined to be 5740 1/mol per cm for serotonin, and was assumed to be the same
for A'-acetylserotonin).
Preparation ofplatelet-rich and platelet-poor plasma (PRP and PPP)
Whole blood was taken from the antecubital vein using a 19 gauge needle with
tourniquet, added to the anticoagulant (citric acid (8 g/1), trisodium citrate (22 g/1),
glucose (20 g/1) in 10 ml plain polystyrene tubes; 9 vol blood: 1 vol anticoagulant)
and used to prepare either PRP or PPP.
PRP The blood was centrifuged immediately at room temperature for 10 min at
121 X g, and the upper three-quarters of the supernatant (PRP) harvested with a
disposable transfer pipette and stored frozen at — 20 °C.
PPP The blood was centrifuged immediately at 4°C for 1 h at 1 720 X g. and,
to avoid inclusion of platelets trapped in the floating lipid layer, or from the
plasma/red cell interface, the middle third of the supernatant (PPP) was removed
and stored frozen at — 20 °C. The serotonin content of the PPP was measured by
the HPLC assay, and was only used for the RIA if the concentration was < 20
nmol/1, as this would be undetectable after the 20-fold dilution step required for the
RIA.
Deproteinisation
Preparation of samples for assay by HPLC
Samples of PRP (400 ju.1) previously frozen and thawed to rupture the platelets
were spiked with 1.25 nmol of the internal standard A-methylserotonin [26] in assay
buffer (50 jul), then deproteinised.
Preparation of samples for RIA
Samples of PRP or standards diluted in PPP were diluted 20-fold in assay buffer,
and aliquots (450 jul) deproteinised.
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Deproteinisation
The prepared sample/standard (450 /xl) was dispensed into a polypropylene
conical microcentrifuge tube (1.5 ml), and the proteins precipitated by adding an
aliquot (50 /j,I) of perchloric acid/cysteine solution (1.5 mol/1 and 2 mmol/1,
respectively). The tube was vortexed, left at 4°C for 15 min, and then centrifuged at
10000 Xg for 15 min at 4°C. The supernatant was removed to a clean polypro¬
pylene tube and stored at 4°C until assayed, which must be within the same day.
HPLC assay
The mobile phase (pH 4.8) contained water (1700 ml), methanol (300 ml),
sodium dihydrogen orthophosphate (10.8 g), ethylenediamine tetra-acetic acid dis-
odium salt (400 mg), and sodium 1-octanesulphonate (240 mg), and was degassed
before use. Flow rates were 0.5-1.0 ml/min, and the detector was set at +0.70 V
with 5 nA full scale deflection. Standards were diluted from the concentrated stock
into perchloric acid/cysteine (0.15 mol/1 and 0.2 mmol/1, respectively) each assay
day, and stored in the dark at 4°C throughout the assay run. Standards and
deproteinised supernatant from samples were injected directly (20-100 ju.1). This
system separated the major 5-HT metabolite 5-hydroxyindoleacetic acid (5-HIAA),
iV-acetylserotonin, serotonin, and the internal standard, TV-methylserotonin.
Radioimmunoassay
Synthesis of N-succinamylserotonin and immunogen
V-Succinamyl serotonin was synthesised and conjugated to bovine serum albumin
by methods modified from those of Delaage and Puizillout [20].
Serotonin creatinine sulphate (61 mg) and succinic anhydride (91 mg) were
stirred under nitrogen for 10 min with 0.68 mol/1 potassium hydroxide (2.16 ml). A
solution of hydroxylamine hydrochloride (21 mg) in water (0.5 ml) was added,
followed by 0.68 mol/1 potassium hydroxide (1.55 ml), and the solution was stirred
for a further 5 min, then adjusted to pH 4 by addition of 1 mol/1 hydrochloric acid.
The solution was rapidly applied to a column of Amberlite XAD-2 (25 ml;
previously freed of UV-absorbing contaminants by exhaustive washing with ethanol)
in water, and the column was then washed with water (approximately 200 ml) until
the eluate showed no UV absorption. The column was eluted with ethanol (150 ml),
and the yield of A-succinamylserotonin determined by its UV absorption at 278 nm
(e278 = 5740 1/mol per cm).
The ethanolic solution was evaporated under reduced pressure, and the residue
redissolved in water (10 ml), and lyophilised to leave the product as a pale foam,
which was either used directly for conjugation to bovine serum albumin, or
redissolved in dry dimethylformamide (DMF) at 17.8 mg/ml. Aliquots of this
solution were sealed under nitrogen in glass ampoules to avoid oxidation and stored
at — 20 °C for use in the preparation of the radioiodinated tracer.
For the preparation of the immunogen, a solution of V-succinamylserotonin (38
mg) in dry dioxan (2.14 ml) was cooled to 10-12° C, and treated with tri-«-butyla-
mine (62 jul), and isobutyl chloroformate (15 jal). After 20 min this solution was
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added under nitrogen to an ice-cold solution of bovine serum albumin (332 mg) in
water (8.8 ml), 1 mol/1 sodium hydroxide (0.33 ml) and dioxan (5.7 ml). This
solution was stirred in an ice bath for 1 h, then treated with 0.25 mol/1 sodium
phosphate, pH 6 (1.4 ml), and dialysed for 1 h against 0.05 mol/1 sodium
phosphate, pH 6 (5 1). The dialysate was subjected to gel filtration on Sephadex
G-50 (40 X 3 cm), eluting with 0.05 mol/1 sodium phosphate, pH 6. The fraction
eluted in the void volume was analysed by UV spectroscopy and Lowry protein
estimation, which showed a conjugation ratio of 24 serotonin residues per protein
molecule. The eluate was lyophilised and the conjugate stored at — 20 °C.
Immunisation and bleeding
Four rabbits (New Zealand White) were used, and immunisation was at 4 sites
sub-cutaneously throughout. The dose was 100 /xg/animal in each case, in 1:1
Freund's complete adjuvant: saline for the primary, and in 1:1 Freund's incomplete
adjuvant: saline for the boosts. Boosts were given 6 wk after the primary immunisa¬
tion, and thereafter at intervals of 6 wk. Bleeds were taken 10 days after each
boosting. Blood was collected as heparinised PPP for the early bleeds and as serum
from later bleeds. This enabled larger volumes of blood to be collected, and had no
effect on titre. The plasma/serum was stored at — 20 °C either neat, or as 1/10
dilution in assay buffer.
Radioiodination
The procedure was similar to that already described [20]. All solutions were
freshly prepared on the day of the iodination. An aliquot (50 /xl) of 7V-succina-
mylserotonin in DMF (17.8 mg/ml) was taken from one of the sealed vials, and
dispensed into a conical polypropylene microcentrifuge tube. To this was added a
solution (10 /xl) of tri-n-butylamine in DMF (17 /xl/ml), followed by a solution (10
jul) of isobutyl chloroformate diluted in DMF (45 /x 1/8.5 ml). The tube was vortexed
and incubated for 20 min at 10-12°C. Glycyl tyrosine (476 ng) in 0.25 mol/1, pH
7.5, phosphate buffer (10 /xl) was added to a 1 mCi solution (10 /xl) of Na125I (spec
act, 13-17 mCi/jug I) and mixed. Chloramine-T (10 /xg) dissolved in the same
phosphate buffer (10 /xl) was added, the solution mixed, and left at room tempera¬
ture for 1 min. The reaction was stopped by the addition of sodium metabisulphite
(12 /xg) in 0.05 mol/1 phosphate buffer, pH 7.5 (20 /xl). The activated A-succina-
mylserotonin solution (50 /xl) was added to the iodinated glycyl tyrosine, the
solutions mixed, and then left at 4°C for 5 min. The reaction mixture was diluted
with 500 /xl of the eluting buffer (0.1 mol/1 citric acid, 0.1 mol/1 sodium chloride, 3
mmol/1 ascorbic acid, final pH 6.2) before being applied to the Sephadex G-25
column (49 X 1 cm). The buffer was pumped through the column at 1 ml/min, and
fractions (6 ml) collected in plain polystyrene tubes. Aliquots (10 /xl) of the fractions
were counted in a multiwell gamma-counter to locate the peaks. The immunoreac-
tive fractions of a single peak (typically fractions 25-30) were pooled, diluted 1+1
with assay buffer, and stored at — 20 °C as aliquots (2 ml) in stoppered polystyrene
tubes. Each aliquot was thawed once only, after which it was stored in the dark at
4°C and discarded after 1 wk.
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Testing of antisera
Antisera were tested by incubation 01 varying dilutions of primary antiserum
(100 /xl) with a fixed mass (1 fmol, 5000 dpm) of tracer in buffer (100 /xl), and
solutions of 30-fold diluted donkey anti-rabbit serum (100 /xl) and 300-fold diluted
normal rabbit serum (100 /xl). Incubation was overnight at 4°C, and prior to
separation, a prewash (1 ml) of cold (4°C) assay buffer was added, and the tubes
centrifuged in pre-cooled carriers at 1720 X g for 30 min at 4°C. The supernatants
were aspirated, and the pellet (bound fraction) counted in a multi-well gamma-
counter.
Acetylation
The acetylating agent A-acetoxysuccinimide (NAS) was prepared according to
the method of Treadway and Schultz [27]. For each assay, a fresh solution of NAS
in methanol (5 mg/ml) was prepared, and aliquots (50 /xl) dispensed into glass
tubes. The methanol was evaporated under a stream of nitrogen whilst warming the
tubes (45 °C). Acidified deproteinised supernatants from standards or samples were
taken in duplicate (each 200 /xl) and added to the dried NAS followed by 37.5 /xmol
sodium hydroxide in protein-free 0.5 mol/1 citrate assay buffer (50 /xl). The tubes
were vortexed, then left 1 h at room temperature. Glycine (8.3 /xmol) was added in
assay buffer (50 /xl), the tubes vortexed, and left a further 30 min at room
temperature. If no acetylation was required (e.g. in some of the cross-reactivity
studies), NAS was omitted from the methanol.
Assay procedure
Samples of PRP or standards in PPP were deproteinised and acetylated. Tracer (1
fmol) diluted in assay buffer (100 /xl) was added, followed by a pre-mix (300 /xl) of
primary antiserum (rabbit 16 bleed 4, R16B4), donkey anti-rabbit antiserum, and
normal rabbit serum, at final dilutions of 1/28000, 1/210, and 1/2100, respec¬
tively, in the final incubate (700 /xl). The tubes were vortexed, incubated overnight
at 4°C, and separated as described above. Calculation of results was by software
supplied with the multi-well gamma-counter, using a regression plot of logit % B/B0
versus log concentration.
Cross-reactivities
These studies were performed with the test compounds and serotonin diluted it,
assay buffer prior to deproteinisation. Cross-reactions were measured for the test
compounds themselves and where appropriate, after A-acetylation as above. Per¬
centage cross-reactivity was calculated from the ratio of the mass A-acetylserotonin
at 50% B/Bq\ mass of cross-reactant at 50% B/B0.
Precision studies
Serotonin was added to PPP from normal subjects at concentrations of 250, 750,
and 2 500 nmol/1, and aliquots (1 ml) frozen at -20°C in polypropylene micro¬
centrifuge tubes. These recovery pools were assayed by HPLC and RIA to de¬
termine intra- and inter-assay precision over a period of 8 wk.
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Validation of R1A by HPLC
Samples of PRP from normal volunteers or from patients were analysed by both
HPLC and RIA, and the results correlated by linear regression analysis.
Results
Stability of standards
Serotonin was found to be acceptably stable when stored as described. When
compared by HPLC analysis with a freshly prepared serotonin standard, a solution
which had been stored and used over a period of 9 mth was found to contain 93.0%
of the original serotonin concentration.
Recovery after deproteinisation
The recovery after deproteinisation of tritiated serotonin (> 90% pure) from
undiluted PRP was (mean + sd) 92.0 + 2.9% for samples of the same plasma
(n = 7), and 91.5 + 1.8% for plasma from different volunteers (n = 7). There was no
significant difference between the two recoveries as calculated by the Student's t
test (p> 0.5).
With the HPLC internal standard, recoveries from samples of the same or
different plasmas were 80.4 + 3.7% (n = 7), and 79.1+2.7% (n = l), respectively.
Again, there was no significant difference between the two. However the recovery of
[3H]serotonin was always significantly greater than the internal standard recoveries
(p < 0.001, Student's t test).
Testing of antisera
All rabbits used gave antisera which bound the tracer and could be displaced by
authentic TV-acetylserotonin. Titres (the dilutions of antisera binding 50% of the
tracer in the absence of cold antigen) from the first bleeds were all greater than
1/2 500, and in one rabbit (R16) rose to a maximum (1/56 000) at bleed 6. No
change in sensitivity was seen in R16 antisera despite the rising titre. Of the rabbits
and bleeds tested, one antiserum (R16B4) was selected for use on the basis of good
titre coupled with good sensitivity.
Radioiodination
Incorporation of 125I into TV-succinamylserotonin-glycyl tyrosine was 28.3 + 8.5%
(mean + sd, n = 5). On incubation with excess antiserum, 80-90% of the tracer
could be recovered in the bound fraction and non-specific binding was 2-4%. The
specific activity as calculated from depression of zero binding associated with
increasing tracer mass was found to be 2011 Ci/mmol. The tracer showed no loss in
immunoreactivity over a period of 5 mth stored in aliquots at — 20 °C, if the mass of
tracer added per tube was kept constant.
N-Acetylation
Preliminary experiments had shown that at pH 6, 250 jag of NAS could acetylate
85-90% of a 3 pmol/1 solution of serotonin in deproteinised PPP (200 pi). This
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mass of NAS was therefore used for all subsequent acetylations. The acetylation
reaction was essentially complete after 40 min, but was routinely left a further 20
min. No degradation of the acetylated product was seen even after 160 min at room
temperature. The optimum pH for acetylation was found to be >5, and the
reaction was almost completely inhibited below pH 3. The added glycine was
intended to react with any remaining NAS, which may otherwise have acetylated the
antibody and impaired immunoreactivity.
Radioimmunoassay
A typical standard curve is shown in Fig. 2, with associated precision profile [28],
The formal sensitivity of the standard curve (2.5 sd from the zero standard) was 2.0
nmol/1 or 0.40 pmol/tube (70.4 pg/tube), which, corrected for dilution, corre¬
sponds to a serotonin concentration in PRP of 40 nmol/1. As precision at the
formal detection limit is generally poor for RIAs, we have limited the working range
of the assay to 80-15% B/B0, which corresponds to 4.75-325 nmol/1 for a sample
of 200 jLtl, or 0.95-65 pmol/tube (0.17-11.44 ng/tube). This represents concentra¬
tions in undiluted PRP of 95-6 500 nmol/1. Addition of the antisera as a preformed
first/second antibody complex had no effect on the characteristics of the standard
curve as compared with a 4 h primary incubation followed by addition and
overnight incubation with the double antibody reagents. Changing the buffer from
pH 6.2 to pH 4 lowered the zero binding from 60% to 53%. The overall recovery of




Fig. 2. Standard serotonin curve (mean value, ), and precision profile (mean value, , ±sd,
) for eight consecutive assays showing intra-assay variation of duplicate mean estimations.
Primary antiserum dilution was 1/28000 (final) added as a pre-formed first antibody/second antibody/
carrier complex. With an added tracer mass of 1 fmol and an overnight incubation at 4°C, zero binding
(B0) was 48.8 + 6.1% of the total added radioactivity.
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TABLE I











The major (0.12%) formal cross-reactant (see Table I) was unacetylated serotonin,
but this would not normally be present in assay incubates. A-Acetylation increased
the cross-reactivity of the other indoleamines, but methylation of the 5-hydroxyl
group of A-acetylserotonin reduced cross-reactivity from 100% to < 0.02%.
Intra- and inter-assay variation
Intra- and inter-assay variation (Table II) in the HPLC assay were lower than in
the RIA at all the tested concentrations, but the recoveries of serotonin from spiked
PPP were very similar for both assays. No decrease in the values obtained from the
spiked pools was seen over a period of 2 months (Fig. 3).
TABLE II





X+SD %CV X + SD %CV
Intra- 250 252.0 + 5.2 2.1 214.8+ 22.5 10.5
assay 750 884.2 + 5.7 0.6 773.6+ 79.6 10.4
variation 2500 2579.0 + 79.1 3.1 2296.8 + 131.1 5.7
n = 5 10
Inter- 250 259.3 + 14.8 5.7 242.4+ 36.6 21.2
assay 750 836.9 + 46.9 5.6 885.0 + 106.6 12.0
variation 2500 2432.0 + 158.8 8.2 2465.5 + 364.8 14.8
n = 12 12
Inter- 250 103.8 + 5.9 _ 97.0+ 20.6 -
assay 750 111.6 + 6.2 - 118.0+ 14.2 -
% recovery 2500 97.3 + 8.0 - 98.6+ 14.6 -























1 2 3 A 5 6 7 8 9 10 11 12
Assay Number
Fig. 3. Serotonin concentrations as measured in the spiked PPP pools in consecutive assays over a period
of 2 mth. The pools were stored as 1 ml aliquots in sealed polypropylene microcentrifuge tubes at













Fig. 4. Correlation of the RIA with the HPLC assay for human PRP samples from healthy volunteers and
drug-free patients attending a hypertension clinic.
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Validation of the RIA by HPLC
Figure 4 shows the regression equation for comparison of serotonin values
measured by HPLC and RIA. The relatively small positive intercept (29 nmol/1)
suggests that endogenous A-acetylserotonin is not present at concentrations suffi¬
cient to interfere with the RIA measurement. Of the normal subjects studied, PRP
serotonin concentrations (mean + sd) were 1 548 + 541 nmol/1 for the females
(n = 5), and 1 404 + 827 for the males (n = 6). This difference was not significant
(p > 0.5, Student's t test).
Discussion
The stability of serotonin at room temperature and in the presence of atmos¬
pheric oxygen decreases at neutral or alkaline pH [22]. Consequently, we found it
necessary to synthesise the /V-succi namyIserotonin under nitrogen, as exposure to
the alkaline hydroxylamine used in cleaving the 5-O-succinyl moiety back to a
5-hydroxyl group otherwise resulted in destruction of the indole nucleus. Similarly,
the preparation of the immunogen, was conducted under nitrogen. Acetylation by
NAS instead of a non amino-specific acylating agent does not require an alkali
hydrolysis step, and thus avoids the risk of oxidising the modified serotonin
molecules. It seems possible that a similar approach could be used to develop assays
for other unstable mono-amines.
The significant difference between the recovery of tritiated serotonin or the
internal standard from PRP may be due to the impurities in the tracer, as it is not
known exactly how the residual (< 10%) of radioactivity behaves, whether it is
distributed throughout the sample, or is concentrated in the supernate, which would
result in a falsely elevated recovery. Although it is assumed that the internal
standard behaves in the same way as serotonin, and reflects the distribution of the
analyte in the deproteinised sample, the fact that serotonin and the internal
standard can be separated by HPLC underlines the point that they are not
chemically identical and may indeed behave differently during the deproteinisation.
If this is the case, and the [3H]serotonin recovery is the true value, the internal
standard recovery would overcompensate for loss of serotonin during deproteinisa¬
tion, giving rise to elevated results by the HPLC assay. However, the small positive
intercept in the correlation between the RIA and the HPLC assay does not support
this, since the RIA needs no recovery correction figure, as the standards are diluted
in the same medium and processed in the same way as the samples, therefore,
respective recoveries should be similar.
The agreement between the RIA and the HPLC reference method shows that in
human PRP the concentration of A-acetylserotonin is negligible compared with the
concentration of serotonin, as the HPLC separates these two compounds, allowing
them to be measured independently. This agrees with a previously published
observation [16]. The present assay has been validated for human PRP, and the
possible presence in other species of appreciable amounts of circulating N-
acetylserotonin requires investigation. The assay could be used to measure N-
acetylserotonin directly.
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The sensitivity of our RIA is comparable both with that of previously published
RIAs (2-10 nmol/1), which used either tritiated serotonin or gamma-emitting
tracers, and also with that of HPLC with electrochemical detection and without
extraction (approximately 2-5 nmol/1), although the precision in the RIA is poorer
than the HPLC at the tested concentrations. This may be partly due to the use of an
internal standard as a recovery marker in the HPLC assay, as this compensates for
imprecision incorporated in sample preparation and analysis.
Of the previously published RIA methods [17-21], only one [19] was validated by
comparison with an established method of serotonin measurement, but this RIA
used tritiated serotonin as a tracer and a low working dilution of antiserum (1/100).
The assay we have developed uses a 125I tracer of high specific activity, and a high
titre antiserum, and has been validated using an HPLC assay. The technical
manipulations required for the RIA are no more difficult than for the HPLC assay,
and up to 100 samples can easily be assayed in a working day, enabling the RIA to
be adapted for routine laboratory use. It is anticipated that the development of this
validated reproducible radioimmunoassay procedure for serotonin will lead to a
better understanding of the role of platelet serotonin in the pathophysiology of
disease states such as hypertension, migraine and depression.
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